{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:20Z","timestamp":1793502680243,"version":"4.5.0"},"reference-count":720,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2026,9,25]]},"DOI":"10.1253\/circj.cj-25-1144","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:10:14Z","timestamp":1782771014000},"page":"1484-1570","source":"Crossref","is-referenced-by-count":8,"title":["JCS\/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism\/Deep Vein Thrombosis"],"prefix":"10.1253","volume":"90","author":[{"given":"Yuichi","family":"Tamura","sequence":"first","affiliation":[{"name":"Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Kusunose","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nephrology, and Neurology, University of the Ryukyus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiji","family":"Akagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Nipppon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Divsion of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyorin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Medicine (Cardiology), Tokai University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[{"name":"Advanced Medical Center for Heart Failure, The University of Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Div of Lower GI, Department of Gastroenterological Surgery, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Chibaken Saiseikai Narashino Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Kataoka","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Occupational and Environmental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Departtment of Cardiology, NHO Okayama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Yokohama Minami Kyosai Hospital"},{"name":"Namiki Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsutaro","family":"Nagaoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ogo","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Sakao","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, International University of Health and Welfare (IUHW), School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Mie University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Shinke","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Pulmonary Hypertension Center, ChIbaken Saiseikai Narashino Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kuwana City Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Children&apos;s Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[{"name":"Div of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medcine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Hosokawa","sequence":"additional","affiliation":[{"name":"Center for Advanced Medical Innovation, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Toho University Medical Center Ohashi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Inami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyorin University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Jinzaki","sequence":"additional","affiliation":[{"name":"Department of Radiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Kato","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Toyama Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kitai","sequence":"additional","affiliation":[{"name":"Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetoyo","family":"Kogaki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neonatology, Osaka General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Radiology, Chiba University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiteru","family":"Morio","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Nishizaki","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, NHO Okayama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Ogihara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Mie University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ohta-Ogo","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, International University of Health and Welfare Mita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Sugimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare, Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanazawa Cardiovascular Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Tsujino","sequence":"additional","affiliation":[{"name":"Division of Respiratory and Cardiovascular Innovative Research\/Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Physiology, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Intensive Care, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yao","sequence":"additional","affiliation":[{"name":"Division for Health Service Promotion, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Yaoita","sequence":"additional","affiliation":[{"name":"Department of Cardiovasular Medicine, Tohoku University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Emoto","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Science, Kobe Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Hidamarinooka Nakamura Medical Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ogino","sequence":"additional","affiliation":[{"name":"Cardiovascular Surgery, Medial Research Institute Kitano Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Satoh","sequence":"additional","affiliation":[{"name":"Iruma Heart Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Japanese Circulation Society and Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u80ba\u8840\u6813\u585e\u6813\u75c7\u304a\u3088\u3073\u6df1\u90e8\u9759\u8108\u8840\u6813\u75c7\u306e\u8a3a\u65ad, \u6cbb\u7642, \u4e88\u9632\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2017\u5e74\u6539\u8a02\u7248)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>Eur Heart J<\/i> 2020; 41: 543\u2013603.","DOI":"10.1093\/eurheartj\/ehz405"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic therapy for VTE disease: Second update of the CHEST Guideline and expert panel report. <i>Chest<\/i> 2021; 160: e545\u2013e608.","DOI":"10.1016\/j.chest.2021.07.055"},{"key":"4","unstructured":"4. \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u80ba\u9ad8\u8840\u5727\u75c7\u6cbb\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3(2017\u5e74\u6539\u8a02\u7248)."},{"key":"5","unstructured":"5. \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5faa\u74b0\u5668\u75c5\u30ac\u30a4\u30c9\u30b7\u30ea\u30fc\u30ba 2014\u5e74\u5ea6\u7248: \u6162\u6027\u80ba\u52d5\u8108\u8840\u6813\u585e\u6813\u75c7\u306b\u5bfe\u3059\u308b balloon pulmonary angioplasty \u306e\u9069\u5fdc\u3068\u5b9f\u65bd\u6cd5\u306b\u95a2\u3059\u308b\u30b9\u30c6\u30fc\u30c8\u30e1\u30f3\u30c8."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. <i>Eur Respir J<\/i> 2019; 53: 1801913.","DOI":"10.1183\/13993003.01913-2018"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RM, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>Eur Heart J<\/i> 2022; 43: 3618\u20133731.","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, et al. An of\ufb01cial European Respiratory Society statement: Pulmonary haemodynamics during exercise. <i>Eur Respir J<\/i> 2017; 50: 1700578.","DOI":"10.1183\/13993003.00578-2017"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zeder K, Olschewski H, Kovacs G. Updated definition of exercise pulmonary hypertension. <i>Breathe (Sheff)<\/i> 2022; 18: 220232.","DOI":"10.1183\/20734735.0232-2022"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kovacs G, Bartolome S, Denton CP, Gatzoulis MA, Gu S, Khanna D, et al. Definition, classification and diagnosis of pulmonary hypertension. <i>Eur Respir J<\/i> 2024; 64: 2401324.","DOI":"10.1183\/13993003.01324-2024"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gerhardt F, Fiessler E, Olsson KM, Kayser MZ, Kovacs G, Gall H, et al. Positive vasoreactivity testing in pulmonary arterial hypertension: Therapeutic consequences, treatment patterns, and outcomes in the modern management era. <i>Circulation<\/i> 2024; 149: 1549\u20131564.","DOI":"10.1161\/CIRCULATIONAHA.122.063821"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hirakawa K, Asano R, Ueda J, Aoki T, Tsuji A, Ogo T. Calcium channel blockers in patients with pulmonary arterial hypertension receiving PAH-specific treatment. <i>Int J Cardiol<\/i> 2024; 406: 132043.","DOI":"10.1016\/j.ijcard.2024.132043"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ohte N, Ishizu T, Izumi C, Itoh H, Iwanaga S, Okura H, et al. JCS 2021 Guideline on the clinical application of echocardiography. <i>Circ J<\/i> 2022; 86: 2045\u20132119.","DOI":"10.1253\/circj.CJ-22-0026"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. D\u2019Alto M, Di Maio M, Romeo E, Argiento P, Blasi E, Di Vilio A, et al. Echocardiographic probability of pulmonary hypertension: A validation study. <i>Eur Respir J<\/i> 2022; 60: 2102548.","DOI":"10.1183\/13993003.02548-2021"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jankowich M, Maron BA, Choudhary G. Mildly elevated pulmonary artery systolic pressure on echocardiography: Bridging the gap in current guidelines. <i>Lancet Respir Med<\/i> 2021; 9: 1185\u20131191.","DOI":"10.1016\/S2213-2600(21)00072-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gall H, Yogeswaran A, Fuge J, Sommer N, Grimminger F, Seeger W, et al. Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. <i>EClinicalMedicine<\/i> 2021; 34: 100822.","DOI":"10.1016\/j.eclinm.2021.100822"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Park JH, Kusunose K, Kwon DH, Park MM, Erzurum SC, Thomas JD, et al. Relationship between right ventricular longitudinal strain, invasive hemodynamics, and functional assessment in pulmonary arterial hypertension. <i>Korean Circ J<\/i> 2015; 45: 398\u2013407.","DOI":"10.4070\/kcj.2015.45.5.398"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hulshof HG, van Dijk AP, Hopman MT, Heesakkers H, George KP, Oxborough DL, et al. 5-year prognostic value of the right ventricular strain-area loop in patients with pulmonary hypertension. <i>Eur Heart J Cardiovasc Imaging<\/i> 2021; 22: 188\u2013195.","DOI":"10.1093\/ehjci\/jeaa143"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lapostolle F, Surget V, Borron SW, Desmaizi\u00e8res M, Sordelet D, Lapandry C, et al. Severe pulmonary embolism associated with air travel. <i>N Engl J Med<\/i> 2001; 345: 779\u2013783.","DOI":"10.1056\/NEJMoa010378"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. <i>Eur Respir J<\/i> 2005; 26: 586\u2013593.","DOI":"10.1183\/09031936.05.00021005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. <i>Arthritis Rheum<\/i> 2003; 48: 516\u2013522.","DOI":"10.1002\/art.10775"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al. Ventilation \u2013 perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. <i>J Nucl Med<\/i> 2007; 48: 680\u2013684.","DOI":"10.2967\/jnumed.106.039438"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. He J, Fang W, Lv B, He JG, Xiong CM, Liu ZH, et al. Diagnosis of chronic thromboembolic pulmonary hypertension: Comparison of ventilation\/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. <i>Nucl Med Commun<\/i> 2012; 33: 459\u2013463.","DOI":"10.1097\/MNM.0b013e32835085d9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Seferian A, Helal B, Ja\u00efs X, Girerd B, Price LC, G\u00fcnther S, et al. Ventilation\/perfusion lung scan in pulmonary veno-occlusive disease. <i>Eur Respir J<\/i> 2012; 40: 75\u201383.","DOI":"10.1183\/09031936.00097911"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. <i>J Am Coll Cardiol<\/i> 2006; 48: 2546\u20132552.","DOI":"10.1016\/j.jacc.2006.07.061"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Tournadre JP, Chassard D, Muchada R. Overestimation of low cardiac output measured by thermodilution. <i>Br J Anaesth<\/i> 1997; 79: 514\u2013516.","DOI":"10.1093\/bja\/79.4.514"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Balik M, Pachl J, Hendl J. Effect of the degree of tricuspid regurgitation on cardiac output measurements by thermodilution. <i>Intensive Care Med<\/i> 2002; 28: 1117\u20131121.","DOI":"10.1007\/s00134-002-1352-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Opotowsky AR, Hess E, Maron BA, Brittain EL, Bar\u00f3n AE, Maddox TM, et al. Thermodilution vs estimated Fick cardiac output measurement in clinical practice: An analysis of mortality from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (VA CART) program and Vanderbilt University. <i>JAMA Cardiol<\/i> 2017; 2: 1090\u20131099.","DOI":"10.1001\/jamacardio.2017.2945"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sitbon O, Humbert M, Ja\u00efs X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. <i>Circulation<\/i> 2005; 111: 3105\u20133111.","DOI":"10.1161\/CIRCULATIONAHA.104.488486"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. <i>N Engl J Med<\/i> 1992; 327: 76\u201381.","DOI":"10.1056\/NEJM199207093270203"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Montani D, Savale L, Natali D, Ja\u00efs X, Herve P, Garcia G, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. <i>Eur Heart J<\/i> 2010; 31: 1898\u20131907.","DOI":"10.1093\/eurheartj\/ehq170"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension: German PPH study group. <i>J Am Coll Cardiol<\/i> 2000; 35: 176\u2013182.","DOI":"10.1016\/S0735-1097(99)00494-5"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, et al. Assessment of the vasodilator response in primary pulmonary hypertension: Comparing prostacyclin and iloprost administered by either infusion or inhalation. <i>Eur Heart J<\/i> 2003; 24: 356\u2013365.","DOI":"10.1016\/S0195-668X(02)00302-0"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hasler ED, M\u00fcller-Mottet S, Furian M, Saxer S, Huber LC, Maggiorini M, et al. Pressure\u2013flow during exercise catheterization predicts survival in pulmonary hypertension. <i>Chest<\/i> 2016; 150: 57\u201367.","DOI":"10.1016\/j.chest.2016.02.634"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ho JE, Zern EK, Lau ES, Wooster L, Bailey CS, Cunningham T, et al. Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort. <i>J Am Coll Cardiol<\/i> 2020; 75: 17\u201326.","DOI":"10.1016\/j.jacc.2019.10.048"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Stamm A, Saxer S, Lichtblau M, Hasler ED, Jordan S, Huber LC, et al. Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. <i>Eur Respir J<\/i> 2016; 48: 1658\u20131667.","DOI":"10.1183\/13993003.00990-2016"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Montani D, Girerd B, Ja\u00efs X, Laveneziana P, Lau EM, Bouchachi A, et al. Screening for pulmonary arterial hypertension in adults carrying a <i>BMPR2<\/i> mutation. <i>Eur Respir J<\/i> 2021; 58: 204229.","DOI":"10.1183\/13993003.04229-2020"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kikuchi H, Goda A, Takeuchi K, Inami T, Kohno T, Sakata K, et al. Exercise intolerance in chronic thromboembolic pulmonary hypertension after pulmonary angioplasty. <i>Eur Respir J<\/i> 2020; 56: 1901982.","DOI":"10.1183\/13993003.01982-2019"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Naeije R, Chin K. Differentiating precapillary from postcapillary pulmonary hypertension. <i>Circulation<\/i> 2019; 140: 712\u2013714.","DOI":"10.1161\/CIRCULATIONAHA.119.040295"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. D\u2019Alto M, Romeo E, Argiento P, Motoji Y, Correra A, Di Marco GM, et al. Clinical relevance of fluid challenge in patients evaluated for pulmonary hypertension. <i>Chest<\/i> 2017; 151: 119\u2013126.","DOI":"10.1016\/j.chest.2016.08.1439"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. van de Bovenkamp AA, Wijkstra N, Oosterveer FP, Vonk Noordegraaf A, Bogaard HJ, van Rossum AC, et al. The value of passive leg raise during right heart catheterization in diagnosing heart failure with preserved ejection fraction. <i>Circ Heart Fail<\/i> 2022; 15: e008935.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008935"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, et al. Genetics and genomics of pulmonary arterial hypertension. <i>Eur Respir J<\/i> 2019; 53: 1801899.","DOI":"10.1183\/13993003.01899-2018"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Welch CL, Aldred MA, Balachandar S, Dooijes D, Eichstaedt CA, Gr\u00e4f S, et al. De\ufb01ning the clinical validity of genes reported to cause pulmonary arterial hypertension. <i>Genet Med<\/i> 2023; 25: 100925.","DOI":"10.1016\/j.gim.2023.100925"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Song J, Eichstaedt CA, Viales RR, Benjamin N, Harutyunova S, Fischer C, et al. Identi\ufb01cation of genetic defects in pulmonary arterial hypertension by a new gene panel diagnostic tool. <i>Clin Sci (Lond)<\/i> 2016; 130: 2043\u20132052.","DOI":"10.1042\/CS20160531"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Hiraide T, Kataoka M, Suzuki H, Aimi Y, Chiba T, Isobe S, et al. Poor outcomes in carriers of the <i>RNF213<\/i> variant (p.Arg4810Lys) with pulmonary arterial hypertension. <i>J Heart Lung Transplant)<\/i> 2020; 39: 103\u2013112.","DOI":"10.1016\/j.healun.2019.08.022"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Tamura Y, Kumamaru H, Abe K, Satoh T, Miyata H, Ogawa A, et al. Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: A subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR). <i>BMC Pulm Med<\/i> 2021; 21: 28.","DOI":"10.1186\/s12890-021-01398-6"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y, et al. Treatment algorithm for pulmonary arterial hypertension. <i>Eur Respir J<\/i> 2024; 64: 2401325.","DOI":"10.1183\/13993003.01325-2024"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. <i>Chest<\/i> 2006; 130: 545\u2013552.","DOI":"10.1016\/S0012-3692(15)51873-4"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Tamura Y, Kimura M, Takei M, Ono T, Kuwana M, Satoh T, et al. Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. <i>Eur Respir J<\/i> 2015; 46: 283\u2013286.","DOI":"10.1183\/09031936.00044915"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, et al. Iron de\ufb01ciency is common in idiopathic pulmonary arterial hypertension. <i>Eur Respir J<\/i> 2011; 37: 1386\u20131391.","DOI":"10.1183\/09031936.00100510"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Sonnweber T, Nairz M, Theurl I, Petzer V, Tymoszuk P, Haschka D, et al. The crucial impact of iron deficiency definition for the course of precapillary pulmonary hypertension. <i>PLoS One<\/i> 2018; 13: e0203396.","DOI":"10.1371\/journal.pone.0203396"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. van Empel VP, Lee J, Williams TJ, Kaye DM. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. <i>Heart Lung Circ<\/i> 2014; 23: 287\u2013292.","DOI":"10.1016\/j.hlc.2013.08.007"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Howard LS, He J, Watson GM, Huang L, Wharton J, Luo Q, et al. Supplementation with iron in pulmonary arterial hypertension: Two randomized crossover trials. <i>Ann Am Thorac Soc<\/i> 2021; 18: 981\u2013988.","DOI":"10.1513\/AnnalsATS.202009-1131OC"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Ruiter G, Manders E, Happ\u00e9 CM, Schalij I, Groepenhoff H, Howard LS, et al. Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron de\ufb01ciency. <i>Pulm Circ<\/i> 2015; 5: 466\u2013472.","DOI":"10.1086\/682217"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Kramer T, Wissm\u00fcller M, Natsina K, Gerhardt F, Ten Freyhaus H, Dumitrescu D, et al. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron de\ufb01ciency: A long-term study. <i>J Cachexia Sarcopenia Muscle<\/i> 2021; 12: 1501\u20131512.","DOI":"10.1002\/jcsm.12764"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: Clinical prevalence, outcomes, and mechanistic insights. <i>J Am Coll Cardiol<\/i> 2011; 58: 300\u2013309.","DOI":"10.1016\/j.jacc.2011.02.057"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Middleton JT, Maulik A, Lewis R, Kiely DG, Toshner M, Charalampopoulos A, et al. Arrhythmic burden and outcomes in pulmonary arterial hypertension. <i>Front Med (Lausanne)<\/i> 2019; 6: 169.","DOI":"10.3389\/fmed.2019.00169"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Mercurio V, Peloquin G, Bourji KI, Diab N, Sato T, Enobun B, et al. Pulmonary arterial hypertension and atrial arrhythmias: Incidence, risk factors, and clinical impact. <i>Pulm Circ<\/i> 2018; 8: 2045894018769874.","DOI":"10.1177\/2045894018769874"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Kamada H, Kaneyama J, Inoue YY, Noda T, Ueda N, Nakajima K, et al. Long term prognosis in patients with pulmonary hypertension undergoing catheter ablation for supraventricular tachycardia. <i>Sci Rep<\/i> 2021; 11: 16176.","DOI":"10.1038\/s41598-021-95508-3"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Ogawa A, Satoh T, Tamura Y, Fukuda K, Matsubara H. Survival of Japanese patients with idiopathic\/heritable pulmonary arterial hypertension. <i>Am J Cardiol<\/i> 2017; 119: 1479\u20131484.","DOI":"10.1016\/j.amjcard.2017.01.015"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Gali\u00e8 N, Barber\u00e0 JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. <i>N Engl J Med<\/i> 2015; 373: 834\u2013844.","DOI":"10.1056\/NEJMoa1413687"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Gr\u00fcnig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, et al. Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. <i>J Am Coll Cardiol<\/i> 2024; 83: 473\u2013484.","DOI":"10.1016\/j.jacc.2023.10.045"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Coghlan JG, Channick R, Chin K, Di Scala L, Gali\u00e8 N, Ghofrani HA, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: Insights from the randomized controlled GRIPHON study. <i>Am J Cardiovasc Drugs<\/i> 2018; 18: 37\u201347.","DOI":"10.1007\/s40256-017-0262-z"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Sitbon O, Ja\u00efs X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: A pilot study. <i>Eur Respir J<\/i> 2014; 43: 1691\u20131697.","DOI":"10.1183\/09031936.00116313"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Boucly A, Savale L, Ja\u00efs X, Bauer F, Bergot E, Bertoletti L, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. <i>Am J Respir Crit Care Med<\/i> 2021; 204: 842\u2013854.","DOI":"10.1164\/rccm.202009-3698OC"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Skoro-Sajer N, Lang I, Naeije R. Treprostinil for pulmonary hypertension. <i>Vasc Health Risk Manag<\/i> 2008; 4: 507\u2013513.","DOI":"10.2147\/VHRM.S2477"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Kikuchi H, Goda A, Takeuchi K, Inami T, Kohno T, Soejima K, et al. Transition from intravenous epoprostenol to treprostinil due to intolerable side effects in patients with pulmonary arterial hypertension. <i>Am J Cardiol<\/i> 2023; 206: 31\u201334.","DOI":"10.1016\/j.amjcard.2023.08.078"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, et al. Ef\ufb01cacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. <i>Chest<\/i> 2006; 129: 1636\u20131643.","DOI":"10.1378\/chest.129.6.1636"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JS, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. <i>N Engl J Med<\/i> 2023; 388: 1478\u20131490.","DOI":"10.1056\/NEJMoa2213558"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry. <i>Chest<\/i> 2010; 137: 376\u2013387.","DOI":"10.1378\/chest.09-1140"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. <i>Am J Respir Crit Care Med<\/i> 2009; 179: 151\u2013157.","DOI":"10.1164\/rccm.200806-953OC"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: A single-centre cohort. <i>Rheumatology (Oxford)<\/i> 2012; 51: 1846\u20131854.","DOI":"10.1093\/rheumatology\/kes140"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Hao YJ, Jiang X, Zhou W, Wang Y, Gao L, Wang Y, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. <i>Eur Respir J<\/i> 2014; 44: 963\u2013972.","DOI":"10.1183\/09031936.00182813"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival. <i>Arthritis Rheum<\/i> 2011; 63: 3522\u20133530.","DOI":"10.1002\/art.30541"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S, et al. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: Results from a real-life screening programme. <i>Arthritis Res Ther<\/i> 2017; 19: 42.","DOI":"10.1186\/s13075-017-1250-z"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Coghlan JG, Denton CP, Gr\u00fcnig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study. <i>Ann Rheum Dis<\/i> 2014; 73: 1340\u20131349.","DOI":"10.1136\/annrheumdis-2013-203301"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E, et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: A cohort study. <i>Arthritis Res Ther<\/i> 2013; 15: R193.","DOI":"10.1186\/ar4383"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Res Ther<\/i> 2015; 17: 7.","DOI":"10.1186\/s13075-015-0517-5"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Dumitrescu D, Nagel C, Kovacs G, Bollmann T, Halank M, Winkler J, et al. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. <i>Heart<\/i> 2017; 103: 774\u2013782.","DOI":"10.1136\/heartjnl-2016-309981"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Santaniello A, Casella R, Vicenzi M, Rota I, Montanelli G, De Santis M, et al. Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis. <i>Rheumatology (Oxford)<\/i> 2020; 59: 1581\u20131586.","DOI":"10.1093\/rheumatology\/kez473"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Hagger D, Condliffe R, Woodhouse N, Elliot CA, Armstrong IJ, Davies C, et al. Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension. <i>Rheumatology (Oxford)<\/i> 2009; 48: 1137\u20131142.","DOI":"10.1093\/rheumatology\/kep187"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Rajaram S, Swift AJ, Capener D, Elliot CA, Condliffe R, Davies C, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. <i>J Rheumatol<\/i> 2012; 39: 1265\u20131274.","DOI":"10.3899\/jrheum.110987"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Rallidis LS, Papangelopoulou K, Anthi A, Tsangaris I, Varounis C, Makavos G, et al. The role of exercise Doppler echocardiography to unmask pulmonary arterial hypertension in selected patients with systemic sclerosis and equivocal baseline echocardiographic values for pulmonary hypertension. <i>Diagnostics (Basel)<\/i> 2021; 11: 1200.","DOI":"10.3390\/diagnostics11071200"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Sanchez O, Sitbon O, Ja\u00efs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. <i>Chest<\/i> 2006; 130: 182\u2013189.","DOI":"10.1378\/chest.130.1.182"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Rhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM. Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. <i>Am J Respir Crit Care Med<\/i> 2015; 192: 1111\u20131117.","DOI":"10.1164\/rccm.201507-1456OC"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H, et al. Risk stratification and treatment goals in pulmonary arterial hypertension. <i>Eur Respir J<\/i> 2024; 64: 2401323.","DOI":"10.1183\/13993003.01323-2024"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Gali\u00e8 N, et al. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Eur J Heart Fail<\/i> 2022; 24: 205\u2013214.","DOI":"10.1002\/ejhf.2369"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Gali\u00e8 N, Barber\u00e0 JA, et al. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. <i>J Heart Lung Transplant<\/i> 2019; 38: 1286\u20131295.","DOI":"10.1016\/j.healun.2019.09.010"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, et al. Phenotyping of idiopathic pulmonary arterial hypertension: A registry analysis. <i>Lancet Respir Med<\/i> 2022; 10: 937\u2013948.","DOI":"10.1016\/S2213-2600(22)00097-2"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Maron BA, Bortman G, De Marco T, Huston JH, Lang IM, Rosenkranz SH, et al. Pulmonary hypertension associated with left heart disease. <i>Eur Respir J<\/i> 2024; 64: 2401344.","DOI":"10.1183\/13993003.01344-2024"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Tamura Y, Kumamaru H, Satoh T, Miyata H, Ogawa A, Tanabe N, et al. Effectiveness and outcome of pulmonary arterial hypertension-speci\ufb01c therapy in Japanese patients with pulmonary arterial hypertension. <i>Circ J<\/i> 2017; 82: 275\u2013282.","DOI":"10.1253\/circj.CJ-17-0139"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Hoeper MM, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, et al. Randomized, multicenter study to assess the effects of different doses of sildenafil on mortality in adults with pulmonary arterial hypertension. <i>Circulation<\/i> 2024; 149: 1949\u20131959.","DOI":"10.1161\/CIRCULATIONAHA.123.068107"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Tokunaga N, Ogawa A, Ito H, Matsubara H. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. <i>J Cardiol<\/i> 2016; 68: 542\u2013547.","DOI":"10.1016\/j.jjcc.2015.11.012"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Kuwana M, et al. Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension. <i>PLoS One<\/i> 2015; 10: e0121894.","DOI":"10.1371\/journal.pone.0121894"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Blette BS, Moutchia J, Al-Naamani N, Ventetuolo CE, Cheng C, Appleby D, et al. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials. <i>Lancet Respir Med<\/i> 2023; 11: 873\u2013882.","DOI":"10.1016\/S2213-2600(23)00155-8"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, et al. Predicting survival in patients with pulmonary arterial hypertension: The REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies. <i>Chest<\/i> 2019; 156: 323\u2013337.","DOI":"10.1016\/j.chest.2019.02.004"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. <i>Circulation<\/i> 2018; 137: 693\u2013704.","DOI":"10.1161\/CIRCULATIONAHA.117.029254"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Badagliacca R, D\u2019Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, et al. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. <i>Am J Respir Crit Care Med<\/i> 2021; 203: 484\u2013492.","DOI":"10.1164\/rccm.202004-1006OC"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. D\u2019Alto M, Badagliacca R, Argiento P, Romeo E, Farro A, Papa S, et al. Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. <i>Chest<\/i> 2020; 157: 376\u2013383.","DOI":"10.1016\/j.chest.2019.09.009"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Gali\u00e8 N, et al. Selexipag for the treatment of pulmonary arterial hypertension. <i>N Engl J Med<\/i> 2015; 373: 2522\u20132533.","DOI":"10.1056\/NEJMoa1503184"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JS, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): A multicentre, open-label, randomised controlled trial. <i>Lancet Respir Med<\/i> 2021; 9: 573\u2013584.","DOI":"10.1016\/S2213-2600(20)30532-4"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. <i>N Engl J Med<\/i> 1998; 338: 273\u2013277.","DOI":"10.1056\/NEJM199801293380501"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Akagi S, Matsubara H, Nakamura K, Ito H. Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension. <i>J Cardiol<\/i> 2018; 72: 466\u2013472.","DOI":"10.1016\/j.jjcc.2018.04.014"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Picken C, Fragkos KC, Eddama M, Coghlan G, Clapp LH. Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: A systematic review and meta-analysis. <i>J Clin Med<\/i> 2019; 8: 481.","DOI":"10.3390\/jcm8040481"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Shirai Y, Tamura Y, Yasuoka H, Satoh T, Kuwana M. IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment. <i>Eur Respir J<\/i> 2014; 43: 1516\u20131519.","DOI":"10.1183\/09031936.00144013"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Souza R, Badesch DB, Ghofrani HA, Gibbs JS, Gomberg-Maitland M, McLaughlin VV, et al. Effects of sotatercept on haemodynamics and right heart function: Analysis of the STELLAR trial. <i>Eur Respir J<\/i> 2023; 62: 2301107.","DOI":"10.1183\/13993003.01107-2023"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Launay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: A rare complication of primary Sj\u00f6gren syndrome: Report of 9 new cases and review of the literature. <i>Medicine (Baltimore)<\/i> 2007; 86: 299\u2013315.","DOI":"10.1097\/MD.0b013e3181579781"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Jais X, Launay D, Yaici A, Le Pavec J, Tch\u00e9rakian C, Sitbon O, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases. <i>Arthritis Rheum<\/i> 2008; 58: 521\u2013531.","DOI":"10.1002\/art.23303"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, Ishii T, Satoh K, Miura Y, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. <i>Circ J<\/i> 2011; 75: 2668\u20132674.","DOI":"10.1253\/circj.CJ-11-0473"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. Kommireddy S, Bhyravavajhala S, Kurimeti K, Chennareddy S, Kanchinadham S, Rajendra Vara Prasad I, et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: An observational study. <i>Rheumatology (Oxford)<\/i> 2015; 54: 1673\u20131679.","DOI":"10.1093\/rheumatology\/kev097"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111. Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M. Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. <i>Circ J<\/i> 2018; 82: 546\u2013554.","DOI":"10.1253\/circj.CJ-17-0351"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112. Kato M, Kataoka H, Odani T, Fujieda Y, Otomo K, Oku K, et al. The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: Report of five cases and a literature review. <i>Lupus<\/i> 2011; 20: 1047\u20131056.","DOI":"10.1177\/0961203311403347"},{"key":"113","unstructured":"113. \u65e5\u672c\u80ba\u9ad8\u8840\u5727\u30fb\u80ba\u5faa\u74b0\u5b66\u4f1a. \u7d50\u5408\u7d44\u7e54\u75c5\u306b\u4f34\u3046\u80ba\u52d5\u8108\u6027\u80ba\u9ad8\u8840\u5727\u75c7\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. 2019."},{"key":"114","unstructured":"114. \u539a\u751f\u52b4\u50cd\u79d1\u5b66\u7814\u7a76\u8cbb\u88dc\u52a9\u91d1\u96e3\u6cbb\u6027\u75be\u60a3\u7b49\u653f\u7b56\u7814\u7a76\u4e8b\u696d \u81ea\u5df1\u514d\u75ab\u75be\u60a3\u306b\u95a2\u3059\u308b\u8abf\u67fb\u7814\u7a76 (\u81ea\u5df1\u514d\u75ab\u73ed), \u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a \u7de8. \u5168\u8eab\u6027\u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 2019. \u5357\u5c71\u5802 2019."},{"key":"115","unstructured":"115. \u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a. \u76ae\u819a\u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9\u304a\u3088\u3073\u5168\u8eab\u6027\u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9\u306b\u5bfe\u3059\u308b\u30d2\u30c9\u30ed\u30ad\u30b7\u30af\u30ed\u30ed\u30ad\u30f3\u4f7f\u7528\u306e\u305f\u3081\u306e\u7c21\u6613\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. 2015."},{"key":"116","unstructured":"116. \u53e4\u5ddd\u798f\u5b9f, \u885b\u85e4\u5149, \u8c37\u5ddd\u745b\u5b50, \u4ed6. \u30d2\u30c9\u30ed\u30ad\u30b7\u30af\u30ed\u30ed\u30ad\u30f3\u9069\u6b63\u4f7f\u7528\u306e\u624b\u5f15\u304d. \u65e5\u672c\u76ae\u819a\u79d1\u5b66\u4f1a\u96d1\u8a8c 2015; <b>125:<\/b> 2049\u20132060."},{"key":"117","unstructured":"117. \u8fd1\u85e4\u5cf0\u751f, \u7be0\u7530\u5553, \u677e\u672c\u60e3\u4e00, \u4ed6. \u30d2\u30c9\u30ed\u30ad\u30b7\u30af\u30ed\u30ed\u30ad\u30f3\u9069\u6b63\u4f7f\u7528\u306e\u305f\u3081\u306e\u624b\u5f15\u304d. \u65e5\u672c\u773c\u79d1\u5b66\u4f1a\u96d1\u8a8c 2016; <b>120:<\/b> 419\u2013428."},{"key":"118","unstructured":"118. \u65e5\u672c\u809d\u81d3\u5b66\u4f1a, \u65e5\u672c\u9580\u8108\u5727\u4ea2\u9032\u75c7\u5b66\u4f1a. \u9580\u8108\u5727\u4ea2\u9032\u75c7\u306e\u8a3a\u7642\u30ac\u30a4\u30c9 2022. \u6587\u5149\u5802 2022."},{"key":"119","unstructured":"119. \u65e5\u672c\u9580\u8108\u5727\u4ea2\u9032\u75c7\u5b66\u4f1a. \u9580\u8108\u5727\u4ea2\u9032\u75c7\u53d6\u6271\u3044\u898f\u7d04 \u7b2c4\u7248. \u91d1\u539f\u51fa\u7248 2022."},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, et al. Sildenafil treatment for portopulmonary hypertension. <i>Eur Respir J<\/i> 2006; 28: 563\u2013567.","DOI":"10.1183\/09031936.06.00030206"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. Savale L, Magnier R, Le Pavec J, Ja\u00efs X, Montani D, O\u2019Callaghan DS, et al. Ef\ufb01cacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. <i>Eur Respir J<\/i> 2013; 41: 96\u2013103.","DOI":"10.1183\/09031936.00117511"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122. Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety and ef\ufb01cacy of ambrisentan for the treatment of portopulmonary hypertension. <i>Chest<\/i> 2011; 139: 109\u2013114.","DOI":"10.1378\/chest.10-0574"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, et al. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. <i>J Heart Lung Transplant<\/i> 2020; 39: 464\u2013472.","DOI":"10.1016\/j.healun.2019.12.008"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124. Sitbon O, Bosch J, Cottreel E, Csonka D, De Groote P, Hoeper MM, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): A multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. <i>Lancet Respir Med<\/i> 2019; 7: 594\u2013604.","DOI":"10.1016\/S2213-2600(19)30091-8"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125. Tamura Y, Tamura Y, Taniguchi Y, Tsujino I, Inami T, Matsubara H, et al. Clinical management and outcomes of patients with portopulmonary hypertension enrolled in the Japanese multicenter registry. <i>Circ Rep<\/i> 2022; 4: 542\u2013549.","DOI":"10.1253\/circrep.CR-22-0098"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. <i>Liver Transpl<\/i> 2000; 6: 443\u2013450.","DOI":"10.1053\/jlts.2000.6356"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. Savale L, Sattler C, Coilly A, Conti F, Renard S, Francoz C, et al. Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology<\/i> 2017; 65: 1683\u20131692.","DOI":"10.1002\/hep.28990"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128. Egidy Assenza G, Krieger EV, Baumgartner H, Cupido B, Dimopoulos K, Louis C, et al. AHA\/ACC vs ESC Guidelines for management of adults with congenital heart disease: JACC Guideline comparison. <i>J Am Coll Cardiol<\/i> 2021; 78: 1904\u20131918.","DOI":"10.1016\/j.jacc.2021.09.010"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129. Brida M, Gatzoulis MA. Pulmonary arterial hypertension in adult congenital heart disease. <i>Heart<\/i> 2018; 104: 1568\u20131574.","DOI":"10.1136\/heartjnl-2017-312106"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130. Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: A review. <i>JAMA<\/i> 2022; 327: 1379\u20131391.","DOI":"10.1001\/jama.2022.4402"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131. Xu Z, Gatzoulis MA, Dimopoulos K, Li Q, Zhang C, Keller BB, et al. Better outcomes in pulmonary arterial hypertension after repair of congenital heart disease, compared with idiopathic pulmonary arterial hypertension. <i>CJC Open<\/i> 2021; 3: 872\u2013879.","DOI":"10.1016\/j.cjco.2021.02.010"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132. Van Bulck L, Goossens E, Morin L, Luyckx K, Ombelet F, Willems R, et al. Last year of life of adults with congenital heart diseases: Causes of death and patterns of care. <i>Eur Heart J<\/i> 2022; 43: 4483\u20134492.","DOI":"10.1093\/eurheartj\/ehac484"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133. Miranda WR, Aboulhosn JA, Hagler DJ. Catheterization in adults with congenital heart disease: A primer for the noncongenital proceduralist. <i>JACC Cardiovasc Interv<\/i> 2022; 15: 907\u2013921.","DOI":"10.1016\/j.jcin.2021.12.020"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134. Takaya Y, Akagi T, Sakamoto I, Kanazawa H, Nakazawa G, Murakami T, et al. Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension. <i>Heart<\/i> 2022; 108: 382\u2013387.","DOI":"10.1136\/heartjnl-2021-319096"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135. Akagi S, Kasahara S, Sarashina T, Nakamura K, Ito H. Treat-and-repair strategy is a feasible therapeutic choice in adult patients with severe pulmonary arterial hypertension associated with a ventricular septal defect: Case series. <i>Eur Heart J Case Rep<\/i> 2018; 2: yty033.","DOI":"10.1093\/ehjcr\/yty033"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136. Kijima Y, Akagi T, Takaya Y, Akagi S, Nakagawa K, Kusano K, et al. Treat and repair strategy in patients with atrial septal defect and signi\ufb01cant pulmonary arterial hypertension. <i>Circ J<\/i> 2016; 80: 227\u2013234.","DOI":"10.1253\/circj.CJ-15-0599"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137. Akagi S, Kasahara S, Akagi T, Nakamura K, Ito H. Medical and surgical management of a pulmonary hypertensive adult patient with unrepaired complex congenital heart disease: A case report. <i>J Congenit Cardiol<\/i> 2020; 4: 2.","DOI":"10.1186\/s40949-020-00033-z"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. <i>Am J Respir Crit Care Med<\/i> 2003; 167: 1433\u20131439.","DOI":"10.1164\/rccm.200204-330OC"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139. Degano B, Guillaume M, Savale L, Montani D, Ja\u00efs X, Yaici A, et al. HIV-associated pulmonary arterial hypertension: Survival and prognostic factors in the modern therapeutic era. <i>AIDS<\/i> 2010; 24: 67\u201375.","DOI":"10.1097\/QAD.0b013e328331c65e"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. <i>Heart<\/i> 2006; 92: 1164\u20131166.","DOI":"10.1136\/hrt.2005.076794"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141. Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, et al. Pulmonary arterial hypertension related to HIV infection: Improved hemodynamics and survival associated with antiretroviral therapy. <i>Clin Infect Dis<\/i> 2004; 38: 1178\u20131185.","DOI":"10.1086\/383037"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. <i>Am J Respir Crit Care Med<\/i> 2004; 170: 1212\u20131217.","DOI":"10.1164\/rccm.200404-445OC"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143. Degano B, Ya\u00efci A, Le Pavec J, Savale L, Ja\u00efs X, Camara B, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. <i>Eur Respir J<\/i> 2009; 33: 92\u201398.","DOI":"10.1183\/09031936.00094808"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144. Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. <i>AIDS<\/i> 2002; 16: 1568\u20131569.","DOI":"10.1097\/00002030-200207260-00021"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. <i>AIDS<\/i> 2001; 15: 1747\u20131748.","DOI":"10.1097\/00002030-200109070-00026"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, et al. <i>EIF2AK4<\/i> mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. <i>Nat Genet<\/i> 2014; 46: 65\u201369.","DOI":"10.1038\/ng.2844"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147. Montani D, Girerd B, Ja\u00efs X, Levy M, Amar D, Savale L, et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: A population-based study. <i>Lancet Respir Med<\/i> 2017; 5: 125\u2013134.","DOI":"10.1016\/S2213-2600(16)30438-6"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148. Hadinnapola C, Bleda M, Haimel M, Screaton N, Swift A, Dorfm\u00fcller P, et al. Phenotypic characterization of <i>EIF2AK4<\/i> mutation carriers in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. <i>Circulation<\/i> 2017; 136: 2022\u20132023.","DOI":"10.1161\/CIRCULATIONAHA.118.033970"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149. Montani D, Achouh L, Dorfm\u00fcller P, Le Pavec J, Sztrymf B, Tch\u00e9rakian C, et al. Pulmonary veno-occlusive disease: Clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. <i>Medicine (Baltimore)<\/i> 2008; 87: 220\u2013233.","DOI":"10.1097\/MD.0b013e31818193bb"},{"key":"150","unstructured":"150. \u539a\u751f\u52b4\u50cd\u7701 \u96e3\u6cbb\u6027\u547c\u5438\u5668\u75be\u60a3\u30fb\u80ba\u9ad8\u8840\u5727\u75c7\u306b\u95a2\u3059\u308b\u8abf\u67fb\u7814\u7a76\u73ed. \u80ba\u9759\u8108\u9589\u585e\u75c7\/\u80ba\u6bdb\u7d30\u8840\u7ba1\u816b\u75c7\u306e\u6982\u8981\u30fb\u8a3a\u65ad\u57fa\u6e96. https:\/\/www.nanbyou.or.jp\/wp-content\/uploads\/upload_files\/File\/087-202404-kijyun.pdf (accessed January 22, 2026)."},{"key":"151","doi-asserted-by":"crossref","unstructured":"151. Resten A, Maitre S, Humbert M, Rabiller A, Sitbon O, Capron F, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. <i>AJR Am J Roentgenol<\/i> 2004; 183: 65\u201370.","DOI":"10.2214\/ajr.183.1.1830065"},{"key":"152","doi-asserted-by":"crossref","unstructured":"152. Holcomb BW Jr, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: A case series and new observations. <i>Chest<\/i> 2000; 118: 1671\u20131679.","DOI":"10.1378\/chest.67.4.487"},{"key":"153","doi-asserted-by":"crossref","unstructured":"153. Rabiller A, Ja\u00efs X, Hamid A, Resten A, Parent F, Haque R, et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. <i>Eur Respir J<\/i> 2006; 27: 108\u2013113.","DOI":"10.1183\/09031936.06.00054105"},{"key":"154","doi-asserted-by":"crossref","unstructured":"154. Ogawa A, Miyaji K, Yamadori I, Shinno Y, Miura A, Kusano KF, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. <i>Circ J<\/i> 2012; 76: 1729\u20131736.","DOI":"10.1253\/circj.CJ-11-0973"},{"key":"155","doi-asserted-by":"crossref","unstructured":"155. Montani D, Ja\u00efs X, Price LC, Achouh L, Degano B, Mercier O, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. <i>Eur Respir J<\/i> 2009; 34: 1348\u20131356.","DOI":"10.1183\/09031936.00017809"},{"key":"156","doi-asserted-by":"crossref","unstructured":"156. Ogawa A, Miyaji K, Matsubara H. Ef\ufb01cacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. <i>Respir Med<\/i> 2017; 131: 215\u2013219.","DOI":"10.1016\/j.rmed.2017.08.032"},{"key":"157","unstructured":"157. \u80ba\u79fb\u690d\u95a2\u9023\u5b66\u4f1a\u5354\u8b70\u4f1a. \u80ba\u79fb\u690d\u30ec\u30b7\u30d4\u30a8\u30f3\u30c8\u306e\u9069\u5fdc\u57fa\u6e96 (\u80ba\u79fb\u690d\u95a2\u9023\u5b66\u4f1a\u5354\u8b70\u4f1a 2023\u5e74). https:\/\/www2.idac.tohoku.ac.jp\/dep\/surg\/shinpai\/kanren\/ (accessed January 22, 2026)."},{"key":"158","unstructured":"158. \u65e5\u672c\u79fb\u690d\u5b66\u4f1a. 2022\u81d3\u5668\u79fb\u690d\u30d5\u30a1\u30af\u30c8\u30d6\u30c3\u30af. https:\/\/www.asas.or.jp\/jst\/pdf\/factbook\/factbook2022.pdf (accessed January 22, 2026)."},{"key":"159","unstructured":"159. \u65e5\u672c\u80ba\u304a\u3088\u3073\u5fc3\u80ba\u79fb\u690d\u7814\u7a76\u4f1a. \u672c\u90a6\u306b\u304a\u3051\u308b\u80ba\u79fb\u690d\u306e\u73fe\u72b6\u2015\u80ba\u304a\u3088\u3073\u5fc3\u80ba\u79fb\u690d\u7814\u7a76\u4f1aRegistry Report\u2015. https:\/\/www2.idac.tohoku.ac.jp\/dep\/surg\/shinpai\/wp-content\/uploads\/sites\/3\/2026\/04\/\u80ba\u79fb\u690d\u30ec\u30b8\u30b9\u30c8\u30ea\u30fc2026_ver.20260420-PDF.pdf (accessed June 1, 2026)."},{"key":"160","doi-asserted-by":"crossref","unstructured":"160. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014 \u2013 an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. <i>J Heart Lung Transplant<\/i> 2015; 34: 1\u201315.","DOI":"10.1016\/j.healun.2014.06.014"},{"key":"161","doi-asserted-by":"crossref","unstructured":"161. Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. <i>J Heart Lung Transplant<\/i> 2021; 40: 1349\u20131379.","DOI":"10.1016\/j.healun.2021.07.005"},{"key":"162","doi-asserted-by":"crossref","unstructured":"162. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary arterial hypertension Disease Management (REVEAL). <i>Circulation<\/i> 2010; 122: 164\u2013172.","DOI":"10.1161\/CIRCULATIONAHA.109.898122"},{"key":"163","doi-asserted-by":"crossref","unstructured":"163. Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). <i>Eur Heart J<\/i> 2016; 37: 67\u2013119.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"164","doi-asserted-by":"crossref","unstructured":"164. Vachi\u00e9ry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. <i>Eur Respir J<\/i> 2019; 53: 1801897.","DOI":"10.1183\/13993003.01897-2018"},{"key":"165","doi-asserted-by":"crossref","unstructured":"165. Pieske B, Tsch\u00f6pe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>Eur Heart J<\/i> 2019; 40: 3297\u20133317.","DOI":"10.1093\/eurheartj\/ehz641"},{"key":"166","doi-asserted-by":"crossref","unstructured":"166. Churchill TW, Li SX, Curreri L, Zern EK, Lau ES, Liu EE, et al. Evaluation of 2 existing diagnostic scores for heart failure with preserved ejection fraction against a comprehensively phenotyped cohort. <i>Circulation<\/i> 2021; 143: 289\u2013291.","DOI":"10.1161\/CIRCULATIONAHA.120.050757"},{"key":"167","doi-asserted-by":"crossref","unstructured":"167. Reddy YN, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. <i>Circulation<\/i> 2018; 138: 861\u2013870.","DOI":"10.1161\/CIRCULATIONAHA.118.034646"},{"key":"168","unstructured":"168. \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a, \u65e5\u672c\u5fc3\u4e0d\u5168\u5b66\u4f1a. 2025\u5e74\u6539\u8a02\u7248 \u5fc3\u4e0d\u5168\u8a3a\u7642\u30ac\u30a4 \u30c9 \u30e9 \u30a4 \u30f3. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2025\/03\/JCS2025_Kato.pdf (accessed January 22, 2026)."},{"key":"169","doi-asserted-by":"crossref","unstructured":"169. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). <i>Am Heart J<\/i> 1997; 134: 44\u201354.","DOI":"10.1016\/S0002-8703(97)70105-4"},{"key":"170","doi-asserted-by":"crossref","unstructured":"170. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: Results of a pilot study. <i>J Card Fail<\/i> 2005; 11: 12\u201320.","DOI":"10.1016\/j.cardfail.2004.05.006"},{"key":"171","doi-asserted-by":"crossref","unstructured":"171. Guazzi M. Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. <i>Circ Heart Fail<\/i> 2008; 1: 272\u2013280.","DOI":"10.1161\/CIRCHEARTFAILURE.108.802116"},{"key":"172","doi-asserted-by":"crossref","unstructured":"172. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. <i>Circulation<\/i> 2013; 128: 502\u2013511.","DOI":"10.1161\/CIRCULATIONAHA.113.001458"},{"key":"173","doi-asserted-by":"crossref","unstructured":"173. Koller B, Steringer-Mascherbauer R, Ebner CH, Weber T, Ammer M, Eichinger J, et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-Trial). <i>Heart Lung Circ<\/i> 2017; 26: 433\u2013441.","DOI":"10.1016\/j.hlc.2016.09.004"},{"key":"174","doi-asserted-by":"crossref","unstructured":"174. Vachi\u00e9ry JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. <i>Eur Respir J<\/i> 2018; 51: 1701886.","DOI":"10.1183\/13993003.01886-2017"},{"key":"175","doi-asserted-by":"crossref","unstructured":"175. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. <i>JAMA<\/i> 2013; 309: 1268\u20131277.","DOI":"10.1001\/jama.2013.2024"},{"key":"176","doi-asserted-by":"crossref","unstructured":"176. Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: A randomized open-label pilot study. <i>BMC Cardiovasc Disord<\/i> 2020; 20: 408.","DOI":"10.1186\/s12872-020-01671-2"},{"key":"177","doi-asserted-by":"crossref","unstructured":"177. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. <i>Circulation<\/i> 2011; 124: 164\u2013174.","DOI":"10.1161\/CIRCULATIONAHA.110.983866"},{"key":"178","doi-asserted-by":"crossref","unstructured":"178. Dachs TM, Duca F, Rettl R, Binder-Rodriguez C, Dalos D, Ligios LC, et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: The haemoDYNAMIC trial. <i>Eur Heart J<\/i> 2022; 43: 3402\u20133413.","DOI":"10.1093\/eurheartj\/ehac389"},{"key":"179","doi-asserted-by":"crossref","unstructured":"179. Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): A randomised, multicentre, blinded, sham-controlled trial. <i>Lancet<\/i> 2022; 399: 1130\u20131140.","DOI":"10.1016\/S0140-6736(22)00016-2"},{"key":"180","doi-asserted-by":"crossref","unstructured":"180. Davies MG, Miserlis D, Hart JP. Current status of pulmonary artery denervation. <i>Front Cardiovasc Med<\/i> 2022; 9: 972256.","DOI":"10.3389\/fcvm.2022.972256"},{"key":"181","doi-asserted-by":"crossref","unstructured":"181. Zhang H, Zhang J, Chen M, Xie DJ, Kan J, Yu W, et al. Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: The PADN-5 Study. <i>JACC Cardiovasc Interv<\/i> 2019; 12: 274\u2013284.","DOI":"10.1016\/j.jcin.2018.09.021"},{"key":"182","doi-asserted-by":"crossref","unstructured":"182. Gaemperli O, Moccetti M, Surder D, Biaggi P, Hurlimann D, Kretschmar O, et al. Acute haemodynamic changes after percutaneous mitral valve repair: Relation to mid-term outcomes. <i>Heart<\/i> 2012; 98: 126\u2013132.","DOI":"10.1136\/heartjnl-2011-300705"},{"key":"183","doi-asserted-by":"crossref","unstructured":"183. O\u2019Sullivan CJ, Wenaweser P, Ceylan O, Rat-Wirtzler J, Stortecky S, Heg D, et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: Insights from the new proposed pulmonary hypertension classification. <i>Circ Cardiovasc Interv<\/i> 2015; 8: e002358.","DOI":"10.1161\/CIRCINTERVENTIONS.114.002358"},{"key":"184","doi-asserted-by":"crossref","unstructured":"184. Tigges E, Blankenberg S, von Bardeleben RS, Z\u00fcrn C, Bekeredjian R, Ouarrak T, et al. Implication of pulmonary hypertension in patients undergoing MitraClip therapy: Results from the German transcatheter mitral valve interventions (TRAMI) registry. <i>Eur J Heart Fail<\/i> 2018; 20: 585\u2013594.","DOI":"10.1002\/ejhf.864"},{"key":"185","unstructured":"185. \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a, \u65e5\u672c\u80f8\u90e8\u5916\u79d1\u5b66\u4f1a, \u65e5\u672c\u8840\u7ba1\u5916\u79d1\u5b66\u4f1a, \u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u5916\u79d1\u5b66\u4f1a. 2020\u5e74\u6539\u8a02\u7248 \u5f01\u819c\u75c7\u6cbb\u7642\u306e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2020\/04\/JCS2020_Izumi_Eishi.pdf (accessed January 22, 2026)."},{"key":"186","doi-asserted-by":"crossref","unstructured":"186. Zlotnick DM, Ouellette ML, Malenka DJ, DeSimone JP, Leavitt BJ, Helm RE, et al. Effect of preoperative pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. <i>Am J Cardiol<\/i> 2013; 112: 1635\u20131640.","DOI":"10.1016\/j.amjcard.2013.07.025"},{"key":"187","doi-asserted-by":"crossref","unstructured":"187. Melby SJ, Moon MR, Lindman BR, Bailey MS, Hill LL, Damiano RJ. Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. <i>J Thorac Cardiovasc Surg<\/i> 2011; 141: 1424\u20131430.","DOI":"10.1016\/j.jtcvs.2011.02.028"},{"key":"188","doi-asserted-by":"crossref","unstructured":"188. Lu\u00e7on A, Oger E, Bedossa M, Boulmier D, Verhoye JP, Eltchaninoff H, et al. Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: Study from the France 2 Registry. <i>Circ Cardiovasc Interv<\/i> 2014; 7: 240\u2013247.","DOI":"10.1161\/CIRCINTERVENTIONS.113.000482"},{"key":"189","doi-asserted-by":"crossref","unstructured":"189. Faggiano P, Antonini-Canterin F, Ribichini F, D\u2019Aloia A, Ferrero V, Cervesato E, et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. <i>Am J Cardiol<\/i> 2000; 85: 204\u2013208.","DOI":"10.1016\/S0002-9149(99)00643-8"},{"key":"190","doi-asserted-by":"crossref","unstructured":"190. Zuern CS, Eick C, Rizas K, Stoleriu C, Woernle B, Wildhirt S, et al. Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. <i>Clin Res Cardiol<\/i> 2012; 101: 81\u201388.","DOI":"10.1007\/s00392-011-0367-3"},{"key":"191","doi-asserted-by":"crossref","unstructured":"191. Roques F, Nashef SA, Michel P, Gauducheau E, De Vincentiis C, Baudet E, et al. Risk factors and outcome in European cardiac surgery: Analysis of the EuroSCORE multinational database of 19030 patients. <i>Eur J Cardiothorac Surg<\/i> 1999; 15: 816\u2013822.","DOI":"10.1016\/S1010-7940(99)00106-2"},{"key":"192","doi-asserted-by":"crossref","unstructured":"192. Bermejo J, Yotti R, Garc\u00eda-Orta R, S\u00e1nchez-Fern\u00e1ndez PL, Casta\u00f1o M, Segovia-Cubero J, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial. <i>Eur Heart J<\/i> 2018; 39: 1255\u20131264.","DOI":"10.1093\/eurheartj\/ehx700"},{"key":"193","doi-asserted-by":"crossref","unstructured":"193. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S, et al. Ventilatory and cardiocirculatory exercise pro\ufb01les in COPD: The role of pulmonary hypertension. <i>Chest<\/i> 2012; 142: 1166\u20131174.","DOI":"10.1378\/chest.11-2798"},{"key":"194","doi-asserted-by":"crossref","unstructured":"194. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. <i>Eur Respir J<\/i> 2019; 53: 1801914.","DOI":"10.1183\/13993003.01914-2018"},{"key":"195","doi-asserted-by":"crossref","unstructured":"195. Kovacs G, Agusti A, Barber\u00e0 JA, Celli B, Criner G, Humbert M, et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease: Is there a pulmonary vascular phenotype? <i>Am J Respir Crit Care Med<\/i> 2018; 198: 1000\u20131011.","DOI":"10.1164\/rccm.201801-0095PP"},{"key":"196","doi-asserted-by":"crossref","unstructured":"196. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. <i>Am J Respir Crit Care Med<\/i> 2003; 167: 735\u2013740.","DOI":"10.1164\/rccm.200210-1130OC"},{"key":"197","doi-asserted-by":"crossref","unstructured":"197. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. <i>Am J Respir Crit Care Med<\/i> 2009; 179: 615\u2013621.","DOI":"10.1164\/rccm.200811-1691OC"},{"key":"198","doi-asserted-by":"crossref","unstructured":"198. Bax S, Bredy C, Kempny A, Dimopoulos K, Devaraj A, Walsh S, et al. A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. <i>ERJ Open Res<\/i> 2018; 4: 00124\u20132017.","DOI":"10.1183\/23120541.00124-2017"},{"key":"199","doi-asserted-by":"crossref","unstructured":"199. Olsson KM, Hoeper MM, Pausch C, Gr\u00fcnig E, Huscher D, Pittrow D, et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: Results from the COMPERA registry. <i>Eur Respir J<\/i> 2021; 58: 2101483.","DOI":"10.1183\/13993003.01483-2021"},{"key":"200","doi-asserted-by":"crossref","unstructured":"200. Tanabe N, Kumamaru H, Tamura Y, Taniguchi H, Emoto N, Yamada Y, et al. Multi-institutional prospective cohort study of patients with pulmonary hypertension associated with respiratory diseases. <i>Circ J<\/i> 2021; 85: 333\u2013342.","DOI":"10.1253\/circj.CJ-20-0939"},{"key":"201","doi-asserted-by":"crossref","unstructured":"201. Zeder K, Avian A, Bachmaier G, Douschan P, Foris V, Sassmann T, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. <i>Eur Respir J<\/i> 2021; 58: 2100944.","DOI":"10.1183\/13993003.00944-2021"},{"key":"202","doi-asserted-by":"crossref","unstructured":"202. Rahaghi FF, Kolaitis NA, Adegunsoye A, De Andrade JA, Flaherty KR, Lancaster LH, et al. Screening strategies for pulmonary hypertension in patients with interstitial lung disease: A multidisciplinary Delphi Study. <i>Chest<\/i> 2022; 162: 145\u2013155.","DOI":"10.1016\/j.chest.2022.02.012"},{"key":"203","doi-asserted-by":"crossref","unstructured":"203. Ruocco G, Cekorja B, Rottoli P, Refini RM, Pellegrini M, Di Tommaso C, et al. Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model. <i>Respir Med<\/i> 2015; 109: 406\u2013415.","DOI":"10.1016\/j.rmed.2014.12.011"},{"key":"204","doi-asserted-by":"crossref","unstructured":"204. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary \ufb01brosis (an update) and progressive pulmonary \ufb01brosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. <i>Am J Respir Crit Care Med<\/i> 2022; 205: e18\u2013e47.","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"205","doi-asserted-by":"crossref","unstructured":"205. Saggar R, Khanna D, Vaidya A, Derhovanessian A, Maranian P, Duffy E, et al. Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. <i>Thorax<\/i> 2014; 69: 123\u2013129.","DOI":"10.1136\/thoraxjnl-2013-204150"},{"key":"206","doi-asserted-by":"crossref","unstructured":"206. Zimmermann GS, von Wulffen W, Huppmann P, Meis T, Ihle F, Geiseler J, et al. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. <i>Respirology<\/i> 2014; 19: 700\u2013706.","DOI":"10.1111\/resp.12294"},{"key":"207","doi-asserted-by":"crossref","unstructured":"207. Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. <i>Am J Respir Crit Care Med<\/i> 2014; 190: 208\u2013217.","DOI":"10.1164\/rccm.201403-0446OC"},{"key":"208","doi-asserted-by":"crossref","unstructured":"208. Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A, et al. Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias. <i>PLoS One<\/i> 2015; 10: e0141911.","DOI":"10.1371\/journal.pone.0141911"},{"key":"209","doi-asserted-by":"crossref","unstructured":"209. Suzuki Y, Nagaoka T, Terayama Y, Nagata Y, Yoshida T, Tsutsumi T, et al. Prognostic analysis of pulmonary hypertension with lung parenchymal lesion: Comparison of mortality with and without connective tissue disease. <i>Respir Investig<\/i> 2024; 62: 167\u2013175.","DOI":"10.1016\/j.resinv.2023.11.006"},{"key":"210","doi-asserted-by":"crossref","unstructured":"210. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. <i>Lancet<\/i> 2002; 360: 895\u2013900.","DOI":"10.1016\/S0140-6736(02)11024-5"},{"key":"211","doi-asserted-by":"crossref","unstructured":"211. Tanabe N, Taniguchi H, Tsujino I, Sakamaki F, Emoto N, Kimura H, et al. Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. <i>Respirology<\/i> 2015; 20: 805\u2013812.","DOI":"10.1111\/resp.12530"},{"key":"212","doi-asserted-by":"crossref","unstructured":"212. Dawes TJ, McCabe C, Dimopoulos K, Stewart I, Bax S, Harries C, et al. Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. <i>Respirology<\/i> 2023; 28: 262\u2013272.","DOI":"10.1111\/resp.14378"},{"key":"213","doi-asserted-by":"crossref","unstructured":"213. Behr J, Kolb M, Song JW, Luppi F, Schinzel B, Stowasser S, et al. Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction: A prespecified subgroup analysis of a double-blind randomized clinical trial (INSTAGE). <i>Am J Respir Crit Care Med<\/i> 2019; 200: 1505\u20131512.","DOI":"10.1164\/rccm.201903-0488OC"},{"key":"214","doi-asserted-by":"crossref","unstructured":"214. Behr J, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, et al. Ef\ufb01cacy and safety of sildena\ufb01l added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A double-blind, randomised, placebo-controlled, phase 2b trial. <i>Lancet Respir Med<\/i> 2021; 9: 85\u201395.","DOI":"10.1016\/S2213-2600(20)30356-8"},{"key":"215","doi-asserted-by":"crossref","unstructured":"215. Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. <i>Eur Respir J<\/i> 2015; 46: 1370\u20131377.","DOI":"10.1183\/13993003.01537-2014"},{"key":"216","doi-asserted-by":"crossref","unstructured":"216. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary \ufb01brosis with ambrisentan: A parallel, randomized trial. <i>Ann Intern Med<\/i> 2013; 158: 641\u2013649.","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"key":"217","doi-asserted-by":"crossref","unstructured":"217. Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): A randomised, placebo-controlled phase 2b study. <i>Lancet Respir Med<\/i> 2019; 7: 780\u2013790.","DOI":"10.1016\/S2213-2600(19)30250-4"},{"key":"218","doi-asserted-by":"crossref","unstructured":"218. Zhao N, Chen J, Zhang M, Zhou L, Liu L, Yuan J, et al. PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis. <i>Front Cardiovasc Med<\/i> 2022; 9: 992879.","DOI":"10.3389\/fcvm.2022.992879"},{"key":"219","doi-asserted-by":"crossref","unstructured":"219. Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. <i>N Engl J Med<\/i> 2021; 384: 325\u2013334.","DOI":"10.1056\/NEJMoa2008470"},{"key":"220","doi-asserted-by":"crossref","unstructured":"220. Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: A post-hoc analysis of the IN-CREASE study. <i>Lancet Respir Med<\/i> 2021; 9: 1266\u20131274.","DOI":"10.1016\/S2213-2600(21)00165-X"},{"key":"221","doi-asserted-by":"crossref","unstructured":"221. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolon\u00e9 A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. <i>Am J Respir Crit Care Med<\/i> 2005; 172: 189\u2013194.","DOI":"10.1164\/rccm.200401-006OC"},{"key":"222","doi-asserted-by":"crossref","unstructured":"222. Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. <i>Am J Respir Crit Care Med<\/i> 2006; 173: 744\u2013750.","DOI":"10.1164\/rccm.200510-1545OC"},{"key":"223","unstructured":"223. \u65e5\u672c\u80ba\u9ad8\u8840\u5727\u30fb\u80ba\u5faa\u74b0\u5b66\u4f1a. \u80ba\u75be\u60a3\u306b\u4f34\u3046\u80ba\u9ad8\u8840\u5727\u75c7\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. 2018. http:\/\/www.jpcphs.org\/pdf\/guideline\/lung_guideline.pdf (accessed January 22, 2026)."},{"key":"224","doi-asserted-by":"crossref","unstructured":"224. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group. <i>Ann Intern Med<\/i> 1980; 93: 391\u2013398.","DOI":"10.7326\/0003-4819-93-3-391"},{"key":"225","doi-asserted-by":"crossref","unstructured":"225. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: Report of the Medical Research Council Working Party. <i>Lancet<\/i> 1981; 1: 681\u2013686.","DOI":"10.1016\/S0140-6736(81)91970-X"},{"key":"226","doi-asserted-by":"crossref","unstructured":"226. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. <i>Am Rev Respir Dis<\/i> 1985; 131: 493\u2013498.","DOI":"10.1164\/arrd.1985.131.4.493"},{"key":"227","doi-asserted-by":"crossref","unstructured":"227. Long-Term Oxygen Treatment Trial Research Group; Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA, et al. A randomized trial of long-term oxygen for COPD with moderate desaturation. <i>N Engl J Med<\/i> 2016; 375: 1617\u20131627.","DOI":"10.1056\/NEJMoa1604344"},{"key":"228","doi-asserted-by":"crossref","unstructured":"228. Suda R, Tanabe N, Terada J, Naito A, Kasai H, Nishimura R, et al. Pulmonary hypertension with a low cardiac index requires a higher PaO2 level to avoid tissue hypoxia. <i>Respirology<\/i> 2020; 25: 97\u2013103.","DOI":"10.1111\/resp.13574"},{"key":"229","doi-asserted-by":"crossref","unstructured":"229. Vitulo P, Stanziola A, Confalonieri M, Libertucci D, Oggionni T, Rottoli P, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. <i>J Heart Lung Transplant<\/i> 2017; 36: 166\u2013174.","DOI":"10.1016\/j.healun.2016.04.010"},{"key":"230","doi-asserted-by":"crossref","unstructured":"230. Maron BA, Choudhary G, Goldstein RL, Garshick E, Jankowich M, Tucker TJ, et al. Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial. <i>Pulm Circ<\/i> 2022; 12: e12043.","DOI":"10.1002\/pul2.12043"},{"key":"231","doi-asserted-by":"crossref","unstructured":"231. Nathan SD, Argula R, Trivieri MG, Aziz S, Gay E, Medarov B, et al. Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results. <i>Eur Respir J<\/i> 2024; 63: 2400172.","DOI":"10.1183\/13993003.00172-2024"},{"key":"232","doi-asserted-by":"crossref","unstructured":"232. Prins KW, Duval S, Markowitz J, Pritzker M, Thenappan T. Chronic use of PAH-speci\ufb01c therapy in World Health Organization Group III Pulmonary hypertension: A systematic review and meta-analysis. <i>Pulm Circ<\/i> 2017; 7: 145\u2013155.","DOI":"10.1086\/690017"},{"key":"233","doi-asserted-by":"crossref","unstructured":"233. Arif R, Pandey A, Zhao Y, Arsenault-Mehta K, Khoujah D, Mehta S. Treatment of pulmonary hypertension associated with COPD: A systematic review. <i>ERJ Open Res<\/i> 2022; 8: 00348\u20132021.","DOI":"10.1183\/23120541.00348-2021"},{"key":"234","doi-asserted-by":"crossref","unstructured":"234. Park J, Song JH, Park DA, Lee JS, Lee SD, Oh YM. Systematic review and meta-analysis of pulmonary hypertension speci\ufb01c therapy for exercise capacity in chronic obstructive pulmonary disease. <i>J Korean Med Sci<\/i> 2013; 28: 1200\u20131206.","DOI":"10.3346\/jkms.2013.28.8.1200"},{"key":"235","unstructured":"235. Chen X, Tang S, Liu K, Li Q, Kong H, Zeng X, et al. Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension: A systematic review and meta-analysis. <i>J Thorac Dis<\/i> 2015; 7: 309\u2013319."},{"key":"236","doi-asserted-by":"crossref","unstructured":"236. Isa N, Mudhafar D, Ju C, Man KK, Lau WC, Cheng LY, et al. Effects of phosphodiesterase-5 inhibitors in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. <i>COPD<\/i> 2022; 19: 300\u2013308.","DOI":"10.1080\/15412555.2022.2067525"},{"key":"237","doi-asserted-by":"crossref","unstructured":"237. Hao Y, Zhu Y, Mao Y, Xu J, He X, Huang S, et al. Efficacy and safety of sildenafil treatment in pulmonary hypertension caused by chronic obstructive pulmonary disease: A meta-analysis. <i>Life Sci<\/i> 2020; 257: 118001.","DOI":"10.1016\/j.lfs.2020.118001"},{"key":"238","doi-asserted-by":"crossref","unstructured":"238. Teramachi R, Taniguchi H, Kondoh Y, Ando M, Kimura T, Kataoka K, et al. Progression of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis with mild to moderate restriction. <i>Respirology<\/i> 2017; 22: 986\u2013990.","DOI":"10.1111\/resp.12986"},{"key":"239","doi-asserted-by":"crossref","unstructured":"239. Klok FA, Dzikowska-Diduch O, Kostrubiec M, Vliegen HW, Pruszczyk P, Hasenfu\u00df G, et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>J Thromb Haemost<\/i> 2016; 14: 121\u2013128.","DOI":"10.1111\/jth.13175"},{"key":"240","doi-asserted-by":"crossref","unstructured":"240. Gu\u00e9rin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: Prevalence of CTEPH after pulmonary embolism. <i>Thromb Haemost<\/i> 2014; 112: 598\u2013605.","DOI":"10.1160\/TH13-07-0538"},{"key":"241","doi-asserted-by":"crossref","unstructured":"241. Klok FA, Delcroix M, Bogaard HJ. Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism. <i>J Thromb Haemost<\/i> 2018; 16: 1040\u20131051.","DOI":"10.1111\/jth.14016"},{"key":"242","doi-asserted-by":"crossref","unstructured":"242. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. ERS statement on chronic thromboembolic pulmonary hypertension. <i>Eur Respir J<\/i> 2021; 57: 2002828.","DOI":"10.1183\/13993003.02828-2020"},{"key":"243","doi-asserted-by":"crossref","unstructured":"243. Bonderman D, Wilkens H, Wakounig S, Sch\u00e4fers HJ, Jansa P, Lindner J, et al. Risk factors for chronic thromboembolic pulmonary hypertension. <i>Eur Respir J<\/i> 2009; 33: 325\u2013331.","DOI":"10.1183\/09031936.00087608"},{"key":"244","doi-asserted-by":"crossref","unstructured":"244. Hosokawa K, Watanabe H, Taniguchi Y, Ikeda N, Inami T, Yasuda S, et al. A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI Trial. <i>Circulation<\/i> 2024; 149: 406\u2013409.","DOI":"10.1161\/CIRCULATIONAHA.123.067528"},{"key":"245","doi-asserted-by":"crossref","unstructured":"245. Bunclark K, Newnham M, Chiu YD, Ruggiero A, Villar SS, Cannon JE, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. <i>J Thromb Haemost<\/i> 2020; 18: 114\u2013122.","DOI":"10.1111\/jth.14649"},{"key":"246","doi-asserted-by":"crossref","unstructured":"246. Humbert M, Simonneau G, Pittrow D, Delcroix M, Pepke-Zaba J, Langleben D, et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. <i>J Heart Lung Transplant<\/i> 2022; 41: 716\u2013721.","DOI":"10.1016\/j.healun.2022.02.002"},{"key":"247","doi-asserted-by":"crossref","unstructured":"247. Hosokawa K, Abe K, Funakoshi K, Tamura Y, Nakashima N, Todaka K, et al. Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: A Japanese prospective cohort study. <i>J Thromb Haemost<\/i> 2023; 21: 2151\u20132162.","DOI":"10.1016\/j.jtha.2023.03.036"},{"key":"248","doi-asserted-by":"crossref","unstructured":"248. Ikeda N, Amemiya K, Sato S, Iijima R, Hara H, Nakamura M. Evolution of patients with chronic thromboembolic pulmonary hypertension treated by balloon pulmonary angioplasty, according to their anticoagulant regimens. <i>Heart Vessels<\/i> 2021; 36: 910\u2013915.","DOI":"10.1007\/s00380-021-01799-x"},{"key":"249","doi-asserted-by":"crossref","unstructured":"249. Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, et al. Dynamic risk strati\ufb01cation of patient long-term outcome after pulmonary endarterectomy: Results from the United Kingdom National Cohort. <i>Circulation<\/i> 2016; 133: 1761\u20131771.","DOI":"10.1161\/CIRCULATIONAHA.115.019470"},{"key":"250","doi-asserted-by":"crossref","unstructured":"250. Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, et al. Pulmonary endarterectomy: Recent changes in a single institution\u2019s experience of more than 2,700 patients. <i>Ann Thorac Surg<\/i> 2012; 94: 97\u2013103.","DOI":"10.1016\/j.athoracsur.2012.04.004"},{"key":"251","doi-asserted-by":"crossref","unstructured":"251. Ja\u00efs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, et al. Balloon pulmonary angioplasty versus Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): A multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. <i>Lancet Respir Med<\/i> 2022; 10: 961\u2013971.","DOI":"10.1016\/S2213-2600(22)00214-4"},{"key":"252","doi-asserted-by":"crossref","unstructured":"252. Ogo T, Shimokawahara H, Kinoshita H, Sakao S, Abe K, Matoba S, et al. Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. <i>Eur Respir J<\/i> 2022; 60: 2101694.","DOI":"10.1183\/13993003.01694-2021"},{"key":"253","doi-asserted-by":"crossref","unstructured":"253. Shimura N, Kataoka M, Inami T, Yanagisawa R, Ishiguro H, Kawakami T, et al. Additional percutaneous transluminal pulmonary angioplasty for residual or recurrent pulmonary hypertension after pulmonary endarterectomy. <i>Int J Cardiol<\/i> 2015; 183: 138\u2013142.","DOI":"10.1016\/j.ijcard.2015.01.034"},{"key":"254","doi-asserted-by":"crossref","unstructured":"254. Inami T, Kataoka M, Kikuchi H, Goda A, Satoh T. Balloon pulmonary angioplasty for symptomatic chronic thromboembolic disease without pulmonary hypertension at rest. <i>Int J Cardiol<\/i> 2019; 289: 116\u2013118.","DOI":"10.1016\/j.ijcard.2019.04.080"},{"key":"255","doi-asserted-by":"crossref","unstructured":"255. Taboada D, Pepke-Zaba J, Jenkins DP, Berman M, Treacy CM, Cannon JE, et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. <i>Eur Respir J<\/i> 2014; 44: 1635\u20131645.","DOI":"10.1183\/09031936.00050114"},{"key":"256","doi-asserted-by":"crossref","unstructured":"256. Yamagata Y, Ikeda S, Nakata T, Yonekura T, Koga S, Muroya T, et al. Balloon pulmonary angioplasty is effective for treating peripheral-type chronic thromboembolic pulmonary hypertension in elderly patients. <i>Geriatr Gerontol Int<\/i> 2018; 18: 678\u2013684.","DOI":"10.1111\/ggi.13224"},{"key":"257","doi-asserted-by":"crossref","unstructured":"257. Nagai T, Ikeda N, Iijima R, Hara H, Nakamura M. Impact and safety of balloon pulmonary angioplasty for elderly patients. <i>Pulm Circ<\/i> 2022; 12: e12009.","DOI":"10.1002\/pul2.12009"},{"key":"258","doi-asserted-by":"crossref","unstructured":"258. Ikeda N, Iijima R, Hara H, Hiroi Y, Nakamura M. Preprocedural frailty is strongly associated with symptoms after balloon pulmonary angioplasty. <i>Glob Health Med<\/i> 2022; 4: 45\u201351.","DOI":"10.35772\/ghm.2021.01019"},{"key":"259","doi-asserted-by":"crossref","unstructured":"259. Nishihara T, Shimokawahara H, Ogawa A, Naito T, Une D, Mukai T, et al. Comparison of the safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension patients with surgically accessible and inaccessible lesions. <i>J Heart Lung Transplant<\/i> 2023; 42: 786\u2013794.","DOI":"10.1016\/j.healun.2023.01.003"},{"key":"260","doi-asserted-by":"crossref","unstructured":"260. Kawakami T, Ogawa A, Miyaji K, Mizoguchi H, Shimokawahara H, Naito T, et al. Novel angiographic classification of each vascular lesion in chronic thromboembolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty. <i>Circ Cardiovasc Interv<\/i> 2016; 9: e003318.","DOI":"10.1161\/CIRCINTERVENTIONS.115.003318"},{"key":"261","doi-asserted-by":"crossref","unstructured":"261. Inami T, Kataoka M, Shimura N, Ishiguro H, Yanagisawa R, Taguchi H, et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. <i>JACC Cardiovasc Interv<\/i> 2013; 6: 725\u2013736.","DOI":"10.1016\/j.jcin.2013.03.009"},{"key":"262","doi-asserted-by":"crossref","unstructured":"262. Inohara T, Kawakami T, Kataoka M, Yamamoto M, Kimura M, Kanazawa H, et al. Lesion morphological classification by OCT to predict therapeutic efficacy after balloon pulmonary angioplasty in CTEPH. <i>Int J Cardiol<\/i> 2015; 197: 23\u201325.","DOI":"10.1016\/j.ijcard.2015.06.036"},{"key":"263","doi-asserted-by":"crossref","unstructured":"263. Horimoto K, Abe K, Ohtani K, Takahara Y, Hosokawa K, Oi K, et al. Optical frequency domain imaging of covered stent-graft for pulmonary artery pseudoaneurysm after balloon pulmonary angioplasty. <i>JACC Cardiovasc Interv<\/i> 2016; 9: 2255\u20132256.","DOI":"10.1016\/j.jcin.2016.08.022"},{"key":"264","doi-asserted-by":"crossref","unstructured":"264. Ikeda N, Kubota S, Okazaki T, Hara H, Hiroi Y. Comparison of intravascular optical frequency domain imaging versus intravascular ultrasound during balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. <i>Catheter Cardiovasc Interv<\/i> 2016; 87: E268\u2013E274.","DOI":"10.1002\/ccd.26437"},{"key":"265","doi-asserted-by":"crossref","unstructured":"265. Lang I, Meyer BC, Ogo T, Matsubara H, Kurzyna M, Ghofrani HA, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. <i>Eur Respir Rev<\/i> 2017; 26: 160119.","DOI":"10.1183\/16000617.0119-2016"},{"key":"266","doi-asserted-by":"crossref","unstructured":"266. Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. <i>Circ Cardiovasc Interv<\/i> 2012; 5: 748\u2013755.","DOI":"10.1161\/CIRCINTERVENTIONS.112.971077"},{"key":"267","doi-asserted-by":"crossref","unstructured":"267. Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: Results of a multicenter registry. <i>Circ Cardiovasc Qual Outcomes<\/i> 2017; 10: e004029.","DOI":"10.1161\/CIRCOUTCOMES.117.004029"},{"key":"268","doi-asserted-by":"crossref","unstructured":"268. Ikeda N. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>Cardiovasc Interv Ther<\/i> 2020; 35: 130\u2013141.","DOI":"10.1007\/s12928-019-00637-2"},{"key":"269","doi-asserted-by":"crossref","unstructured":"269. Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: The initial German experience. <i>Eur Respir J<\/i> 2017; 49: 1602409.","DOI":"10.1183\/13993003.02409-2016"},{"key":"270","doi-asserted-by":"crossref","unstructured":"270. Kataoka M, Inami T, Kawakami T, Fukuda K, Satoh T. Balloon pulmonary angioplasty (percutaneous transluminal pulmonary angioplasty) for chronic thromboembolic pulmonary hypertension: A Japanese perspective. <i>JACC Cardiovasc Interv<\/i> 2019; 12: 1382\u20131388.","DOI":"10.1016\/j.jcin.2019.01.237"},{"key":"271","doi-asserted-by":"crossref","unstructured":"271. Ikeda N, Kubota S, Okazaki T, Iijima R, Hara H, Hiroi Y, et al. The predictors of complications in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>Catheter Cardiovasc Interv<\/i> 2019; 93: E349\u2013E356.","DOI":"10.1002\/ccd.28133"},{"key":"272","doi-asserted-by":"crossref","unstructured":"272. Gerges C, Friewald R, Gerges M, Shafran I, Sadushi-Koli\u00e7i R, Skoro-Sajer N, et al. Ef\ufb01cacy and safety of percutaneous pulmonary artery subtotal occlusion and chronic total occlusion intervention in chronic thromboembolic pulmonary hypertension. <i>Circ Cardiovasc Interv<\/i> 2021; 14: e010243.","DOI":"10.1161\/CIRCINTERVENTIONS.120.010243"},{"key":"273","doi-asserted-by":"crossref","unstructured":"273. Fujii S, Nagayoshi S, Ogawa K, Muto M, Tanaka TD, Minai K, et al. A pilot cohort study assessing the feasibility of complete revascularization with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>PLoS One<\/i> 2021; 16: e0254770.","DOI":"10.1371\/journal.pone.0254770"},{"key":"274","doi-asserted-by":"crossref","unstructured":"274. Kawakami T, Kataoka M, Arai T, Yanagisawa R, Maekawa Y, Fukuda K. Retrograde approach in balloon pulmonary angioplasty: Useful novel strategy for chronic total occlusion lesions in pulmonary arteries. <i>JACC Cardiovasc Interv<\/i> 2016; 9: e19\u2013e20.","DOI":"10.1016\/j.jcin.2015.10.031"},{"key":"275","doi-asserted-by":"crossref","unstructured":"275. Inami T, Kataoka M, Shimura N, Ishiguro H, Yanagisawa R, Fukuda K, et al. Pressure-wire-guided percutaneous transluminal pulmonary angioplasty: A breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hypertension. <i>JACC Cardiovasc Interv<\/i> 2014; 7: 1297\u20131306.","DOI":"10.1016\/j.jcin.2014.06.010"},{"key":"276","doi-asserted-by":"crossref","unstructured":"276. Toi S, Ikeda N, Iijima R, Hara H, Nakamura M. Successful transcollateral bidirectional balloon pulmonary angioplasty in a patient with chronic thromboembolic pulmonary hypertension. <i>JACC Cardiovasc Interv<\/i> 2021; 14: e281\u2013e282.","DOI":"10.1016\/j.jcin.2021.07.049"},{"key":"277","doi-asserted-by":"crossref","unstructured":"277. Nagayoshi S, Fujii S, Nakajima T, Muto M. Intravenous ultrasound-guided balloon pulmonary angioplasty in the treatment of totally occluded chronic thromboembolic pulmonary hypertension. <i>EuroIntervention<\/i> 2018; 14: 234\u2013235.","DOI":"10.4244\/EIJ-D-17-00770"},{"key":"278","doi-asserted-by":"crossref","unstructured":"278. Aoki T, Sugimura K, Tatebe S, Miura M, Yamamoto S, Yaoita N, et al. Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: Long-term effects and procedure-related complications. <i>Eur Heart J<\/i> 2017; 38: 3152\u20133159.","DOI":"10.1093\/eurheartj\/ehx530"},{"key":"279","doi-asserted-by":"crossref","unstructured":"279. Ejiri K, Ogawa A, Fujii S, Ito H, Matsubara H. Vascular injury is a major cause of lung injury after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. <i>Circ Cardiovasc Interv<\/i> 2018; 11: e005884.","DOI":"10.1161\/CIRCINTERVENTIONS.117.005884"},{"key":"280","doi-asserted-by":"crossref","unstructured":"280. Shimokawahara H, Nagayoshi S, Ogawa A, Matsubara H. Continual improvement in pressure gradient at the lesion after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>Can J Cardiol<\/i> 2021; 37: 1232\u20131239.","DOI":"10.1016\/j.cjca.2021.03.009"},{"key":"281","doi-asserted-by":"crossref","unstructured":"281. Shigetoshi M, Hatanaka K, Ogawa A, Tabuchi I, Shimokawahara H, Munemasa M, et al. Oxygen inhalation can selectively dilate pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension before balloon angioplasty. <i>J Cardiol<\/i> 2022; 79: 265\u2013269.","DOI":"10.1016\/j.jjcc.2021.09.003"},{"key":"282","doi-asserted-by":"crossref","unstructured":"282. Saito S, Ikeda N, Iijima R, Hara H, Nakamura M. Evaluation of the effect of nitric oxide inhalation in the patients with chronic thromboembolic pulmonary hypertension or pulmonary disease during balloon pulmonary angioplasty. <i>Pulm Circ<\/i> 2022; 12: e12032.","DOI":"10.1002\/pul2.12032"},{"key":"283","doi-asserted-by":"crossref","unstructured":"283. Inami T, Kataoka M, Shimura N, Ishiguro H, Yanagisawa R, Kawakami T, et al. Incidence, avoidance, and management of pulmonary artery injuries in percutaneous transluminal pulmonary angioplasty. <i>Int J Cardiol<\/i> 2015; 201: 35\u201337.","DOI":"10.1016\/j.ijcard.2015.08.052"},{"key":"284","doi-asserted-by":"crossref","unstructured":"284. Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. <i>Circ Cardiovasc Interv<\/i> 2012; 5: 756\u2013762.","DOI":"10.1161\/CIRCINTERVENTIONS.112.971390"},{"key":"285","doi-asserted-by":"crossref","unstructured":"285. Kawakami T, Matsubara H, Shinke T, Abe K, Kohsaka S, Hosokawa K, et al. Balloon pulmonary angioplasty versus Riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): An open-label, randomised controlled trial. <i>Lancet Respir Med<\/i> 2022; 10: 949\u2013960.","DOI":"10.1016\/S2213-2600(22)00171-0"},{"key":"286","doi-asserted-by":"crossref","unstructured":"286. Isobe S, Itabashi Y, Kawakami T, Kataoka M, Kohsaka S, Tsugu T, et al. Increasing mixed venous oxygen saturation is a predictor of improved renal function after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. <i>Heart Vessels<\/i> 2019; 34: 688\u2013697.","DOI":"10.1007\/s00380-018-1284-4"},{"key":"287","doi-asserted-by":"crossref","unstructured":"287. Feinstein JA, Goldhaber SZ, Lock JE, Ferndandes SM, Landzberg MJ. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. <i>Circulation<\/i> 2001; 103: 10\u201313.","DOI":"10.1161\/01.CIR.103.1.10"},{"key":"288","doi-asserted-by":"crossref","unstructured":"288. Brenot P, Ja\u00efs X, Taniguchi Y, Garcia Alonso C, Gerardin B, Mussot S, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>Eur Respir J<\/i> 2019; 53: 1802095.","DOI":"10.1183\/13993003.02095-2018"},{"key":"289","doi-asserted-by":"crossref","unstructured":"289. Darocha S, Roik M, Kope\u0107 G, Araszkiewicz A, Furdal M, Lewandowski M, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: A multicentre registry. <i>EuroIntervention<\/i> 2022; 17: 1104\u20131111.","DOI":"10.4244\/EIJ-D-21-00230"},{"key":"290","doi-asserted-by":"crossref","unstructured":"290. Daigo K, Katsumata Y, Esaki K, Iwasawa Y, Ichihara G, Miura K, et al. Predictors of improvement in exercise tolerance after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>J Am Heart Assoc<\/i> 2023; 12: e8137.","DOI":"10.1161\/JAHA.122.027395"},{"key":"291","doi-asserted-by":"crossref","unstructured":"291. Taniguchi Y, Matsuoka Y, Onishi H, Yanaka K, Emoto N, Nakai H, et al. The role of balloon pulmonary angioplasty and pulmonary endarterectomy: Is chronic thromboembolic pulmonary hypertension still a life-threatening disease? <i>Int J Cardiol<\/i> 2021; 326: 170\u2013177.","DOI":"10.1016\/j.ijcard.2020.10.026"},{"key":"292","doi-asserted-by":"crossref","unstructured":"292. Minatsuki S, Takahara M, Kiyosue A, Kodera S, Hatano M, Ando J, et al. Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A time-trend analysis from the Japanese nationwide registry. <i>Open Heart<\/i> 2021; 8: e001721.","DOI":"10.1136\/openhrt-2021-001721"},{"key":"293","doi-asserted-by":"crossref","unstructured":"293. Inami T, Kataoka M, Yanagisawa R, Ishiguro H, Shimura N, Fukuda K, et al. Long-term outcomes after percutaneous transluminal pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>Circulation<\/i> 2016; 134: 2030\u20132032.","DOI":"10.1161\/CIRCULATIONAHA.116.024201"},{"key":"294","doi-asserted-by":"crossref","unstructured":"294. Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism: Late prognosis and evolution of hemodynamic and respiratory data. <i>Chest<\/i> 1982; 81: 151\u2013158.","DOI":"10.1378\/chest.81.2.151"},{"key":"295","doi-asserted-by":"crossref","unstructured":"295. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D\u2019Armini AM, Snijder R, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an International Prospective Registry. <i>Circulation<\/i> 2016; 133: 859\u2013871.","DOI":"10.1161\/CIRCULATIONAHA.115.016522"},{"key":"296","doi-asserted-by":"crossref","unstructured":"296. Hoole SP, Coghlan JG, Cannon JE, Taboada D, Toshner M, Sheares K, et al. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: The UK experience. <i>Open Heart<\/i> 2020; 7: e001144.","DOI":"10.1136\/openhrt-2019-001144"},{"key":"297","doi-asserted-by":"crossref","unstructured":"297. Mayer E, Jenkins D, Lindner J, D\u2019Armini A, Kloek J, Meyns B, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry. <i>J Thorac Cardiovasc Surg<\/i> 2011; 141: 702\u2013710.","DOI":"10.1016\/j.jtcvs.2010.11.024"},{"key":"298","doi-asserted-by":"crossref","unstructured":"298. Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery; Yoshimura N, Sato Y, Takeuchi H, Abe T, Endo S, et al. Thoracic and cardiovascular surgeries in Japan during 2021: Annual report by the Japanese Association for Thoracic Surgery. <i>Gen Thorac Cardiovasc Surg<\/i> 2024; 72: 254\u2013291.","DOI":"10.1007\/s11748-023-01997-6"},{"key":"299","unstructured":"299. \u539a\u751f\u52b4\u50cd\u7701. NDB \u30aa\u30fc\u30d7\u30f3\u30c7\u30fc\u30bf\u5206\u6790\u30b5\u30a4\u30c8. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177182.html (accessed January 22, 2026)."},{"key":"300","doi-asserted-by":"crossref","unstructured":"300. Tanabe N, Sugiura T, Tatsumi K. Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension. <i>Respir Investig<\/i> 2013; 51: 134\u2013146.","DOI":"10.1016\/j.resinv.2013.02.005"},{"key":"301","doi-asserted-by":"crossref","unstructured":"301. Guth S, D\u2019Armini AM, Delcroix M, Nakayama K, Fadel E, Hoole SP, et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: Results of the worldwide prospective CTEPH Registry. <i>ERJ Open Res<\/i> 2021; 7: 00850-2020.","DOI":"10.1183\/23120541.00850-2020"},{"key":"302","doi-asserted-by":"crossref","unstructured":"302. D\u2019Armini AM, Morsolini M, Mattiucci G, Grazioli V, Pin M, Valentini A, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. <i>J Thorac Cardiovasc Surg<\/i> 2014; 148: 1005\u20131011; 1012.e1\u20132.","DOI":"10.1016\/j.jtcvs.2014.06.052"},{"key":"303","doi-asserted-by":"crossref","unstructured":"303. Madani M, Ogo T, Simonneau G. The changing landscape of chronic thromboembolic pulmonary hypertension management. <i>Eur Respir Rev<\/i> 2017; 26: 170105.","DOI":"10.1183\/16000617.0105-2017"},{"key":"304","doi-asserted-by":"crossref","unstructured":"304. Fernandes TM, Kim NH, Kerr KM, Auger WR, Fedullo PF, Poch DS, et al. Distal vessel pulmonary thromboendarterectomy: Results from a single institution. <i>J Heart Lung Transplant<\/i> 2023; 42: 1112\u20131119.","DOI":"10.1016\/j.healun.2023.02.1500"},{"key":"305","doi-asserted-by":"crossref","unstructured":"305. Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, et al. Pulmonary endarterectomy: Experience and lessons learned in 1,500 cases. <i>Ann Thorac Surg<\/i> 2003; 76: 1457\u20131462.","DOI":"10.1016\/S0003-4975(03)00828-2"},{"key":"306","doi-asserted-by":"crossref","unstructured":"306. Madani M, Mayer E, Fadel E, Jenkins DP. Pulmonary endarterectomy: Patient selection, technical challenges, and outcomes. <i>Ann Am Thorac Soc<\/i> 2016; 13(Suppl 3): S240\u2013S247.","DOI":"10.1513\/AnnalsATS.201601-014AS"},{"key":"307","doi-asserted-by":"crossref","unstructured":"307. Jenkins DP, Tsui SS, Taghavi J, Kaul P, Ali J, Ng C. Pulmonary thromboendarterectomy: The Royal Papworth experience. <i>Ann Cardiothorac Surg<\/i> 2022; 11: 128\u2013132.","DOI":"10.21037\/acs-2021-pte-17"},{"key":"308","doi-asserted-by":"crossref","unstructured":"308. Guth S, Mayer E, Pr\u00fcfer D, Wiedenroth CB. Pulmonary endarterectomy: Technique and pitfalls. <i>Ann Cardiothorac Surg<\/i> 2022; 11: 180\u2013188.","DOI":"10.21037\/acs-2021-pte-185"},{"key":"309","doi-asserted-by":"crossref","unstructured":"309. de Perrot M, McRae K, Donahoe L, Abdelnour-Berchtold E, Thenganatt J, Granton J, et al. Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension: The Toronto experience. <i>Ann Cardiothorac Surg<\/i> 2022; 11: 133\u2013142.","DOI":"10.21037\/acs-2021-pte-14"},{"key":"310","doi-asserted-by":"crossref","unstructured":"310. de Perrot M, Thenganatt J, McRae K, Moric J, Mercier O, Pierre A, et al. Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension. <i>J Heart Lung Transplant<\/i> 2015; 34: 369\u2013375.","DOI":"10.1016\/j.healun.2014.09.008"},{"key":"311","doi-asserted-by":"crossref","unstructured":"311. Skoro-Sajer N, Marta G, Gerges C, Hlavin G, Nierlich P, Taghavi S, et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. <i>Thorax<\/i> 2014; 69: 116\u2013122.","DOI":"10.1136\/thoraxjnl-2013-203746"},{"key":"312","doi-asserted-by":"crossref","unstructured":"312. Mercier O, Dubost C, Delaporte A, Genty T, Fabre D, Mitilian D, et al. Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. <i>Ann Cardiothorac Surg<\/i> 2022; 11: 143\u2013150.","DOI":"10.21037\/acs-2021-pte-20"},{"key":"313","doi-asserted-by":"crossref","unstructured":"313. Jenkins D, Madani M, Fadel E, D\u2019Armini AM, Mayer E. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. <i>Eur Respir Rev<\/i> 2017; 26: 160111.","DOI":"10.1183\/16000617.0111-2016"},{"key":"314","doi-asserted-by":"crossref","unstructured":"314. Jenkins DP, Martinez G, Salaunkey K, Reddy SA, Pepke-Zaba J. Perioperative management in pulmonary endarterectomy. <i>Semin Respir Crit Care Med<\/i> 2023; 44: 851\u2013865.","DOI":"10.1055\/s-0043-1770123"},{"key":"315","doi-asserted-by":"crossref","unstructured":"315. Ng O, Gim\u00e9nez-Mil\u00e0 M, Jenkins DP, Vuylsteke A. Perioperative management of pulmonary endarterectomy-perspective from the UK National Health Service. <i>J Cardiothorac Vasc Anesth<\/i> 2019; 33: 3101\u20133109.","DOI":"10.1053\/j.jvca.2018.11.033"},{"key":"316","doi-asserted-by":"crossref","unstructured":"316. Benza RL, Ghofrani HA, Gr\u00fcnig E, Hoeper MM, Jansa P, Jing ZC, et al. Effect of Riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>J Heart Lung Transplant<\/i> 2021; 40: 1172\u20131180.","DOI":"10.1016\/j.healun.2021.06.020"},{"key":"317","doi-asserted-by":"crossref","unstructured":"317. Gali\u00e8 N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. <i>Proc Am Thorac Soc<\/i> 2006; 3: 571\u2013576.","DOI":"10.1513\/pats.200605-113LR"},{"key":"318","doi-asserted-by":"crossref","unstructured":"318. Ghofrani HA, D\u2019Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. <i>N Engl J Med<\/i> 2013; 369: 319\u2013329.","DOI":"10.1056\/NEJMoa1209657"},{"key":"319","doi-asserted-by":"crossref","unstructured":"319. Simonneau G, D\u2019Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, et al. Predictors of long-term outcomes in patients treated with Riociguat for chronic thromboembolic pulmonary hypertension: Data from the CHEST-2 open-label, randomised, long-term extension trial. <i>Lancet Respir Med<\/i> 2016; 4: 372\u2013380.","DOI":"10.1016\/S2213-2600(16)30022-4"},{"key":"320","doi-asserted-by":"crossref","unstructured":"320. Tanabe N, Fukuda K, Matsubara H, Nakanishi N, Tahara N, Ikeda S, et al. Selexipag for chronic thromboembolic pulmonary hypertension in Japanese patients: A double-blind, randomized, placebo-controlled, multicenter phase II study. <i>Circ J<\/i> 2020; 84: 1866\u20131874.","DOI":"10.1253\/circj.CJ-20-0438"},{"key":"321","doi-asserted-by":"crossref","unstructured":"321. Sena S, Bulent M, Derya K, Deniz K, Halil A, Okan E, et al. Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: An observational retrospective study. <i>Pulm Circ<\/i> 2020; 10: 2045894019873545.","DOI":"10.1177\/2045894019873545"},{"key":"322","doi-asserted-by":"crossref","unstructured":"322. Fukushima H, Takenouchi T, Kosaki K. Homozygosity for moyamoya disease risk allele leads to moyamoya disease with extracranial systemic and pulmonary vasculopathy. <i>Am J Med Genet A<\/i> 2016; 170: 2453\u20132456.","DOI":"10.1002\/ajmg.a.37829"},{"key":"323","doi-asserted-by":"crossref","unstructured":"323. Ozaki D, Endo H, Tashiro R, Sugimura K, Tatebe S, Yasuda S, et al. Association between <i>RNF213<\/i> c.14576G&gt;A Variant (rs112735431) and peripheral pulmonary artery stenosis in moyamoya disease. <i>Cerebrovasc Dis<\/i> 2022; 51: 282\u2013287.","DOI":"10.1159\/000519717"},{"key":"324","doi-asserted-by":"crossref","unstructured":"324. Tamura Y, Tamura Y, Shigeta A, Hosokawa K, Taniguchi Y, Inami T, et al. Adult-onset idiopathic peripheral pulmonary artery stenosis. <i>Eur Respir J<\/i> 2023; 62: 2300763.","DOI":"10.1183\/13993003.00763-2023"},{"key":"325","doi-asserted-by":"crossref","unstructured":"325. Chang SA, Song JS, Park TK, Yang JH, Kwon WC, Kim SR, et al. Nonsyndromic peripheral pulmonary artery stenosis is associated with homozygosity of <i>RNF213<\/i> p.Arg4810Lys regardless of co-occurrence of moyamoya disease. <i>Chest<\/i> 2018; 153: 404\u2013413.","DOI":"10.1016\/j.chest.2017.09.023"},{"key":"326","doi-asserted-by":"crossref","unstructured":"326. Kreutzer J, Landzberg MJ, Preminger TJ, Mandell VS, Treves ST, Reid LM, et al. Isolated peripheral pulmonary artery stenoses in the adult. <i>Circulation<\/i> 1996; 93: 1417\u20131423.","DOI":"10.1161\/01.CIR.93.7.1417"},{"key":"327","doi-asserted-by":"crossref","unstructured":"327. Kanezawa M, Shimokawahara H, Tsuji M, Suruga K, Miyagi A, Marunaka M, et al. The results of genetic analysis and clinical outcomes after stent deployment in adult patients with isolated peripheral pulmonary artery stenosis. <i>Eur Respir J<\/i> 2023; 62: 2301511.","DOI":"10.1183\/13993003.01511-2023"},{"key":"328","doi-asserted-by":"crossref","unstructured":"328. Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan: Age and sex specificity. <i>Circulation<\/i> 2015; 132: 1701\u20131709.","DOI":"10.1161\/CIRCULATIONAHA.114.012547"},{"key":"329","doi-asserted-by":"crossref","unstructured":"329. Kong X, Ma L, Lv P, Cui X, Chen R, Ji Z, et al. Involvement of the pulmonary arteries in patients with Takayasu arteritis: A prospective study from a single centre in China. <i>Arthritis Res Ther<\/i> 2020; 22: 131.","DOI":"10.1186\/s13075-020-02203-1"},{"key":"330","doi-asserted-by":"crossref","unstructured":"330. He Y, Lv N, Dang A, Cheng N. Pulmonary artery involvement in patients with Takayasu arteritis. <i>J Rheumatol<\/i> 2020; 47: 264\u2013272.","DOI":"10.3899\/jrheum.190045"},{"key":"331","doi-asserted-by":"crossref","unstructured":"331. Jiang X, Zhu YJ, Zhou YP, Peng FH, Wang L, Ma W, et al. Clinical features and survival in Takayasu\u2019s arteritis-associated pulmonary hypertension: A nationwide study. <i>Eur Heart J<\/i> 2021; 42: 4298\u20134305.","DOI":"10.1093\/eurheartj\/ehab599"},{"key":"332","doi-asserted-by":"crossref","unstructured":"332. Zhou YP, Wei YP, Yang YJ, Xu XQ, Wu T, Liu C, et al. Percutaneous pulmonary angioplasty for patients with Takayasu arteritis and pulmonary hypertension. <i>J Am Coll Cardiol<\/i> 2022; 79: 1477\u20131488.","DOI":"10.1016\/j.jacc.2022.01.052"},{"key":"333","doi-asserted-by":"crossref","unstructured":"333. Suda T, Zoshima T, Ito K, Mizushima I, Kawano M. Successful early immunosuppressive therapy for pulmonary arterial hypertension due to Takayasu arteritis: Two case reports and a review of similar case reports in the English literature. <i>Intern Med<\/i> 2022; 61: 1767\u20131774.","DOI":"10.2169\/internalmedicine.8095-21"},{"key":"334","doi-asserted-by":"crossref","unstructured":"334. van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, et al. Pediatric pulmonary hypertension in the Netherlands: Epidemiology and characterization during the period 1991 to 2005. <i>Circulation<\/i> 2011; 124: 1755\u20131764.","DOI":"10.1161\/CIRCULATIONAHA.110.969584"},{"key":"335","doi-asserted-by":"crossref","unstructured":"335. del Cerro Mar\u00edn MJ, Sabat\u00e9 Rot\u00e9s A, Rodriguez Ogando A, Mendoza Soto A, Quero Jim\u00e9nez M, Gavil\u00e1n Camacho JL, et al. Assessing pulmonary hypertensive vascular disease in childhood: Data from the Spanish registry. <i>Am J Respir Crit Care Med<\/i> 2014; 190: 1421\u20131429.","DOI":"10.1164\/rccm.201406-1052OC"},{"key":"336","doi-asserted-by":"crossref","unstructured":"336. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: A registry study. <i>Lancet<\/i> 2012; 379: 537\u2013546.","DOI":"10.1016\/S0140-6736(11)61621-8"},{"key":"337","doi-asserted-by":"crossref","unstructured":"337. Abman SH, Mullen MP, Sleeper LA, Austin ED, Rosenzweig EB, Kinsella JP, et al. Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry. <i>Eur Respir J<\/i> 2022; 59: 2003337.","DOI":"10.1183\/13993003.03337-2020"},{"key":"338","doi-asserted-by":"crossref","unstructured":"338. Hansmann G, Sallmon H, Roehr CC, Kourembanas S, Austin ED, Koestenberger M, et al. Pulmonary hypertension in bronchopulmonary dysplasia. <i>Pediatr Res<\/i> 2021; 89: 446\u2013455.","DOI":"10.1038\/s41390-020-0993-4"},{"key":"339","doi-asserted-by":"crossref","unstructured":"339. Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. <i>Heart<\/i> 2010; 96: 1401\u20131406.","DOI":"10.1136\/hrt.2009.182378"},{"key":"340","doi-asserted-by":"crossref","unstructured":"340. Fraisse A, Jais X, Schleich JM, Di Filippo S, Maragn\u00e8s P, Beghetti M, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. <i>Arch Cardiovasc Dis<\/i> 2010; 103: 66\u201374.","DOI":"10.1016\/j.acvd.2009.12.001"},{"key":"341","unstructured":"341. \u65e5\u672c\u5c0f\u5150\u5faa\u74b0\u5668\u5b66\u4f1a. \u5c0f\u5150\u671f\u767a\u751f\u5fc3\u75be\u60a3\u5b9f\u614b\u8abf\u67fb2020 \u96c6\u8a08\u7d50\u679c\u5831\u544a\u66f8. https:\/\/jspccs.jp\/wp-content\/uploads\/rare_disease_surveillance_2020 (accessed January 22, 2026)."},{"key":"342","doi-asserted-by":"crossref","unstructured":"342. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: A national prospective study. <i>Ann Intern Med<\/i> 1987; 107: 216\u2013223.","DOI":"10.7326\/0003-4819-107-2-216"},{"key":"343","doi-asserted-by":"crossref","unstructured":"343. Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, et al. United States Pulmonary Hypertension Scienti\ufb01c Registry: Baseline characteristics. <i>Chest<\/i> 2021; 159: 311\u2013327.","DOI":"10.1016\/j.chest.2020.07.088"},{"key":"344","doi-asserted-by":"crossref","unstructured":"344. D\u2019Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. <i>Ann Intern Med<\/i> 1991; 115: 343\u2013349.","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"345","unstructured":"345. \u4f50\u5730\u52c9, \u9580\u9593\u548c\u592b, \u67f4\u7530\u5229\u6e80, \u4ed6. \u5c0f\u5150\u671f\u539f\u767a\u6027\u80ba\u9ad8\u8840\u5727\u75c7\u306e\u5168\u56fd\u8abf\u67fb\u7d50\u679c: \u80ba\u79fb\u690d\u9069\u5fdc\u60a3\u8005\u306e\u5b9f\u614b\u8abf\u67fb (\u7b2c1\u5831). \u65e5\u5c0f\u5faa\u8a8c 2000; <b>16:<\/b> 230\u2013237."},{"key":"346","doi-asserted-by":"crossref","unstructured":"346. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: The UK Pulmonary Hypertension Service for Children 2001\u20132006. <i>Heart<\/i> 2009; 95: 312\u2013317.","DOI":"10.1136\/hrt.2008.150086"},{"key":"347","doi-asserted-by":"crossref","unstructured":"347. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. <i>Circulation<\/i> 2012; 125: 113\u2013122.","DOI":"10.1161\/CIRCULATIONAHA.111.026591"},{"key":"348","doi-asserted-by":"crossref","unstructured":"348. Sawada H, Mitani Y, Nakayama T, Fukushima H, Kogaki S, Igarashi T, et al. Detection of pediatric pulmonary arterial hypertension by school electrocardiography mass screening. <i>Am J Respir Crit Care Med<\/i> 2019; 199: 1397\u20131406.","DOI":"10.1164\/rccm.201802-0375OC"},{"key":"349","doi-asserted-by":"crossref","unstructured":"349. Zhu N, Gonzaga-Jauregui C, Welch CL, Ma L, Qi H, King AK, et al. Exome sequencing in children with pulmonary arterial hypertension demonstrates differences compared with adults. <i>Circ Genom Precis Med<\/i> 2018; 11: e001887.","DOI":"10.1161\/CIRCGEN.117.001887"},{"key":"350","doi-asserted-by":"crossref","unstructured":"350. Kerstjens-Frederikse WS, Bongers EM, Roofthooft MT, Leter EM, Douwes JM, Van Dijk A, et al. <i>TBX4<\/i> mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. <i>J Med Genet<\/i> 2013; 50: 500\u2013506.","DOI":"10.1136\/jmedgenet-2012-101152"},{"key":"351","doi-asserted-by":"crossref","unstructured":"351. Levy M, Eyries M, Szezepanski I, Ladouceur M, Nadaud S, Bonnet D, et al. Genetic analyses in a cohort of children with pulmonary hypertension. <i>Eur Respir J<\/i> 2016; 48: 1118\u20131126.","DOI":"10.1183\/13993003.00211-2016"},{"key":"352","doi-asserted-by":"crossref","unstructured":"352. Haarman MG, Kerstjens-Frederikse WS, Vissia-Kazemier TR, Breeman KT, Timens W, Vos YJ, et al. The genetic epidemiology of pediatric pulmonary arterial hypertension. <i>J Pediatr<\/i> 2020; 225: 65\u201373.e5.","DOI":"10.1016\/j.jpeds.2020.05.051"},{"key":"353","doi-asserted-by":"crossref","unstructured":"353. Karolak JA, Welch CL, Mosimann C, Bzd\u0119ga K, West JD, Montani D, et al. Molecular function and contribution of <i>TBX4<\/i> in development and disease. <i>Am J Respir Crit Care Med<\/i> 2023; 207: 855\u2013864.","DOI":"10.1164\/rccm.202206-1039TR"},{"key":"354","doi-asserted-by":"crossref","unstructured":"354. Prapa M, Lago-Docampo M, Swietlik EM, Montani D, Eyries M, Humbert M, et al. First genotype-phenotype study in TBX4 syndrome: Gain-of-function mutations causative for lung disease. <i>Am J Respir Crit Care Med<\/i> 2022; 206: 1522\u20131533.","DOI":"10.1164\/rccm.202203-0485OC"},{"key":"355","doi-asserted-by":"crossref","unstructured":"355. Chida A, Shintani M, Yagi H, Fujiwara M, Kojima Y, Sato H, et al. Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. <i>Am J Cardiol<\/i> 2012; 110: 586\u2013593.","DOI":"10.1016\/j.amjcard.2012.04.035"},{"key":"356","doi-asserted-by":"crossref","unstructured":"356. Pattathu J, Gorenflo M, Hilgendorff A, Koskenvuo JW, Apitz C, Hansmann G, et al. Genetic testing and blood biomarkers in paediatric pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart<\/i> 2016; 102(Suppl 2): ii36\u2013ii41.","DOI":"10.1136\/heartjnl-2014-307238"},{"key":"357","doi-asserted-by":"crossref","unstructured":"357. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: Results from a national registry. <i>Am J Respir Crit Care Med<\/i> 2006; 173: 1023\u20131030.","DOI":"10.1164\/rccm.200510-1668OC"},{"key":"358","doi-asserted-by":"crossref","unstructured":"358. Hopper RK, Abman SH, Ivy DD. Persistent challenges in pediatric pulmonary hypertension. <i>Chest<\/i> 2016; 150: 226\u2013236.","DOI":"10.1016\/j.chest.2016.01.007"},{"key":"359","doi-asserted-by":"crossref","unstructured":"359. Sandoval J, Bauerle O, Gomez A, Palomar A, Mart\u00ednez Guerra ML, Furuya ME. Primary pulmonary hypertension in children: Clinical characterization and survival. <i>J Am Coll Cardiol<\/i> 1995; 25: 466\u2013474.","DOI":"10.1016\/0735-1097(94)00391-3"},{"key":"360","doi-asserted-by":"crossref","unstructured":"360. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: A comparison between children and adults. <i>Eur Respir J<\/i> 2011; 37: 665\u2013677.","DOI":"10.1183\/09031936.00056110"},{"key":"361","doi-asserted-by":"crossref","unstructured":"361. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric pulmonary hypertension: Guidelines from the American Heart Association and American Thoracic Society. <i>Circulation<\/i> 2015; 132: 2037\u20132099.","DOI":"10.1161\/CIR.0000000000000329"},{"key":"362","doi-asserted-by":"crossref","unstructured":"362. Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. <i>J Heart Lung Transplant<\/i> 2019; 38: 879\u2013901.","DOI":"10.1016\/j.healun.2019.06.022"},{"key":"363","doi-asserted-by":"crossref","unstructured":"363. Haarman MG, Douwes JM, Ploegstra MJ, Roofthooft MT, Vissia-Kazemier TR, Hillege HL, et al. The clinical value of proposed risk stratification tools in pediatric pulmonary arterial hypertension. <i>Am J Respir Crit Care Med<\/i> 2019; 200: 1312\u20131315.","DOI":"10.1164\/rccm.201902-0266LE"},{"key":"364","doi-asserted-by":"crossref","unstructured":"364. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. <i>Int J Cardiol<\/i> 2009; 135: 21\u201326.","DOI":"10.1016\/j.ijcard.2008.03.009"},{"key":"365","doi-asserted-by":"crossref","unstructured":"365. Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. <i>Chest<\/i> 2009; 135: 745\u2013751.","DOI":"10.1378\/chest.08-0187"},{"key":"366","doi-asserted-by":"crossref","unstructured":"366. Takatsuki S, Wagner BD, Ivy DD. B-Type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. <i>Congenit Heart Dis<\/i> 2012; 7: 259\u2013267.","DOI":"10.1111\/j.1747-0803.2011.00620.x"},{"key":"367","doi-asserted-by":"crossref","unstructured":"367. Leberk\u00fchne LJ, Ploegstra MJ, Douwes JM, Bartelds B, Roofthooft MT, Hillege HL, et al. Serially measured uric acid levels predict disease severity and outcome in pediatric pulmonary arterial hypertension. <i>Am J Respir Crit Care Med<\/i> 2017; 195: 401\u2013404.","DOI":"10.1164\/rccm.201606-1152LE"},{"key":"368","doi-asserted-by":"crossref","unstructured":"368. Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, et al. Evaluation of macitentan in patients with Eisenmenger syndrome. <i>Circulation<\/i> 2019; 139: 51\u201363.","DOI":"10.1161\/CIRCULATIONAHA.118.033575"},{"key":"369","doi-asserted-by":"crossref","unstructured":"369. Hopper RK, Wang Y, DeMatteo V, Santo A, Kawut SM, Elci OU, et al. Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. <i>Pulm Circ<\/i> 2018; 8: 2045894018759247.","DOI":"10.1177\/2045894018759247"},{"key":"370","doi-asserted-by":"crossref","unstructured":"370. Baruteau AE, Serraf A, L\u00e9vy M, Petit J, Bonnet D, Jais X, et al. Potts shunt in children with idiopathic pulmonary arterial hypertension: Long-term results. <i>Ann Thorac Surg<\/i> 2012; 94: 817\u2013824.","DOI":"10.1016\/j.athoracsur.2012.03.099"},{"key":"371","doi-asserted-by":"crossref","unstructured":"371. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. <i>Circulation<\/i> 2012; 125: 324\u2013334.","DOI":"10.1161\/CIRCULATIONAHA.110.016667"},{"key":"372","doi-asserted-by":"crossref","unstructured":"372. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2: Long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. <i>Circulation<\/i> 2014; 129: 1914\u20131923.","DOI":"10.1161\/CIRCULATIONAHA.113.005698"},{"key":"373","doi-asserted-by":"crossref","unstructured":"373. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. <i>Pediatr Cardiol<\/i> 2012; 33: 683\u2013688.","DOI":"10.1007\/s00246-012-0180-4"},{"key":"374","doi-asserted-by":"crossref","unstructured":"374. Ivy D, Bonnet D, Berger RM, Meyer GM, Baygani S, Li B, et al. Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: Phase 3 randomized, double-blind placebo-controlled study. <i>Pulm Circ<\/i> 2021; 11: 20458940211024955.","DOI":"10.1177\/20458940211024955"},{"key":"375","doi-asserted-by":"crossref","unstructured":"375. Issapour A, Frank B, Crook S, Hite MD, Dorn ML, Rosenzweig EB, et al. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience. <i>Pediatr Pulmonol<\/i> 2022; 57: 724\u2013733.","DOI":"10.1002\/ppul.25796"},{"key":"376","doi-asserted-by":"crossref","unstructured":"376. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. <i>Clin Pharmacol Ther<\/i> 2003; 73: 372\u2013382.","DOI":"10.1016\/S0009-9236(03)00005-5"},{"key":"377","doi-asserted-by":"crossref","unstructured":"377. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. <i>J Am Coll Cardiol<\/i> 2005; 46: 697\u2013704.","DOI":"10.1016\/j.jacc.2005.01.066"},{"key":"378","doi-asserted-by":"crossref","unstructured":"378. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: The FUTURE-1 study. <i>Br J Clin Pharmacol<\/i> 2009; 68: 948\u2013955.","DOI":"10.1111\/j.1365-2125.2009.03532.x"},{"key":"379","doi-asserted-by":"crossref","unstructured":"379. Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Gali\u00e8 N, et al. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric formulation of bosentan in pulmonary arterial hypertension. <i>Int J Cardiol<\/i> 2016; 202: 52\u201358.","DOI":"10.1016\/j.ijcard.2015.08.080"},{"key":"380","doi-asserted-by":"crossref","unstructured":"380. Berger RM, Gehin M, Beghetti M, Ivy D, Kusic-Pajic A, Cornelisse P, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. <i>Br J Clin Pharmacol<\/i> 2017; 83: 1734\u20131744.","DOI":"10.1111\/bcp.13267"},{"key":"381","doi-asserted-by":"crossref","unstructured":"381. Ivy D, Beghetti M, Juaneda-Simian E, Miller D, Lukas MA, Ioannou C, et al. A Randomized study of safety and efficacy of two doses of ambrisentan to treat pulmonary arterial hypertension in pediatric patients aged 8 years up to 18 years. <i>J Pediatr X<\/i> 2020; 5: 100055.","DOI":"10.1016\/j.ympdx.2020.100055"},{"key":"382","doi-asserted-by":"crossref","unstructured":"382. Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. <i>Pediatr Pulmonol<\/i> 2013; 48: 27\u201334.","DOI":"10.1002\/ppul.22555"},{"key":"383","doi-asserted-by":"crossref","unstructured":"383. Schweintzger S, Koestenberger M, Schlagenhauf A, Grangl G, Burmas A, Kurath-Koller S, et al. Safety and ef\ufb01cacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. <i>Cardiovasc Diagn Ther<\/i> 2020; 10: 1675\u20131685.","DOI":"10.21037\/cdt.2020.04.01"},{"key":"384","doi-asserted-by":"crossref","unstructured":"384. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. <i>Circulation<\/i> 1999; 99: 1197\u20131208.","DOI":"10.1161\/01.CIR.99.9.1197"},{"key":"385","doi-asserted-by":"crossref","unstructured":"385. Douwes JM, Zijlstra WM, Rosenzweig EB, Ploegstra MJ, Krishnan US, Haarman MG, et al. Parenteral prostanoids in pediatric pulmonary arterial hypertension: Start early, dose high, combine. <i>Ann Am Thorac Soc<\/i> 2022; 19: 227\u2013237.","DOI":"10.1513\/AnnalsATS.202012-1563OC"},{"key":"386","doi-asserted-by":"crossref","unstructured":"386. Tella JB, Kulik TJ, McSweeney JE, Sleeper LA, Lu M, Mullen MP. Prostanoids in pediatric pulmonary hypertension: Clinical response, time-to-effect, and dose-response. <i>Pulm Circ<\/i> 2020; 10: 2045894020944858.","DOI":"10.1177\/2045894020944858"},{"key":"387","doi-asserted-by":"crossref","unstructured":"387. Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. <i>Heart<\/i> 2007; 93: 739\u2013743.","DOI":"10.1136\/hrt.2006.096412"},{"key":"388","doi-asserted-by":"crossref","unstructured":"388. Levy M, Del Cerro MJ, Nadaud S, Vadlamudi K, Colgazier E, Fineman J, et al. Safety, efficacy and management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. <i>Int J Cardiol<\/i> 2018; 264: 153\u2013157.","DOI":"10.1016\/j.ijcard.2018.03.067"},{"key":"389","doi-asserted-by":"crossref","unstructured":"389. Hall K, Ogawa M, Sakarovitch C, Hopper RK, Adamson GT, Hanna B, et al. Subcutaneous and intravenous treprostinil pharmacokinetics in children with pulmonary vascular disease. <i>J Cardiovasc Pharmacol<\/i> 2019; 73: 383\u2013393.","DOI":"10.1097\/FJC.0000000000000674"},{"key":"390","doi-asserted-by":"crossref","unstructured":"390. Ivy DD, Doran AK, Smith KJ, Mallory GB, Beghetti M, Barst RJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. <i>J Am Coll Cardiol<\/i> 2008; 51: 161\u2013169.","DOI":"10.1016\/j.jacc.2007.09.031"},{"key":"391","doi-asserted-by":"crossref","unstructured":"391. Takatsuki S, Nakayama T, Shimizu Y, Kawai R, Matsuura H. Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension. <i>Cardiol Young<\/i> 2023; 33: 196\u2013200.","DOI":"10.1017\/S1047951122000415"},{"key":"392","doi-asserted-by":"crossref","unstructured":"392. Hansmann G, Meinel K, Bukova M, Chouvarine P, W\u00e5hlander H, Koestenberger M, et al. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. <i>J Heart Lung Transplant<\/i> 2020; 39: 695\u2013706.","DOI":"10.1016\/j.healun.2020.03.029"},{"key":"393","doi-asserted-by":"crossref","unstructured":"393. Li M, Liu L, Liu C, Chen Z, Li W, Li X, et al. Selexipag for the treatment of pediatric pulmonary hypertension: A systematic review. <i>Clin Ther<\/i> 2024; 46: 59\u201368.","DOI":"10.1016\/j.clinthera.2023.09.026"},{"key":"394","doi-asserted-by":"crossref","unstructured":"394. Willmann S, Keller AK, Meyer M, Van Der Mey D, Wirsching G, Zhang Y, et al. Population pharmacokinetics of riociguat in a pediatric population (aged \u22656 years) with pulmonary arterial hypertension. <i>Pediatr Pulmonol<\/i> 2023; 58: 908\u2013917.","DOI":"10.1002\/ppul.26277"},{"key":"395","doi-asserted-by":"crossref","unstructured":"395. Garc\u00eda Aguilar H, Gorenflo M, Ivy DD, Moledina S, Castaldi B, Ishida H, et al. Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study. <i>Pulm Circ<\/i> 2022; 12: e12133.","DOI":"10.1002\/pul2.12133"},{"key":"396","doi-asserted-by":"crossref","unstructured":"396. Douwes JM, Humpl T, Bonnet D, Beghetti M, Ivy DD, Berger RM, et al. Acute vasodilator response in pediatric pulmonary arterial hypertension: Current clinical practice from the TOPP Registry. <i>J Am Coll Cardiol<\/i> 2016; 67: 1312\u20131323.","DOI":"10.1016\/j.jacc.2016.01.015"},{"key":"397","doi-asserted-by":"crossref","unstructured":"397. Apitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart<\/i> 2016; 102(Suppl 2): ii23\u2013ii29.","DOI":"10.1136\/heartjnl-2014-307340"},{"key":"398","doi-asserted-by":"crossref","unstructured":"398. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: Updates on definition, classification, diagnostics and management. <i>Eur Respir J<\/i> 2019; 53: 1801916.","DOI":"10.1183\/13993003.01916-2018"},{"key":"399","doi-asserted-by":"crossref","unstructured":"399. Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, et al. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. <i>Am J Respir Crit Care Med<\/i> 2013; 187: 572\u2013575.","DOI":"10.1164\/rccm.201210-1928PP"},{"key":"400","doi-asserted-by":"crossref","unstructured":"400. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. <i>Cochrane Database Syst Rev<\/i> 2006; (4): CD000399.","DOI":"10.1002\/14651858.CD000399.pub2"},{"key":"401","doi-asserted-by":"crossref","unstructured":"401. Askie LM, Ballard RA, Cutter GR, Dani C, Elbourne D, Field D, et al. Inhaled nitric oxide in preterm infants: An individual-patient data meta-analysis of randomized trials. <i>Pediatrics<\/i> 2011; 128: 729\u2013739.","DOI":"10.1542\/peds.2010-2725"},{"key":"402","doi-asserted-by":"crossref","unstructured":"402. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. <i>Pediatrics<\/i> 2006; 117: 1077\u20131083.","DOI":"10.1542\/peds.2005-0523"},{"key":"403","doi-asserted-by":"crossref","unstructured":"403. Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates. <i>Cochrane Database Syst Rev<\/i> 2017; 8: CD005494.","DOI":"10.1002\/14651858.CD005494.pub4"},{"key":"404","doi-asserted-by":"crossref","unstructured":"404. Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, et al. Outpatient treatment in patients with acute pulmonary embolism: The Hestia Study. <i>J Thromb Haemost<\/i> 2011; 9: 1500\u20131507.","DOI":"10.1111\/j.1538-7836.2011.04388.x"},{"key":"405","doi-asserted-by":"crossref","unstructured":"405. den Exter PL, Zondag W, Klok FA, Brouwer RE, Dolsma J, Eijsvogel M, et al. Ef\ufb01cacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without N-terminal pro-brain natriuretic peptide testing in patients with acute pulmonary embolism: A randomized clinical trial. <i>Am J Respir Crit Care Med<\/i> 2016; 194: 998\u20131006.","DOI":"10.1164\/rccm.201512-2494OC"},{"key":"406","doi-asserted-by":"crossref","unstructured":"406. Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: An international, open-label, randomised, non-inferiority trial. <i>Lancet<\/i> 2011; 378: 41\u201348.","DOI":"10.1016\/S0140-6736(11)60824-6"},{"key":"407","doi-asserted-by":"crossref","unstructured":"407. Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al. Validation of simplified PESI score for identification of low-risk patients with pulmonary embolism: From the COMMAND VTE Registry. <i>Eur Heart J Acute Cardiovasc Care<\/i> 2020; 9: 262\u2013270.","DOI":"10.1177\/2048872618799993"},{"key":"408","doi-asserted-by":"crossref","unstructured":"408. Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E, et al. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: An international multicentre single-arm clinical trial. <i>Eur Heart J<\/i> 2020; 41: 509\u2013518.","DOI":"10.1093\/eurheartj\/ehz367"},{"key":"409","doi-asserted-by":"crossref","unstructured":"409. Chatani R, Yamashita Y, Morimoto T, Muraoka N, Shioyama W, Shibata T, et al. Home treatment for active cancer patients with low-risk pulmonary embolism: A predetermined companion report from the ONCO PE trial. <i>Circ J<\/i> 2026; 90: 427\u2013435.","DOI":"10.1253\/circj.CJ-24-0004"},{"key":"410","doi-asserted-by":"crossref","unstructured":"410. Ota M, Nakamura M, Yamada N, Yazu T, Ishikura K, Fujioka H, et al. Association between antithrombotic treatments and prognosis of patients with acute pulmonary thromboembolism in Japan. <i>Circ J<\/i> 2003; 67: 612\u2013616.","DOI":"10.1253\/circj.67.612"},{"key":"411","unstructured":"411. Molloy WD, Lee KY, Girling L, Schick U, Prewitt RM. Treatment of shock in a canine model of pulmonary embolism. <i>Am Rev Respir Dis<\/i> 1984; 130: 870\u2013874."},{"key":"412","doi-asserted-by":"crossref","unstructured":"412. Ghignone M, Girling L, Prewitt RM. Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. <i>Anesthesiology<\/i> 1984; 60: 132\u2013135.","DOI":"10.1097\/00000542-198402000-00009"},{"key":"413","unstructured":"413. Goldhaber SZ. Pulmonary embolism. <i>In<\/i>: Braunwald E, Zipes DP, Libby P, editors. Heart disease, 6th edn. Saunders, 2001; 1886\u20131907."},{"key":"414","doi-asserted-by":"crossref","unstructured":"414. Mercat A, Diehl JL, Meyer G, Teboul JL, Sors H. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. <i>Crit Care Med<\/i> 1999; 27: 540\u2013544.","DOI":"10.1097\/00003246-199903000-00032"},{"key":"415","doi-asserted-by":"crossref","unstructured":"415. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. <i>N Engl J Med<\/i> 2010; 362: 779\u2013789.","DOI":"10.1056\/NEJMoa0907118"},{"key":"416","doi-asserted-by":"crossref","unstructured":"416. Jardin F, Genevray B, Brun-Ney D, Margairaz A. Dobutamine: A hemodynamic evaluation in pulmonary embolism shock. <i>Crit Care Med<\/i> 1985; 13: 1009\u20131012.","DOI":"10.1097\/00003246-198512000-00004"},{"key":"417","doi-asserted-by":"crossref","unstructured":"417. Manier G, Castaing Y. Influence of cardiac output on oxygen exchange in acute pulmonary embolism. <i>Am Rev Respir Dis<\/i> 1992; 145: 130\u2013136.","DOI":"10.1164\/ajrccm\/145.1.130"},{"key":"418","doi-asserted-by":"crossref","unstructured":"418. Tanaka H, Tajimi K, Matsumoto A, Kobayashi K. Vasodilatory effects of milrinone on pulmonary vasculature in dogs with pulmonary hypertension due to pulmonary embolism: A comparison with those of dopamine and dobutamine. <i>Clin Exp Pharmacol Physiol<\/i> 1990; 17: 681\u2013690.","DOI":"10.1111\/j.1440-1681.1990.tb01267.x"},{"key":"419","doi-asserted-by":"crossref","unstructured":"419. B\u00f6ttiger BW, Motsch J, D\u00f6rsam J, Mieck U, Gries A, Weimann J, et al. Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets. <i>Chest<\/i> 1996; 110: 1041\u20131047.","DOI":"10.1378\/chest.110.4.1041"},{"key":"420","doi-asserted-by":"crossref","unstructured":"420. Capellier G, Jacques T, Balvay P, Blasco G, Belle E, Barale F. Inhaled nitric oxide in patients with pulmonary embolism. <i>Intensive Care Med<\/i> 1997; 23: 1089\u20131092.","DOI":"10.1007\/s001340050461"},{"key":"421","doi-asserted-by":"crossref","unstructured":"421. Bhat T, Neuman A, Tantary M, Bhat H, Glass D, Mannino W, et al. Inhaled nitric oxide in acute pulmonary embolism: A systematic review. <i>Rev Cardiovasc Med<\/i> 2015; 16: 1\u20138.","DOI":"10.3909\/ricm0718"},{"key":"422","doi-asserted-by":"crossref","unstructured":"422. Minakawa M, Fukuda I, Miyata H, Motomura N, Takamoto S, Taniguchi S, et al. Outcomes of pulmonary embolectomy for acute pulmonary embolism. <i>Circ J<\/i> 2018; 82: 2184\u20132190.","DOI":"10.1253\/circj.CJ-18-0371"},{"key":"423","doi-asserted-by":"crossref","unstructured":"423. Rivers J, Pilcher D, Kim J, Bartos JA, Burrell A. Extracorporeal membrane oxygenation for the treatment of massive pulmonary embolism: An analysis of the ELSO database. <i>Resuscitation<\/i> 2023; 191: 109940.","DOI":"10.1016\/j.resuscitation.2023.109940"},{"key":"424","doi-asserted-by":"crossref","unstructured":"424. Kaso ER, Pan JA, Salerno M, Kadl A, Aldridge C, Haskal ZJ, et al. Venoarterial extracorporeal membrane oxygenation for acute massive pulmonary embolism: A meta-analysis and call to action. <i>J Cardiovasc Transl Res<\/i> 2022; 15: 258\u2013267.","DOI":"10.1007\/s12265-021-10158-0"},{"key":"425","doi-asserted-by":"crossref","unstructured":"425. Sakuraya M, Hifumi T, Inoue A, Sakamoto T, Kuroda Y; SAVE-J II Study Group. Neurological outcomes and reperfusion strategies in out-of-hospital cardiac arrest patients due to pulmonary embolism who underwent venoarterial extracorporeal membrane oxygenation: A post-hoc analysis of a multicenter retrospective cohort study. <i>Resuscitation<\/i> 2023; 191: 109926.","DOI":"10.1016\/j.resuscitation.2023.109926"},{"key":"426","doi-asserted-by":"crossref","unstructured":"426. Chopard R, Nielsen P, Ius F, Cebotari S, Ecarnot F, Pilichowski H, et al. Optimal reperfusion strategy in acute high-risk pulmonary embolism requiring extracorporeal membrane oxygenation support: A systematic review and meta-analysis. <i>Eur Respir J<\/i> 2022; 60: 2102977.","DOI":"10.1183\/13993003.02977-2021"},{"key":"427","doi-asserted-by":"crossref","unstructured":"427. Nishimoto Y, Ohbe H, Matsui H, Nakajima M, Sasabuchi Y, Sato Y, et al. Effectiveness of systemic thrombolysis on clinical outcomes in high-risk pulmonary embolism patients with venoarterial extracorporeal membrane oxygenation: A nationwide inpatient database study. <i>J Intensive Care<\/i> 2023; 11: 4.","DOI":"10.1186\/s40560-023-00651-w"},{"key":"428","doi-asserted-by":"crossref","unstructured":"428. Karami M, Mandigers L, Miranda DD, Rietdijk WJ, Binnekade JM, Knijn DC, et al. Survival of patients with acute pulmonary embolism treated with venoarterial extracorporeal membrane oxygenation: A systematic review and meta-analysis. <i>J Crit Care<\/i> 2021; 64: 245\u2013254.","DOI":"10.1016\/j.jcrc.2021.03.006"},{"key":"429","doi-asserted-by":"crossref","unstructured":"429. Ishiguro S, Nishimura K, Nakamura Y, Kanaoka Y, Nishimura M. Pitfall of percutaneous cardiopulmonary support for acute massive pulmonary embolism. <i>Circ J<\/i> 2007; 71: 1657\u20131658.","DOI":"10.1253\/circj.71.1657"},{"key":"430","unstructured":"430. JRC\u8607\u751f\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3ALS\u4f5c\u696d\u90e8\u4f1a. \u80ba\u8840\u6813\u585e\u6813\u75c7\u306b\u3088\u308b\u5fc3\u505c\u6b62. \u65e5\u672c\u8607\u751f\u5354\u8b70\u4f1a \u76e3\u4fee. JRC\u8607\u751f\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 2020. \u533b\u5b66\u66f8\u9662 2021: 108\u2013109."},{"key":"431","doi-asserted-by":"crossref","unstructured":"431. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GV, Dawley D, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. <i>Lancet<\/i> 1988; 2: 293\u2013298.","DOI":"10.1016\/S0140-6736(88)92354-9"},{"key":"432","doi-asserted-by":"crossref","unstructured":"432. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. <i>Am J Cardiol<\/i> 1997; 80: 184\u2013188.","DOI":"10.1016\/S0002-9149(97)00315-9"},{"key":"433","doi-asserted-by":"crossref","unstructured":"433. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: A meta-analysis. <i>JAMA<\/i> 2014; 311: 2414\u20132421.","DOI":"10.1001\/jama.2014.5990"},{"key":"434","doi-asserted-by":"crossref","unstructured":"434. Jerjes-Sanchez C, Ram\u00edrez-Rivera A, de Lourdes Garc\u00eda M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. <i>J Thromb Thrombolysis<\/i> 1995; 2: 227\u2013229.","DOI":"10.1007\/BF01062714"},{"key":"435","doi-asserted-by":"crossref","unstructured":"435. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. <i>N Engl J Med<\/i> 2014; 370: 1402\u20131411.","DOI":"10.1056\/NEJMoa1302097"},{"key":"436","doi-asserted-by":"crossref","unstructured":"436. Niwa A, Nakamura M, Harada N, Musha T. Observational investigation of thrombolysis with the tissue-type plasminogen activator monteplase for acute pulmonary embolism in Japan. <i>Circ J<\/i> 2012; 76: 2471\u20132480.","DOI":"10.1253\/circj.CJ-12-0091"},{"key":"437","doi-asserted-by":"crossref","unstructured":"437. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M; \u201cMOPETT\u201d Investigators. Moderate pulmonary embolism treated with thrombolysis (from the \u201cMOPETT\u201d Trial). <i>Am J Cardiol<\/i> 2013; 111: 273\u2013277.","DOI":"10.1016\/j.amjcard.2012.09.027"},{"key":"438","doi-asserted-by":"crossref","unstructured":"438. Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: A randomized, multicenter, controlled trial. <i>Chest<\/i> 2010; 137: 254\u2013262.","DOI":"10.1378\/chest.09-0765"},{"key":"439","unstructured":"439. Amini S, Bakhshandeh H, Mosaed R, Abtahi H, Sadeghi K, Mojtahedzadeh M. Efficacy and safety of different dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: A systematic review and meta-analysis. <i>Iran J Pharm Res<\/i> 2021; 20: 441\u2013454."},{"key":"440","doi-asserted-by":"crossref","unstructured":"440. Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: Cardiopulmonary outcomes at 3 months: Multicenter double-blind, placebocontrolled randomized trial. <i>J Thromb Haemost<\/i> 2014; 12: 459\u2013468.","DOI":"10.1111\/jth.12521"},{"key":"441","doi-asserted-by":"crossref","unstructured":"441. Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. <i>J Am Coll Cardiol<\/i> 2017; 69: 1536\u20131544.","DOI":"10.1016\/j.jacc.2016.12.039"},{"key":"442","doi-asserted-by":"crossref","unstructured":"442. Kauppila A. The use of oestrogens and progestin and the risk of breast cancer in post-menopausal women. G.A. Colditz et al. N. Engl. J. Med. 1995; 332: 1589\u201393. <i>Pharmacol Res<\/i> 1995; 32: 327.","DOI":"10.1016\/S1043-6618(05)80035-0"},{"key":"443","doi-asserted-by":"crossref","unstructured":"443. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. <i>N Engl J Med<\/i> 1999; 340: 901\u2013907.","DOI":"10.1056\/NEJM199903253401201"},{"key":"444","doi-asserted-by":"crossref","unstructured":"444. Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: Randomised trial. <i>BMJ<\/i> 2007; 334: 674.","DOI":"10.1136\/bmj.39098.583356.55"},{"key":"445","doi-asserted-by":"crossref","unstructured":"445. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. <i>Ann Intern Med<\/i> 2003; 139: 19\u201325.","DOI":"10.7326\/0003-4819-139-1-200307010-00008"},{"key":"446","doi-asserted-by":"crossref","unstructured":"446. Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The PADIS-PE randomized clinical trial. <i>JAMA<\/i> 2015; 314: 31\u201340.","DOI":"10.1001\/jama.2015.7046"},{"key":"447","doi-asserted-by":"crossref","unstructured":"447. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. <i>N Engl J Med<\/i> 2010; 363: 2499\u20132510.","DOI":"10.1056\/NEJMoa1007903"},{"key":"448","doi-asserted-by":"crossref","unstructured":"448. Weitz JI, Lensing AW, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. <i>N Engl J Med<\/i> 2017; 376: 1211\u20131222.","DOI":"10.1056\/NEJMoa1700518"},{"key":"449","doi-asserted-by":"crossref","unstructured":"449. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. <i>N Engl J Med<\/i> 2013; 368: 699\u2013708.","DOI":"10.1056\/NEJMoa1207541"},{"key":"450","doi-asserted-by":"crossref","unstructured":"450. Fukamachi D, Okumura Y, Fukuda I, Nakamura M, Yamada N, Takayama M, et al. Characteristics and clinical outcomes of Japanese patients with venous thromboembolism receiving under-dose rivaroxaban: Subanalysis of J\u2019xactly. <i>Curr Med Res Opin<\/i> 2022; 38: 1059\u20131068.","DOI":"10.1080\/03007995.2022.2070379"},{"key":"451","doi-asserted-by":"crossref","unstructured":"451. Ogino Y, Ishigami T, Minamimoto Y, Kimura Y, Akiyama E, Okada K, et al. Direct oral anticoagulant therapy for cancer-associated venous thromboembolism in routine clinical practice. <i>Circ J<\/i> 2020; 84: 1330\u20131338.","DOI":"10.1253\/circj.CJ-20-0084"},{"key":"452","doi-asserted-by":"crossref","unstructured":"452. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. Aspirin for preventing the recurrence of venous thromboembolism. <i>N Engl J Med<\/i> 2012; 366: 1959\u20131967.","DOI":"10.1056\/NEJMoa1114238"},{"key":"453","doi-asserted-by":"crossref","unstructured":"453. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. <i>N Engl J Med<\/i> 2012; 367: 1979\u20131987.","DOI":"10.1056\/NEJMoa1210384"},{"key":"454","doi-asserted-by":"crossref","unstructured":"454. Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: Guidance from the SSC of ISTH. <i>J Thromb Haemost<\/i> 2016; 14: 1480\u20131483.","DOI":"10.1111\/jth.13336"},{"key":"455","doi-asserted-by":"crossref","unstructured":"455. Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, et al. Risk of recurrence after a \ufb01rst episode of symptomatic venous thromboembolism provoked by a transient risk factor: A systematic review. <i>Arch Intern Med<\/i> 2010; 170: 1710\u20131716.","DOI":"10.1001\/archinternmed.2010.367"},{"key":"456","doi-asserted-by":"crossref","unstructured":"456. Ensor J, Riley RD, Moore D, Snell KI, Bayliss S, Fitzmaurice D. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of \ufb01rst unprovoked VTE. <i>BMJ Open<\/i> 2016; 6: e011190.","DOI":"10.1136\/bmjopen-2016-011190"},{"key":"457","doi-asserted-by":"crossref","unstructured":"457. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: A prospective cohort study in 1,626 patients. <i>Haematologica<\/i> 2007; 92: 199\u2013205.","DOI":"10.3324\/haematol.10516"},{"key":"458","doi-asserted-by":"crossref","unstructured":"458. Hansson PO, S\u00f6rbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. <i>Arch Intern Med<\/i> 2000; 160: 769\u2013774.","DOI":"10.1001\/archinte.160.6.769"},{"key":"459","doi-asserted-by":"crossref","unstructured":"459. Takahashi K, Yamashita Y, Morimoto T, Tada T, Sakamoto H, Takase T, et al. Age and long-term outcomes of patients with venous thromboembolism: From the COMMAND VTE Registry. <i>Int J Cardiol<\/i> 2023; 383: 89\u201395.","DOI":"10.1016\/j.ijcard.2023.04.050"},{"key":"460","doi-asserted-by":"crossref","unstructured":"460. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient\u2019s sex on risk of recurrent venous thromboembolism: A meta-analysis. <i>Lancet<\/i> 2006; 368: 371\u2013378.","DOI":"10.1016\/S0140-6736(06)69110-1"},{"key":"461","doi-asserted-by":"crossref","unstructured":"461. Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, et al. Risk of recurrence after venous thromboembolism in men and women: Patient level meta-analysis. <i>BMJ<\/i> 2011; 342: d813.","DOI":"10.1136\/bmj.d813"},{"key":"462","doi-asserted-by":"crossref","unstructured":"462. Yoshikawa Y, Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, et al. Sex differences in clinical characteristics and outcomes of patients with venous thromboembolism: From the COMMAND VTE Registry. <i>Circ J<\/i> 2019; 83: 1581\u20131589.","DOI":"10.1253\/circj.CJ-19-0229"},{"key":"463","doi-asserted-by":"crossref","unstructured":"463. Kaneda K, Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, et al. Influence of low body weight on long-term clinical outcomes in patients with venous thromboembolism: From the COMMAND VTE registry. <i>Thromb Res<\/i> 2021; 198: 26\u201333.","DOI":"10.1016\/j.thromres.2020.11.022"},{"key":"464","doi-asserted-by":"crossref","unstructured":"464. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: Analysis of individual participants\u2019 data from seven trials. <i>BMJ<\/i> 2011; 342: d3036.","DOI":"10.1136\/bmj.d3036"},{"key":"465","doi-asserted-by":"crossref","unstructured":"465. Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. <i>J Thromb Haemost<\/i> 2010; 8: 2436\u20132442.","DOI":"10.1111\/j.1538-7836.2010.04022.x"},{"key":"466","doi-asserted-by":"crossref","unstructured":"466. Yamashita Y, Murata K, Morimoto T, Amano H, Takase T, Hiramori S, et al. Clinical outcomes of patients with pulmonary embolism versus deep vein thrombosis: From the COMMAND VTE Registry. <i>Thromb Res<\/i> 2019; 184: 50\u201357.","DOI":"10.1016\/j.thromres.2019.10.029"},{"key":"467","doi-asserted-by":"crossref","unstructured":"467. Schulman S, W\u00e5hlander K, Lundstr\u00f6m T, Clason SB, Eriksson H; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. <i>N Engl J Med<\/i> 2003; 349: 1713\u20131721.","DOI":"10.1056\/NEJMoa030104"},{"key":"468","doi-asserted-by":"crossref","unstructured":"468. Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: A management study. <i>Blood<\/i> 2014; 124: 196\u2013203.","DOI":"10.1182\/blood-2014-01-548065"},{"key":"469","doi-asserted-by":"crossref","unstructured":"469. Editor\u2019s choice \u2013 European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. <i>Eur J Vasc Endovasc Surg<\/i> 2021; 61: 9\u201382.","DOI":"10.1016\/j.ejvs.2020.09.023"},{"key":"470","doi-asserted-by":"crossref","unstructured":"470. Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 Guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Adv<\/i> 2020; 4: 4693\u20134738.","DOI":"10.1182\/bloodadvances.2020001830"},{"key":"471","doi-asserted-by":"crossref","unstructured":"471. Kaneda K, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Ikeda N, et al. Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants. <i>Eur J Intern Med<\/i> 2023; 118: 59\u201372.","DOI":"10.1016\/j.ejim.2023.08.007"},{"key":"472","doi-asserted-by":"crossref","unstructured":"472. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: A meta-analysis. <i>Ann Intern Med<\/i> 2003; 139: 893\u2013900.","DOI":"10.7326\/0003-4819-139-11-200312020-00007"},{"key":"473","doi-asserted-by":"crossref","unstructured":"473. Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor\u2019s choice \u2013 efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: A systematic review and meta-analysis of phase III trials. <i>Eur J Vasc Endovasc Surg<\/i> 2014; 48: 565\u2013575.","DOI":"10.1016\/j.ejvs.2014.05.001"},{"key":"474","doi-asserted-by":"crossref","unstructured":"474. Nakamura M, Wang YQ, Wang C, Oh D, Yin WH, Kimura T, et al. Ef\ufb01cacy and safety of edoxaban for treatment of venous thromboembolism: A subanalysis of East Asian patients in the Hokusai-VTE trial. <i>J Thromb Haemost<\/i> 2015; 13: 1606\u20131614.","DOI":"10.1111\/jth.13055"},{"key":"475","doi-asserted-by":"crossref","unstructured":"475. Kim K, Yamashita Y, Morimoto T, Kitai T, Yamane T, Ehara N, et al. Risk factors for major bleeding during prolonged anticoagulation therapy in patients with venous thromboembolism: From the COMMAND VTE Registry. <i>Thromb Haemost<\/i> 2019; 119: 1498\u20131507.","DOI":"10.1055\/s-0039-1692425"},{"key":"476","doi-asserted-by":"crossref","unstructured":"476. Nishimoto Y, Yamashita Y, Morimoto T, Saga S, Amano H, Takase T, et al. Validation of the VTE-BLEED score\u2019s long-term performance for major bleeding in patients with venous thromboembolisms: From the COMMAND VTE registry. <i>J Thromb Haemost<\/i> 2020; 18: 624\u2013632.","DOI":"10.1111\/jth.14691"},{"key":"477","doi-asserted-by":"crossref","unstructured":"477. Yamashita Y, Morimoto T, Kimura T. Venous thromboembolism: Recent advancement and future perspective. <i>J Cardiol<\/i> 2022; 79: 79\u201389.","DOI":"10.1016\/j.jjcc.2021.08.026"},{"key":"478","doi-asserted-by":"crossref","unstructured":"478. Mountain D, Jacobs I, Haig A. The VIDAS D-dimer test for venous thromboembolism: A prospective surveillance study shows maintenance of sensitivity and specificity when used in normal clinical practice. <i>Am J Emerg Med<\/i> 2007; 25: 464\u2013471.","DOI":"10.1016\/j.ajem.2006.09.004"},{"key":"479","doi-asserted-by":"crossref","unstructured":"479. Zhao Y, Arya R, Couchman L, Patel JP. Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations? <i>Blood<\/i> 2020; 136: 1783\u20131785.","DOI":"10.1182\/blood.2020006231"},{"key":"480","doi-asserted-by":"crossref","unstructured":"480. Yamashita Y, Hira D, Morita M, Katsube Y, Takakura M, Tomotaki H, et al. Potential treatment option of rivaroxaban for breastfeeding women: A case series. <i>Thromb Res<\/i> 2024; 237: 141\u2013144.","DOI":"10.1016\/j.thromres.2024.04.003"},{"key":"481","doi-asserted-by":"crossref","unstructured":"481. Burton JR, Madhavan MV, Finn M, Ingrassia JJ, Bikdeli B, Nabavi Nouri S, et al. Advanced therapies for acute pulmonary embolism: A focus on catheter-based therapies and future directions. <i>Struct Heart<\/i> 2021; 5: 103\u2013119.","DOI":"10.1080\/24748706.2020.1853860"},{"key":"482","unstructured":"482. \u65e5\u672c\u9759\u8108\u5b66\u4f1a. \u8840\u6813\u9664\u53bb\u30c7\u30d0\u30a4\u30b9\u9759\u8108\u30b9\u30c6\u30f3\u30c8\u9069\u6b63\u4f7f\u7528\u6307\u91dd. https:\/\/js-phlebology.jp\/?page_id=3099 (accessed January 22, 2026)."},{"key":"483","doi-asserted-by":"crossref","unstructured":"483. Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. <i>Circulation<\/i> 1988; 77: 353\u2013360.","DOI":"10.1161\/01.CIR.77.2.353"},{"key":"484","doi-asserted-by":"crossref","unstructured":"484. Kucher N, Boekstegers P, M\u00fcller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. <i>Circulation<\/i> 2014; 129: 479\u2013486.","DOI":"10.1161\/CIRCULATIONAHA.113.005544"},{"key":"485","doi-asserted-by":"crossref","unstructured":"485. Avgerinos ED, Jaber W, Lacomis J, Markel K, McDaniel M, Rivera-Lebron BN, et al. Randomized trial comparing standard versus ultrasound-assisted thrombolysis for submassive pulmonary embolism: The SUNSET sPE Trial. <i>JACC Cardiovasc Interv<\/i> 2021; 14: 1364\u20131373.","DOI":"10.1016\/j.jcin.2021.04.049"},{"key":"486","doi-asserted-by":"crossref","unstructured":"486. Tu T, Toma C, Tapson VF, Adams C, Jaber WA, Silver M, et al. A prospective, single-arm, multicenter trial of catheter-directed mechanical thrombectomy for intermediate-risk acute pulmonary embolism: The FLARE Study. <i>JACC Cardiovasc Interv<\/i> 2019; 12: 859\u2013869.","DOI":"10.1016\/j.jcin.2018.12.022"},{"key":"487","doi-asserted-by":"crossref","unstructured":"487. Toma C, Bunte MC, Cho KH, Jaber WA, Chambers J, Stegman B, et al. Percutaneous mechanical thrombectomy in a real-world pulmonary embolism population: Interim results of the FLASH registry. <i>Catheter Cardiovasc Interv<\/i> 2022; 99: 1345\u20131355.","DOI":"10.1002\/ccd.30091"},{"key":"488","doi-asserted-by":"crossref","unstructured":"488. Sista AK, Horowitz JM, Tapson VF, Rosenberg M, Elder MD, Schiro BJ, et al. Indigo aspiration system for treatment of pulmonary embolism: Results of the EXTRACT-PE Trial. <i>JACC Cardiovasc Interv<\/i> 2021; 14: 319\u2013329.","DOI":"10.1016\/j.jcin.2020.09.053"},{"key":"489","doi-asserted-by":"crossref","unstructured":"489. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. <i>Circulation<\/i> 2006; 113: 577\u2013582.","DOI":"10.1161\/CIRCULATIONAHA.105.592592"},{"key":"490","doi-asserted-by":"crossref","unstructured":"490. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. <i>J Am Coll Cardiol<\/i> 1997; 30: 1165\u20131171.","DOI":"10.1016\/S0735-1097(97)00319-7"},{"key":"491","doi-asserted-by":"crossref","unstructured":"491. Torbicki A, Gali\u00e9 N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ, et al. Right heart thrombi in pulmonary embolism: Results from the International Cooperative Pulmonary Embolism Registry. <i>J Am Coll Cardiol<\/i> 2003; 41: 2245\u20132251.","DOI":"10.1016\/S0735-1097(03)00479-0"},{"key":"492","doi-asserted-by":"crossref","unstructured":"492. Pasrija C, Kronfli A, Rouse M, Raithel M, Bittle GJ, Pousatis S, et al. Outcomes after surgical pulmonary embolectomy for acute submassive and massive pulmonary embolism: A single-center experience. <i>J Thorac Cardiovasc Surg<\/i> 2018; 155: 1095\u20131106.e2.","DOI":"10.1016\/j.jtcvs.2017.10.139"},{"key":"493","doi-asserted-by":"crossref","unstructured":"493. Goldberg JB, Spevack DM, Ahsan S, Rochlani Y, Dutta T, Ohira S, et al. Survival and right ventricular function after surgical management of acute pulmonary embolism. <i>J Am Coll Cardiol<\/i> 2020; 76: 903\u2013911.","DOI":"10.1016\/j.jacc.2020.06.065"},{"key":"494","doi-asserted-by":"crossref","unstructured":"494. Keeling WB, Sundt T, Leacche M, Okita Y, Binongo J, Lasajanak Y, et al. Outcomes after surgical pulmonary embolectomy for acute pulmonary embolus: A multi-institutional study. <i>Ann Thorac Surg<\/i> 2016; 102: 1498\u20131502.","DOI":"10.1016\/j.athoracsur.2016.05.004"},{"key":"495","doi-asserted-by":"crossref","unstructured":"495. Neely RC, Byrne JG, Gosev I, Cohn LH, Javed Q, Rawn JD, et al. Surgical embolectomy for acute massive and submassive pulmonary embolism in a series of 115 patients. <i>Ann Thorac Surg<\/i> 2015; 100: 1245\u20131251.","DOI":"10.1016\/j.athoracsur.2015.03.111"},{"key":"496","doi-asserted-by":"crossref","unstructured":"496. QiMin W, LiangWan C, DaoZhong C, HanFan Q, ZhongYao H, XiaoFu D, et al. Clinical outcomes of acute pulmonary embolectomy as the first-line treatment for massive and submassive pulmonary embolism: A single-centre study in China. <i>J Cardiothorac Surg<\/i> 2020; 15: 321.","DOI":"10.1186\/s13019-020-01364-z"},{"key":"497","doi-asserted-by":"crossref","unstructured":"497. Kalra R, Bajaj NS, Arora P, Arora G, Crosland WA, McGiffin DC, et al. Surgical embolectomy for acute pulmonary embolism: Systematic review and comprehensive meta-analyses. <i>Ann Thorac Surg<\/i> 2017; 103: 982\u2013990.","DOI":"10.1016\/j.athoracsur.2016.11.016"},{"key":"498","doi-asserted-by":"crossref","unstructured":"498. Dohle K, Dohle DS, El Beyrouti H, Buschmann K, Emrich AL, Brendel L, et al. Short- and long-term outcomes for the surgical treatment of acute pulmonary embolism. <i>Innov Surg Sci<\/i> 2018; 3: 271\u2013276.","DOI":"10.1515\/iss-2018-0024"},{"key":"499","doi-asserted-by":"crossref","unstructured":"499. Aymard T, Kadner A, Widmer A, Basciani R, Tevaearai H, Weber A, et al. Massive pulmonary embolism: Surgical embolectomy versus thrombolytic therapy \u2013 should surgical indications be revisited? <i>Eur J Cardiothorac Surg<\/i> 2013; 43: 90\u201394.","DOI":"10.1093\/ejcts\/ezs123"},{"key":"500","doi-asserted-by":"crossref","unstructured":"500. Choi JH, O\u2019Malley TJ, Maynes EJ, Weber MP, D\u2019Antonio ND, Mellado M, et al. Surgical pulmonary embolectomy outcomes for acute pulmonary embolism. <i>Ann Thorac Surg<\/i> 2020; 110: 1072\u20131080.","DOI":"10.1016\/j.athoracsur.2020.01.075"},{"key":"501","doi-asserted-by":"crossref","unstructured":"501. Kaufman JA, Kinney TB, Streiff MB, Sing RF, Proctor MC, Becker D, et al. Guidelines for the use of retrievable and convertible vena cava filters: Report from the Society of Interventional Radiology multidisciplinary consensus conference. <i>J Vasc Interv Radiol<\/i> 2006; 17: 449\u2013459.","DOI":"10.1097\/01.RVI.0000203418-39769.0D"},{"key":"502","doi-asserted-by":"crossref","unstructured":"502. Streiff MB. Vena caval \ufb01lters: A comprehensive review. <i>Blood<\/i> 2000; 95: 3669\u20133677.","DOI":"10.1182\/blood.V95.12.3669.012k49_3669_3677"},{"key":"503","doi-asserted-by":"crossref","unstructured":"503. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Pr\u00e9vention du Risque d\u2019Embolie Pulmonaire par Interruption Cave Study Group. <i>N Engl J Med<\/i> 1998; 338: 409\u2013415.","DOI":"10.1056\/NEJM199802123380701"},{"key":"504","doi-asserted-by":"crossref","unstructured":"504. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava \ufb01lters in the prevention of pulmonary embolism: The PREPIC (Prevention du Risque d\u2019Embolie Pulmonaire par Interruption Cave) randomized study. <i>Circulation<\/i> 2005; 112: 416\u2013422.","DOI":"10.1161\/CIRCULATIONAHA.104.512834"},{"key":"505","doi-asserted-by":"crossref","unstructured":"505. Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: A randomized clinical trial. <i>JAMA<\/i> 2015; 313: 1627\u20131635.","DOI":"10.1001\/jama.2015.3780"},{"key":"506","doi-asserted-by":"crossref","unstructured":"506. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest<\/i> 2016; 149: 315\u2013352.","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"507","doi-asserted-by":"crossref","unstructured":"507. Kaufman JA, Barnes GD, Chaer RA, Cuschieri J, Eberhardt RT, Johnson MS, et al. Society of Interventional Radiology clinical practice guideline for inferior vena cava \ufb01lters in the treatment of patients with venous thromboembolic disease: Developed in collaboration with the American College of Cardiology, American College of Chest Physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and Society for Vascular Medicine. <i>J Vasc Interv Radiol<\/i> 2020; 31: 1529\u20131544.","DOI":"10.1016\/j.jvir.2020.06.014"},{"key":"508","doi-asserted-by":"crossref","unstructured":"508. Stein PD, Matta F, Keyes DC, Willyerd GL. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. <i>Am J Med<\/i> 2012; 125: 478\u2013484.","DOI":"10.1016\/j.amjmed.2011.05.025"},{"key":"509","doi-asserted-by":"crossref","unstructured":"509. Stein PD, Matta F. Vena cava \ufb01lters in unstable elderly patients with acute pulmonary embolism. <i>Am J Med<\/i> 2014; 127: 222\u2013225.","DOI":"10.1016\/j.amjmed.2013.11.003"},{"key":"510","doi-asserted-by":"crossref","unstructured":"510. Isogai T, Yasunaga H, Matsui H, Tanaka H, Horiguchi H, Fushimi K. Effectiveness of inferior vena cava filters on mortality as an adjuvant to antithrombotic therapy. <i>Am J Med<\/i> 2015; 128: 312.e23\u2013e31.","DOI":"10.1016\/j.amjmed.2014.10.034"},{"key":"511","doi-asserted-by":"crossref","unstructured":"511. Harris SA, Velineni R, Davies AH. Inferior vena cava \ufb01lters in pregnancy: A systematic review. <i>J Vasc Interv Radiol<\/i> 2016; 27: 354\u2013360.e8.","DOI":"10.1016\/j.jvir.2015.11.024"},{"key":"512","doi-asserted-by":"crossref","unstructured":"512. Ho KM, Rao S, Honeybul S, Zellweger R, Wibrow B, Lipman J, et al. A multicenter trial of vena cava filters in severely injured patients. <i>N Engl J Med<\/i> 2019; 381: 328\u2013337.","DOI":"10.1056\/NEJMoa1806515"},{"key":"513","doi-asserted-by":"crossref","unstructured":"513. Ramanathan R, Gu Z, Limkemann AJ, Chandrasekhar S, Rensing E, Mays C, et al. Association between interruptions in chemical prophylaxis and VTE formation. <i>Am Surg<\/i> 2015; 81: 732\u2013737.","DOI":"10.1177\/000313481508100725"},{"key":"514","doi-asserted-by":"crossref","unstructured":"514. Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al. Anticoagulation therapy for venous thromboembolism in the real world: From the COMMAND VTE Registry. <i>Circ J<\/i> 2018; 82: 1262\u20131270.","DOI":"10.1253\/circj.CJ-17-1128"},{"key":"515","doi-asserted-by":"crossref","unstructured":"515. Hokusai-VTE Investigators; B\u00fcller HR, D\u00e9cousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. <i>N Engl J Med<\/i> 2013; 369: 1406\u20131415.","DOI":"10.1056\/NEJMoa1306638"},{"key":"516","doi-asserted-by":"crossref","unstructured":"516. EINSTEIN\u2013PE Investigators; B\u00fcller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>N Engl J Med<\/i> 2012; 366: 1287\u20131297.","DOI":"10.1056\/NEJMoa1113572"},{"key":"517","doi-asserted-by":"crossref","unstructured":"517. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. <i>N Engl J Med<\/i> 2013; 369: 799\u2013808.","DOI":"10.1056\/NEJMoa1302507"},{"key":"518","doi-asserted-by":"crossref","unstructured":"518. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest<\/i> 2012; 141(Suppl): e419S\u2013e496S.","DOI":"10.1378\/chest.11-2301"},{"key":"519","doi-asserted-by":"crossref","unstructured":"519. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). <i>Chest<\/i> 2008; 133(Suppl): 454S\u2013545S.","DOI":"10.1378\/chest.08-0658"},{"key":"520","unstructured":"520. National Institute for Heath and Care Excellence (NICE). Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing. Clinical guideline CG144. 2012. https:\/\/www.nice.org.uk\/guidance\/cg144 (accessed January 22, 2026)."},{"key":"521","doi-asserted-by":"crossref","unstructured":"521. Horner D, Hogg K, Body R, Nash MJ, Baglin T, Mackway-Jones K. The anticoagulation of calf thrombosis (ACT) project: Results from the randomized controlled external pilot trial. <i>Chest<\/i> 2014; 146: 1468\u20131477.","DOI":"10.1378\/chest.14-0235"},{"key":"522","doi-asserted-by":"crossref","unstructured":"522. Righini M, Galanaud JP, Guenneguez H, Brisot D, Diard A, Faisse P, et al. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): A randomised, double-blind, placebo-controlled trial. <i>Lancet Haematol<\/i> 2016; 3: e556\u2013e562.","DOI":"10.1016\/S2352-3026(16)30131-4"},{"key":"523","doi-asserted-by":"crossref","unstructured":"523. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. <i>Lancet<\/i> 1985; 2: 515\u2013518.","DOI":"10.1016\/S0140-6736(85)90459-3"},{"key":"524","doi-asserted-by":"crossref","unstructured":"524. Shimabukuro N, Mo M, Hashiyama N, Matsubara S, Nemoto H, Kobayashi Y, et al. Clinical course of asymptomatic isolated distal deep vein thrombosis of the leg: A single-institution study. <i>Ann Vasc Dis<\/i> 2019; 12: 487\u2013492.","DOI":"10.3400\/avd.oa.19-00128"},{"key":"525","unstructured":"525. \u5c71\u7530\u5178\u4e00, \u516b\u5dfb\u9686, \u5ca9\u7530\u535a\u82f1, \u4ed6. \u672c\u90a6\u306b\u304a\u3051\u308b\u4e0b\u817f\u9650\u5c40\u578b\u6df1\u90e8\u9759\u8108\u8840\u6813\u75c7\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u306e\u73fe\u72b6 (\u65e5\u672c\u9759\u8108\u5b66\u4f1a\u30b5\u30fc\u30d9\u30a4\u8abf\u67fb\u7814\u7a76\u5831\u544a). \u9759\u8108\u5b66 2013; <b>24:<\/b> 211."},{"key":"526","doi-asserted-by":"crossref","unstructured":"526. Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, et al. One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry. <i>Thromb Res<\/i> 2022; 213: 203\u2013213.","DOI":"10.1016\/j.thromres.2021.09.012"},{"key":"527","doi-asserted-by":"crossref","unstructured":"527. \u699b\u6ca2\u548c\u5f66, \u4f0a\u5009\u771f\u8863\u5b50. \u65e5\u672c\u306b\u304a\u3051\u308b\u707d\u5bb3\u306e\u7121\u3044\u5730\u57df (\u707d\u5bb3\u5bfe\u7167\u5730) \u306e\u4e0b\u817f\u6df1\u90e8\u9759\u8108\u8840\u6813\u306e\u967d\u6027\u7387. \u8840\u6813\u6b62\u8840\u8a8c 2022; <b>33:<\/b> 675\u2013682.","DOI":"10.2491\/jjsth.33.675"},{"key":"528","doi-asserted-by":"crossref","unstructured":"528. Kuroiwa M, Morimatsu H, Tsuzaki K, Irita K, Sanuki M, Nakatsuka H, et al. Changes in the incidence, case fatality rate, and characteristics of symptomatic perioperative pulmonary thromboembolism in Japan: Results of the 2002\u20132011 Japanese Society of Anesthesiologists Perioperative Pulmonary Thromboembolism (JSA-PTE) Study. <i>J Anesth<\/i> 2015; 29: 433\u2013441.","DOI":"10.1007\/s00540-014-1939-y"},{"key":"529","doi-asserted-by":"crossref","unstructured":"529. Nishimoto Y, Ohbe H, Matsui H, Nakajima M, Sasabuchi Y, Sato Y, et al. Trends in treatment patterns and outcomes of patients with pulmonary embolism in Japan, 2010 to 2020: A nationwide inpatient database study. <i>J Am Heart Assoc<\/i> 2023; 12: e028981.","DOI":"10.1161\/JAHA.122.028981"},{"key":"530","doi-asserted-by":"crossref","unstructured":"530. Singh K, Yakoub D, Giangola P, DeCicca M, Patel CA, Marzouk F, et al. Early follow-up and treatment recommendations for isolated calf deep venous thrombosis. <i>J Vasc Surg<\/i> 2012; 55: 136\u2013140.","DOI":"10.1016\/j.jvs.2011.07.088"},{"key":"531","doi-asserted-by":"crossref","unstructured":"531. Ageno W, Bert\u00f9 L, Bucherini E, Camporese G, Dentali F, Iotti M, et al. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: Randomised controlled trial. <i>BMJ<\/i> 2022; 379: e072623.","DOI":"10.1136\/bmj-2022-072623"},{"key":"532","doi-asserted-by":"crossref","unstructured":"532. Xiong W, Yamashita Y, Morimoto T, Muraoka N, Umetsu M, Nishimoto Y, et al. Utility of the modi\ufb01ed Ottawa score for identi\ufb01cation of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: Insight from the ONCO DVT Study. <i>J Thromb Haemost<\/i> 2024; 22: 3542\u20133551.","DOI":"10.1016\/j.jtha.2024.09.003"},{"key":"533","doi-asserted-by":"crossref","unstructured":"533. Yamada N, Ishikura K, Ota S, Tsuji A, Nakamura M, Ito M, et al. Pulse-spray pharmacomechanical thrombolysis for proximal deep vein thrombosis. <i>Eur J Vasc Endovasc Surg<\/i> 2006; 31: 204\u2013211.","DOI":"10.1016\/j.ejvs.2005.08.010"},{"key":"534","doi-asserted-by":"crossref","unstructured":"534. Delomez M, Beregi JP, Willoteaux S, Bauchart JJ, Janne D\u2019Oth\u00e9e B, Asseman P, et al. Mechanical thrombectomy in patients with deep venous thrombosis. <i>Cardiovasc Intervent Radiol<\/i> 2001; 24: 42\u201348.","DOI":"10.1007\/s002700001658"},{"key":"535","doi-asserted-by":"crossref","unstructured":"535. Enden T, Haig Y, Kl\u00f8w NE, Slagsvold CE, Sandvik L, Ghanima W, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): A randomised controlled trial. <i>Lancet<\/i> 2012; 379: 31\u201338.","DOI":"10.1016\/S0140-6736(11)61753-4"},{"key":"536","doi-asserted-by":"crossref","unstructured":"536. Haig Y, Enden T, Gr\u00f8tta O, Kl\u00f8w NE, Slagsvold CE, Ghanima W, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. <i>Lancet Haematol<\/i> 2016; 3: e64\u2013e71.","DOI":"10.1016\/S2352-3026(15)00248-3"},{"key":"537","doi-asserted-by":"crossref","unstructured":"537. Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. <i>N Engl J Med<\/i> 2017; 377: 2240\u20132252.","DOI":"10.1056\/NEJMoa1615066"},{"key":"538","doi-asserted-by":"crossref","unstructured":"538. Comerota AJ, Kearon C, Gu CS, Julian JA, Goldhaber SZ, Kahn SR, et al. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. <i>Circulation<\/i> 2019; 139: 1162\u20131173.","DOI":"10.1161\/CIRCULATIONAHA.118.037425"},{"key":"539","doi-asserted-by":"crossref","unstructured":"539. Notten P, Ten Cate-Hoek AJ, Arnoldussen CW, Strijkers RH, De Smet AA, Tick LW, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): A single-blind, multicentre, randomised trial. <i>Lancet Haematol<\/i> 2020; 7: e40\u2013e49.","DOI":"10.1016\/S2352-3026(19)30209-1"},{"key":"540","doi-asserted-by":"crossref","unstructured":"540. Sharifi M, Bay C, Skrocki L, Lawson D, Mazdeh S. Role of IVC filters in endovenous therapy for deep venous thrombosis: The FILTER-PEVI (Filter Implantation to Lower Thromboembolic Risk in Percutaneous Endovenous Intervention) trial. <i>Cardiovasc Intervent Radiol<\/i> 2012; 35: 1408\u20131413.","DOI":"10.1007\/s00270-012-0342-z"},{"key":"541","doi-asserted-by":"crossref","unstructured":"541. Lee SH, Kim HK, Hwang JK, Kim SD, Park SC, Kim JI, et al. Efficacy of retrievable inferior vena cava \ufb01lter placement in the prevention of pulmonary embolism during catheter-directed thrombectomy for proximal lower-extremity deep vein thrombosis. <i>Ann Vasc Surg<\/i> 2016; 33: 181\u2013186.","DOI":"10.1016\/j.avsg.2015.10.034"},{"key":"542","doi-asserted-by":"crossref","unstructured":"542. Jiang J, Tu J, Jia Z, Chen J, Cao H, Meng Q, et al. Incidence and outcomes of inferior vena cava \ufb01lter thrombus during catheter-directed thrombolysis for proximal deep venous thrombosis. <i>Ann Vasc Surg<\/i> 2017; 38: 305\u2013309.","DOI":"10.1016\/j.avsg.2016.05.108"},{"key":"543","doi-asserted-by":"crossref","unstructured":"543. Matsuda A, Yamada N, Ogihara Y, Tsuji A, Ota S, Ishikura K, et al. Early and long-term outcomes of venous stent implantation for iliac venous stenosis after catheter-directed thrombolysis for acute deep vein thrombosis. <i>Circ J<\/i> 2014; 78: 1234\u20131239.","DOI":"10.1253\/circj.CJ-13-1247"},{"key":"544","doi-asserted-by":"crossref","unstructured":"544. Funatsu A, Anzai H, Komiyama K, Oi K, Araki H, Tanabe Y, et al. Stent implantation for May\u2013Thurner syndrome with acute deep venous thrombosis: Acute and long-term results from the ATOMIC (AcTive stenting for May\u2013Thurner Iliac Compression syndrome) registry. <i>Cardiovasc Interv Ther<\/i> 2019; 34: 131\u2013138.","DOI":"10.1007\/s12928-018-0532-y"},{"key":"545","doi-asserted-by":"crossref","unstructured":"545. Pouncey AL, Kahn T, Morris RI, Saha P, Thulasidasan N, Black SA. Risk factors and classification of reintervention following deep venous stenting for acute iliofemoral deep vein thrombosis. <i>J Vasc Surg Venous Lymphat Disord<\/i> 2022; 10: 1051\u20131058.e3.","DOI":"10.1016\/j.jvsv.2022.03.006"},{"key":"546","doi-asserted-by":"crossref","unstructured":"546. Lopez R, DeMartino R, Fleming M, Bjarnason H, Neisen M. Aspiration thrombectomy for acute iliofemoral or central deep venous thrombosis. <i>J Vasc Surg Venous Lymphat Disord<\/i> 2019; 7: 162\u2013168.","DOI":"10.1016\/j.jvsv.2018.09.015"},{"key":"547","doi-asserted-by":"crossref","unstructured":"547. Robertson B, Neville E, Muck A, Broering M, Kulwicki A, Kuhn B, et al. Technical success and shortterm results from mechanical thrombectomy for lower extremity iliofemoral deep vein thrombosis using a computer aided mechanical aspiration thrombectomy device. <i>J Vasc Surg Venous Lymphat Disord<\/i> 2022; 10: 594\u2013601.","DOI":"10.1016\/j.jvsv.2021.11.002"},{"key":"548","doi-asserted-by":"crossref","unstructured":"548. Shaikh A, Zybulewski A, Paulisin J, Bisharat M, Mouawad NJ, Raskin A, et al. Six-month outcomes of mechanical thrombectomy for treating deep vein thrombosis: Analysis from the 500-patient CLOUT Registry. <i>Cardiovasc Intervent Radiol<\/i> 2023; 46: 1571\u20131580.","DOI":"10.1007\/s00270-023-03509-8"},{"key":"549","doi-asserted-by":"crossref","unstructured":"549. Chinsakchai K, Ten Duis K, Moll FL, De Borst GJ. Trends in management of phlegmasia cerulea dolens. <i>Vasc Endovasc Surg<\/i> 2011; 45: 5\u201314.","DOI":"10.1177\/1538574410388309"},{"key":"550","doi-asserted-by":"crossref","unstructured":"550. Yin M, Shi H, Ye K, Lu X, Li W, Huang X, et al. Clinical Assessment of endovascular stenting compared with compression therapy alone in post-thrombotic patients with iliofemoral obstruction. <i>Eur J Vasc Endovasc Surg<\/i> 2015; 50: 101\u2013107.","DOI":"10.1016\/j.ejvs.2015.03.029"},{"key":"551","doi-asserted-by":"crossref","unstructured":"551. Badesha AS, Bains PR, Bains BR, Khan T. A systematic review and meta-analysis of the treatment of obstructive chronic deep venous disease using dedicated venous stents. <i>J Vasc Surg Venous Lymphat Disord<\/i> 2022; 10: 267\u2013282.e4.","DOI":"10.1016\/j.jvsv.2021.04.014"},{"key":"552","unstructured":"552. \u661f\u91ce\u7950\u4e8c, \u6a2a\u4e95\u5b8f\u4f73. \u8840\u6813\u5f8c\u75c7\u5019\u7fa4\u306b\u5bfe\u3059\u308b\u8178\u9aa8\u5927\u817f\u9759\u8108\u30b9\u30c6\u30f3\u30c8\u7559\u7f6e\u8853\u306e\u6cbb\u7642\u6210\u7e3e. \u8108\u7ba1\u5b66 2021; <b>61:<\/b> 99\u2013105."},{"key":"553","doi-asserted-by":"crossref","unstructured":"553. \u5ee3\u677e\u4f38\u4e00. \u65e5\u672c\u4eba\u306b\u304a\u3051\u308b\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306e\u5b9f\u614b. \u9759\u8108\u5b66 2024; <b>35:<\/b> 75\u201382.","DOI":"10.7134\/phlebol.23-38"},{"key":"554","unstructured":"554. Laohapensang K, Hanpipat S, Aworn S, Orrapin S. Surgical venous thrombectomy for phlegmasia cerulea dolens and venous gangrene of the lower extremities. <i>J Med Assoc Thai<\/i> 2013; 96: 1463\u20131469."},{"key":"555","doi-asserted-by":"crossref","unstructured":"555. Plate G, Akesson H, Einarsson E, Ohlin P, Ekl\u00f6f B. Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. <i>Eur J Vasc Surg<\/i> 1990; 4: 483\u2013489.","DOI":"10.1016\/S0950-821X(05)80788-1"},{"key":"556","doi-asserted-by":"crossref","unstructured":"556. Plate G, Ekl\u00f6f B, Norgren L, Ohlin P, Dahlstr\u00f6m JA. Venous thrombectomy for iliofemoral vein thrombosis: 10-year results of a prospective randomised study. <i>Eur J Vasc Endovasc Surg<\/i> 1997; 14: 367\u2013374.","DOI":"10.1016\/S1078-5884(97)80286-9"},{"key":"557","doi-asserted-by":"crossref","unstructured":"557. Koopmann MC, McLafferty RB. Advances in operative thrombectomy for lower extremity venous thrombosis. <i>Surg Clin North Am<\/i> 2018; 98: 267\u2013277.","DOI":"10.1016\/j.suc.2017.11.005"},{"key":"558","doi-asserted-by":"crossref","unstructured":"558. Aissaoui N, Martins E, Mouly S, Weber S, Meune C. A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both. <i>Int J Cardiol<\/i> 2009; 137: 37\u201341.","DOI":"10.1016\/j.ijcard.2008.06.020"},{"key":"559","doi-asserted-by":"crossref","unstructured":"559. Kahn SR, Shrier I, Kearon C. Physical activity in patients with deep venous thrombosis: A systematic review. <i>Thromb Res<\/i> 2008; 122: 763\u2013773.","DOI":"10.1016\/j.thromres.2007.10.011"},{"key":"560","doi-asserted-by":"crossref","unstructured":"560. Liu Z, Tao X, Chen Y, Fan Z, Li Y. Bed rest versus early ambulation with standard anticoagulation in the management of deep vein thrombosis: A meta-analysis. <i>PLoS One<\/i> 2015; 10: e0121388.","DOI":"10.1371\/journal.pone.0121388"},{"key":"561","doi-asserted-by":"crossref","unstructured":"561. Monreal M, Ruiz J, Salvador R, Morera J, Arias A. Recurrent pulmonary embolism: A prospective study. <i>Chest<\/i> 1989; 95: 976\u2013979.","DOI":"10.1378\/chest.95.5.976"},{"key":"562","doi-asserted-by":"crossref","unstructured":"562. Yamashita Y, Morimoto T, Yoshikawa Y, Yaku H, Sumita Y, Nakai M, et al. Temporal trends in the practice pattern for venous thromboembolism in Japan: Insight from JROAD-DPC. <i>J Am Heart Assoc<\/i> 2020; 9: e014582.","DOI":"10.1161\/JAHA.119.014582"},{"key":"563","doi-asserted-by":"crossref","unstructured":"563. Nakamura M, Miyata T, Ozeki Y, Takayama M, Komori K, Yamada N, et al. Current venous thromboembolism management and outcomes in Japan. <i>Circ J<\/i> 2014; 78: 708\u2013717.","DOI":"10.1253\/circj.CJ-13-0886"},{"key":"564","doi-asserted-by":"crossref","unstructured":"564. Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AG, Goto S, et al. Characteristics and management of patients with venous thromboembolism: The GARFIELD-VTE Registry. <i>Thromb Haemost<\/i> 2019; 119: 319\u2013327.","DOI":"10.1055\/s-0038-1676611"},{"key":"565","doi-asserted-by":"crossref","unstructured":"565. Galanaud JP, Genty-Vermorel C, Barrellier MT, Becker F, Jabbour V, Blaise S, et al. 25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): A randomised, double-blind, non-inferiority trial. <i>Lancet Haematol<\/i> 2022; 9: e886\u2013896.","DOI":"10.1016\/S2352-3026(22)00247-2"},{"key":"566","unstructured":"566. \u897f\u672c\u88d5\u4e8c. CQ7: \u6df1\u90e8\u9759\u8108\u8840\u6813\u75c7\u306e\u6025\u6027\u671f\u75c7\u72b6\u6539\u5584\u306b\u5727\u8feb\u7642\u6cd5\u306f\u6709\u7528\u304b? \u65e5\u672c\u9759\u8108\u5b66\u4f1a \u76e3\u4fee. \u5727\u8feb\u7642\u6cd5\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u5c0f\u59d4\u54e1\u4f1a\u7de8. \u9759\u8108\u75be\u60a3\u306b\u304a\u3051\u308b\u5727\u8feb\u7642\u6cd5\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 2025. \u65e5\u672c\u533b\u4e8b\u65b0\u5831\u793e 2025; 53\u201355."},{"key":"567","unstructured":"567. \u837b\u539f\u7fa9\u4eba. CQ8: \u9759\u8108\u8840\u6813\u5f8c\u75c7\u5019\u7fa4\u306e\u4e88\u9632\u306b\u5727\u8feb\u7642\u6cd5\u306f\u6709\u7528\u304b? \u65e5\u672c\u9759\u8108\u5b66\u4f1a \u76e3\u4fee. \u5727\u8feb\u7642\u6cd5\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u5c0f\u59d4\u54e1\u4f1a \u7de8. \u9759\u8108\u75be\u60a3\u306b\u304a\u3051\u308b\u5727\u8feb\u7642\u6cd5\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 2025. \u65e5\u672c\u533b\u4e8b\u65b0\u5831\u793e 2025; 56\u201360."},{"key":"568","doi-asserted-by":"crossref","unstructured":"568. Partsch H, Bl\u00e4ttler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. <i>J Vasc Surg<\/i> 2000; 32: 861\u2013869.","DOI":"10.1067\/mva.2000.110352"},{"key":"569","unstructured":"569. Bl\u00e4ttler W, Partsch H. Leg compression and ambulation is better than bed rest for the treatment of acute deep venous thrombosis. <i>Int Angiol<\/i> 2003; 22: 393\u2013400."},{"key":"570","doi-asserted-by":"crossref","unstructured":"570. Roumen-Klappe EM, den Heijer M, van Rossum J, Wollersheim H, Van Der Vleuten C, Thien T, et al. Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome. <i>J Thromb Thrombolysis<\/i> 2009; 27: 400\u2013405.","DOI":"10.1007\/s11239-008-0229-7"},{"key":"571","doi-asserted-by":"crossref","unstructured":"571. Kahn SR, Shapiro S, Ducruet T, Wells PS, Rodger MA, Kovacs MJ, et al. Graduated compression stockings to treat acute leg pain associated with proximal DVT: A randomised controlled trial. <i>Thromb Haemost<\/i> 2014; 112: 1137\u20131141.","DOI":"10.1160\/th14-05-0430"},{"key":"572","doi-asserted-by":"crossref","unstructured":"572. Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A, Bernardi E, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: A randomized, controlled trial. <i>Ann Intern Med<\/i> 2004; 141: 249\u2013256.","DOI":"10.7326\/0003-4819-141-4-200408170-00004"},{"key":"573","doi-asserted-by":"crossref","unstructured":"573. Brandjes DP, B\u00fcller HR, Heijboer H, Huisman MV, De Rijk M, Jagt H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. <i>Lancet<\/i> 1997; 349: 759\u2013762.","DOI":"10.1016\/S0140-6736(96)12215-7"},{"key":"574","unstructured":"574. Partsch H, Kaulich M, Mayer W. Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome. <i>Int Angiol<\/i> 2004; 23: 206\u2013212."},{"key":"575","doi-asserted-by":"crossref","unstructured":"575. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, et al. Compression stockings to prevent post-thrombotic syndrome: A randomised placebo-controlled trial. <i>Lancet<\/i> 2014; 383: 880\u2013888.","DOI":"10.1016\/S0140-6736(13)61902-9"},{"key":"576","doi-asserted-by":"crossref","unstructured":"576. Mol GC, van de Ree MA, Klok FA, Tegelberg MJ, Sanders FB, Koppen S, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): Randomised controlled trial. <i>BMJ<\/i> 2016; 353: i2691.","DOI":"10.1136\/bmj.i2691"},{"key":"577","doi-asserted-by":"crossref","unstructured":"577. Ten Cate-Hoek AJ, Amin EE, Bouman AC, Meijer K, Tick LW, Middeldorp S, et al. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): A multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. <i>Lancet Haematol<\/i> 2018; 5: e25\u2013e33.","DOI":"10.1016\/j.jvsv.2018.03.005"},{"key":"578","unstructured":"578. \u65e5\u672c\u9759\u8108\u5b66\u4f1a \u76e3\u4fee. \u5727\u8feb\u7642\u6cd5\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u5c0f\u59d4\u54e1\u4f1a \u7de8. \u9759\u8108\u75be\u60a3\u306b\u304a\u3051\u308b\u5727\u8feb\u7642\u6cd5\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 2025. \u65e5\u672c\u533b\u4e8b\u65b0\u5831\u793e 2025."},{"key":"579","doi-asserted-by":"crossref","unstructured":"579. Ginsberg JS, Hirsh J, Julian J, Vander LaandeVries M, Magier D, MacKinnon B, et al. Prevention and treatment of postphlebitic syndrome: Results of a 3-part study. <i>Arch Intern Med<\/i> 2001; 161: 2105\u20132109.","DOI":"10.1001\/archinte.161.17.2105"},{"key":"580","doi-asserted-by":"crossref","unstructured":"580. Patton D, Avsar P, Sayeh A, Budri A, O\u2019Connor T, Walsh S, et al. A meta-review of the impact of compression therapy on venous leg ulcer healing. <i>Int Wound J<\/i> 2023; 20: 430\u2013447.","DOI":"10.1111\/iwj.13891"},{"key":"581","doi-asserted-by":"crossref","unstructured":"581. Patton D, Avsar P, Sayeh A, Budri A, O\u2019Connor T, Walsh S, et al. Assessing the healthcare costs associated with venous leg ulcer compression bandages: A scoping review. <i>J Tissue Viability<\/i> 2023; 32: 618\u2013626.","DOI":"10.1016\/j.jtv.2023.06.009"},{"key":"582","doi-asserted-by":"crossref","unstructured":"582. Shi C, Dumville JC, Cullum N, Connaughton E, Norman G. Compression bandages or stockings versus no compression for treating venous leg ulcers. <i>Cochrane Database Syst Rev<\/i> 2021; 7: CD013397.","DOI":"10.1002\/14651858.CD013397.pub2"},{"key":"583","doi-asserted-by":"crossref","unstructured":"583. O\u2019Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers. <i>Cochrane Database Syst Rev<\/i> 2012; 11: CD000265.","DOI":"10.1002\/14651858.CD000265.pub3"},{"key":"584","doi-asserted-by":"crossref","unstructured":"584. Vandongen YK, Stacey MC. Graduated compression elastic stockings reduce lipodermatosclerosis and ulcer recurrence. <i>Phlebology<\/i> 2000; 15: 33\u201337.","DOI":"10.1007\/s005230070035"},{"key":"585","unstructured":"585. \u5b5f\u771f. \u6162\u6027\u9759\u8108\u4e0d\u5168\u75c7\u306b\u3088\u308b\u9759\u8108\u6027\u4e0b\u80a2\u6f70\u760d\u3068\u5727\u8feb\u7642\u6cd5. \u9759\u8108\u5b66 2021; <b>32:<\/b> 45\u201353."},{"key":"586","doi-asserted-by":"crossref","unstructured":"586. De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L, et al. Editor\u2019s choice  \u2013  European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. <i>Eur J Vasc Endovasc Surg<\/i> 2022; 63: 184\u2013267.","DOI":"10.1016\/j.ejvs.2022.06.022"},{"key":"587","doi-asserted-by":"crossref","unstructured":"587. Prandoni P, Noventa F, Quintavalla R, Bova C, Cosmi B, Siragusa S, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: A randomized trial. <i>Blood<\/i> 2012; 119: 1561\u20131565.","DOI":"10.1182\/blood-2011-11-391961"},{"key":"588","doi-asserted-by":"crossref","unstructured":"588. Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, et al. Cancer-associated venous thromboembolism. <i>Nat Rev Dis Primers<\/i> 2022; 8: 11.","DOI":"10.1038\/s41572-022-00336-y"},{"key":"589","doi-asserted-by":"crossref","unstructured":"589. Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous thromboembolism: An update. <i>Semin Thromb Hemost<\/i> 2019; 45: 321\u2013325.","DOI":"10.1055\/s-0039-1688494"},{"key":"590","doi-asserted-by":"crossref","unstructured":"590. Raskob GE, Wendelboe AM, Campbell J, Ford L, Ding K, Bratzler DW, et al. Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. <i>J Thromb Haemost<\/i> 2022; 20: 2366\u20132378.","DOI":"10.1111\/jth.15818"},{"key":"591","doi-asserted-by":"crossref","unstructured":"591. Nose T, Imamura Y, Ohata S, Kimbara S, Miyata Y, Hyogo Y, et al. Incidence of venous thromboembolism in patients with solid cancers in Japan: Retrospective study of 2735 patients. <i>Int J Hematol<\/i> 2021; 114: 319\u2013324.","DOI":"10.1007\/s12185-021-03167-x"},{"key":"592","doi-asserted-by":"crossref","unstructured":"592. Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, et al. Venous thromboembolism in cancer patients: Report of baseline data from the multicentre, prospective Cancer-VTE Registry. <i>Jpn J Clin Oncol<\/i> 2020; 50: 1246\u20131253.","DOI":"10.1093\/jjco\/hyaa112"},{"key":"593","doi-asserted-by":"crossref","unstructured":"593. Suzuki T, Hori R, Takeuchi K, Yamamura R, Katoh H, Noji Y, et al. Venous thromboembolism in Japanese patients with pancreatic cancer. <i>Clin Appl Thromb Hemost<\/i> 2021; 27: 10760296211051766.","DOI":"10.1177\/10760296211051766"},{"key":"594","doi-asserted-by":"crossref","unstructured":"594. Sakamoto J, Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, et al. Cancer-associated venous thromboembolism in the real world: From the COMMAND VTE Registry. <i>Circ J<\/i> 2019; 83: 2271\u20132281.","DOI":"10.1253\/circj.CJ-19-0515"},{"key":"595","doi-asserted-by":"crossref","unstructured":"595. Wu J, Fu Z, Liu G, Xu P, Xu J, Jia X. Clinical signi\ufb01cance of plasma D-dimer in ovarian cancer: A meta-analysis. <i>Medicine (Baltimore)<\/i> 2017; 96: e7062.","DOI":"10.1097\/MD.0000000000007062"},{"key":"596","doi-asserted-by":"crossref","unstructured":"596. Yang M, Qi J, Tang Y, Wu D, Han Y. Increased D-dimer predicts the risk of cancer-associated recurrent venous thromboembolism and venous thromboembolism: A systematic review and meta-analysis. <i>Thromb Res<\/i> 2020; 196: 410\u2013413.","DOI":"10.1016\/j.thromres.2020.09.031"},{"key":"597","doi-asserted-by":"crossref","unstructured":"597. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. <i>Blood<\/i> 2008; 111: 4902\u20134907.","DOI":"10.1182\/blood-2007-10-116327"},{"key":"598","doi-asserted-by":"crossref","unstructured":"598. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. <i>Blood<\/i> 2010; 116: 5377\u20135382.","DOI":"10.1182\/blood-2010-02-270116"},{"key":"599","doi-asserted-by":"crossref","unstructured":"599. Akasaka-Kihara F, Sueta D, Ishii M, Maki Y, Hirakawa K, Tabata N, et al. Validation of the Khorana venous thromboembolism risk score in Japanese cancer patients. <i>JACC Asia<\/i> 2021; 1: 259\u2013270.","DOI":"10.1016\/j.jacasi.2021.07.006"},{"key":"600","doi-asserted-by":"crossref","unstructured":"600. Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, et al. Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (ONCO DVT Study): An open-label, multicenter, randomized clinical trial. <i>Circulation<\/i> 2023; 148: 1665\u20131676.","DOI":"10.1161\/CIRCULATIONAHA.123.066360"},{"key":"601","doi-asserted-by":"crossref","unstructured":"601. Takahashi S, Imura M, Katada J. Epidemiology and treatment patterns of venous thromboembolism: An observational study of nationwide time-series trends in Japan. <i>Cardiol Ther<\/i> 2022; 11: 589\u2013609.","DOI":"10.1007\/s40119-022-00284-4"},{"key":"602","doi-asserted-by":"crossref","unstructured":"602. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. <i>J Clin Oncol<\/i> 2023; 41: 3063\u20133071.","DOI":"10.1200\/JCO.23.00294"},{"key":"603","doi-asserted-by":"crossref","unstructured":"603. Imura M, Katada J, Shiga T. Epidemiological study regarding the incidence of venous thromboembolism in patients after cancer remission. <i>Cardiol Ther<\/i> 2022; 11: 611\u2013623.","DOI":"10.1007\/s40119-022-00285-3"},{"key":"604","doi-asserted-by":"crossref","unstructured":"604. Dentali F, Pegoraro S, Barco S, Di Minno MN, Mastroiacovo D, Pomero F, et al. Clinical course of isolated distal deep vein thrombosis in patients with active cancer: A multicenter cohort study. <i>J Thromb Haemost<\/i> 2017; 15: 1757\u20131763.","DOI":"10.1111\/jth.13761"},{"key":"605","doi-asserted-by":"crossref","unstructured":"605. Galanaud JP, Sevestre MA, Pernod G, Genty C, Richelet S, Kahn SR, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: The OPTIMEV study. <i>J Thromb Haemost<\/i> 2017; 15: 907\u2013916.","DOI":"10.1111\/jth.13664"},{"key":"606","doi-asserted-by":"crossref","unstructured":"606. Yamashita Y, Shiomi H, Morimoto T, Yoneda T, Yamada C, Makiyama T, et al. Asymptomatic lower extremity deep vein thrombosis: Clinical characteristics, management strategies, and long-term outcomes. <i>Circ J<\/i> 2017; 81: 1936\u20131944.","DOI":"10.1253\/circj.CJ-17-0445"},{"key":"607","doi-asserted-by":"crossref","unstructured":"607. Endoh H, Shiratori K, Horigome M, Uematsu D, Takehana T, Sakamoto T, et al. The necessity of routine screening for deep vein thrombosis before surgery. <i>Ann Med Surg (Lond)<\/i> 2022; 77: 103627.","DOI":"10.1016\/j.amsu.2022.103627"},{"key":"608","doi-asserted-by":"crossref","unstructured":"608. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. <i>Ann Intern Med<\/i> 1996; 125: 1\u20137.","DOI":"10.7326\/0003-4819-125-1-199607010-00001"},{"key":"609","doi-asserted-by":"crossref","unstructured":"609. Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P; American Venous Forum, et al. Updated terminology of chronic venous disorders: The VEIN-TERM transatlantic interdisciplinary consensus document. <i>J Vasc Surg<\/i> 2009; 49: 498\u2013501.","DOI":"10.1016\/j.jvs.2008.09.014"},{"key":"610","unstructured":"610. Meissner MH. The clinical presentation and natural history of acute deep venous thrombosis. <i>In<\/i>: Gloviczki P, Dalsing MC, Moneta GL, et al., editors. Handbook of venous disorders: Guidelines of the American Venous Forum, 3rd edn. CRC Press, 2009: 195\u2013220."},{"key":"611","doi-asserted-by":"crossref","unstructured":"611. Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. <i>Ann Intern Med<\/i> 2008; 149: 698\u2013707.","DOI":"10.7326\/0003-4819-149-10-200811180-00004"},{"key":"612","doi-asserted-by":"crossref","unstructured":"612. Cheung YW, Middeldorp S, Prins MH, Pap AF, Lensing AW, Ten Cate-Hoek AJ, et al. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin\/vitamin K antagonists for acute deep-vein thrombosis: A post-hoc analysis. <i>Thromb Haemost<\/i> 2016; 116: 733\u2013738.","DOI":"10.1160\/TH16-01-0041"},{"key":"613","doi-asserted-by":"crossref","unstructured":"613. Ziegler S, Schillinger M, Maca TH, Minar E. Post-thrombotic syndrome after primary event of deep venous thrombosis 10 to 20 years ago. <i>Thromb Res<\/i> 2001; 101: 23\u201333.","DOI":"10.1016\/S0049-3848(00)00370-4"},{"key":"614","doi-asserted-by":"crossref","unstructured":"614. de Athayde Soares R, Matielo MF, Brochado Neto FC, Nogueira MP, Almeida RD, Sacilotto R. Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. <i>Surgery<\/i> 2019; 166: 1076\u20131083.","DOI":"10.1016\/j.surg.2019.05.030"},{"key":"615","doi-asserted-by":"crossref","unstructured":"615. Nishimoto Y, Yamashita Y, Morimoto T, Saga S, Amano H, Takase T, et al. Risk factors for post-thrombotic syndrome in patients with deep vein thrombosis: From the COMMAND VTE registry. <i>Heart Vessels<\/i> 2019; 34: 669\u2013677.","DOI":"10.1007\/s00380-018-1277-3"},{"key":"616","doi-asserted-by":"crossref","unstructured":"616. Kahn SR. The post-thrombotic syndrome. <i>Hematology Am Soc Hematol Educ Program<\/i> 2010; 2010: 216\u2013220.","DOI":"10.1182\/asheducation-2010.1.216"},{"key":"617","doi-asserted-by":"crossref","unstructured":"617. Lefebvre P, Lalibert\u00e9 F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, et al. All-cause and disease-related health care costs associated with recurrent venous thromboembolism. <i>Thromb Haemost<\/i> 2013; 110: 1288\u20131297.","DOI":"10.1160\/TH13-05-0425"},{"key":"618","unstructured":"618. Nicolaides AN, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, et al. Prevention and treatment of venous thromboembolism: International Consensus Statement. <i>Int Angiol<\/i> 2013; 32: 111\u2013260."},{"key":"619","doi-asserted-by":"crossref","unstructured":"619. van Dongen CJ, Prandoni P, Frulla M, Marchiori A, Prins MH, Hutten BA. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. <i>J Thromb Haemost<\/i> 2005; 3: 939\u2013942.","DOI":"10.1111\/j.1538-7836.2005.01333.x"},{"key":"620","doi-asserted-by":"crossref","unstructured":"620. Chitsike RS, Rodger MA, Kovacs MJ, Betancourt MT, Wells PS, Anderson DR, et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: Results from the REVERSE study. <i>J Thromb Haemost<\/i> 2012; 10: 2039\u20132044.","DOI":"10.1111\/j.1538-7836.2012.04872.x"},{"key":"621","doi-asserted-by":"crossref","unstructured":"621. Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: A recommendation for standardization. <i>J Thromb Haemost<\/i> 2009; 7: 879\u2013883.","DOI":"10.1111\/j.1538-7836.2009.03294.x"},{"key":"622","doi-asserted-by":"crossref","unstructured":"622. Stevinson BG, Hernandez-Nino J, Rose G, Kline JA. Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients. <i>Eur Heart J<\/i> 2007; 28: 2517\u20132524.","DOI":"10.1093\/eurheartj\/ehm295"},{"key":"623","doi-asserted-by":"crossref","unstructured":"623. Klok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV. Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolism. <i>Respir Med<\/i> 2010; 104: 1744\u20131749.","DOI":"10.1016\/j.rmed.2010.06.006"},{"key":"624","doi-asserted-by":"crossref","unstructured":"624. Sista AK, Klok FA. Late outcomes of pulmonary embolism: The post-PE syndrome. <i>Thromb Res<\/i> 2018; 164: 157\u2013162.","DOI":"10.1016\/j.thromres.2017.06.017"},{"key":"625","doi-asserted-by":"crossref","unstructured":"625. Albaghdadi MS, Dudzinski DM, Giordano N, Kabrhel C, Ghoshhajra B, Jaff MR, et al. Cardiopulmonary exercise testing in patients following massive and submassive pulmonary embolism. <i>J Am Heart Assoc<\/i> 2018; 7: e006841.","DOI":"10.1161\/JAHA.117.006841"},{"key":"626","doi-asserted-by":"crossref","unstructured":"626. Pesavento R, Filippi L, Palla A, Vison\u00e0 A, Bova C, Marzolo M, et al. Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism. <i>Eur Respir J<\/i> 2017; 49: 1601980.","DOI":"10.1183\/13993003.01980-2016"},{"key":"627","doi-asserted-by":"crossref","unstructured":"627. Nakano Y, Adachi S, Nishiyama I, Yasuda K, Imai R, Yoshida M, et al. Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism: The Nagoya PE study. <i>J Thromb Haemost<\/i> 2022; 20: 888\u2013898.","DOI":"10.2139\/ssrn.4133625"},{"key":"628","doi-asserted-by":"crossref","unstructured":"628. Fathala A, Aldurabi A. Frequency of computed tomography abnormalities in patients with chronic thromboembolic pulmonary hypertension: A comparative study between lung perfusion scan and computed tomography pulmonary angiography. <i>Multidiscip Respir Med<\/i> 2021; 16: 753.","DOI":"10.4081\/mrm.2021.753"},{"key":"629","doi-asserted-by":"crossref","unstructured":"629. Bilgi K, Muthusamy A, Subair M, Srinivasan S, Kumar A, Ravi R, et al. Assessing the risk for development of venous thromboembolism (VTE) in surgical patients using adapted Caprini scoring system. <i>Int J Surg<\/i> 2016; 30: 68\u201373.","DOI":"10.1016\/j.ijsu.2016.04.030"},{"key":"630","doi-asserted-by":"crossref","unstructured":"630. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. <i>Dis Mon<\/i> 2005; 51: 70\u201378.","DOI":"10.1016\/j.disamonth.2005.02.003"},{"key":"631","doi-asserted-by":"crossref","unstructured":"631. Hayssen H, Cires-Drouet R, Englum B, Nguyen P, Sahoo S, Mayorga-Carlin M, et al. Systematic review of venous thromboembolism risk categories derived from Caprini score. <i>J Vasc Surg Venous Lymphat Disord<\/i> 2022; 10: 1401\u20131409.e7.","DOI":"10.1016\/j.jvsv.2022.05.003"},{"key":"632","doi-asserted-by":"crossref","unstructured":"632. Zhou HX, Peng LQ, Yan Y, Yi Q, Tang YJ, Shen YC, et al. Validation of the Caprini risk assessment model in Chinese hospitalized patients with venous thromboembolism. <i>Thromb Res<\/i> 2012; 130: 735\u2013740.","DOI":"10.1016\/j.thromres.2012.08.001"},{"key":"633","doi-asserted-by":"crossref","unstructured":"633. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identi\ufb01cation of hospitalized medical patients at risk for venous thromboembolism: The Padua prediction score. <i>J Thromb Haemost<\/i> 2010; 8: 2450\u20132457.","DOI":"10.1111\/j.1538-7836.2010.04044.x"},{"key":"634","doi-asserted-by":"crossref","unstructured":"634. Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. <i>Chest<\/i> 2011; 140: 706\u2013714.","DOI":"10.1378\/chest.10-1944"},{"key":"635","doi-asserted-by":"crossref","unstructured":"635. Khorana AA, DeSancho MT, Liebman H, Rosovsky R, Connors JM, Zwicker J. Prediction and prevention of cancer-associated thromboembolism. <i>Oncologist<\/i> 2021; 26: e2\u2013e7.","DOI":"10.1002\/onco.13569"},{"key":"636","doi-asserted-by":"crossref","unstructured":"636. Hayssen H, Sahoo S, Nguyen P, Mayorga-Carlin M, Siddiqui T, Englum B, et al. Ability of Caprini and Padua risk-assessment models to predict venous thromboembolism in a nationwide Veterans Affairs study. <i>J Vasc Surg Venous Lymphat Disord<\/i> 2024; 12: 101693.","DOI":"10.1016\/j.jvsv.2023.101693"},{"key":"637","doi-asserted-by":"crossref","unstructured":"637. Arakaki D, Iwata M, Terasawa T. External validation of the Padua and IMPROVE-VTE risk assessment models for predicting venous thromboembolism in hospitalized adult medical patients: A retrospective single-center study in Japan. <i>Ann Vasc Dis<\/i> 2023; 16: 60\u201368.","DOI":"10.3400\/avd.oa.22-00108"},{"key":"638","doi-asserted-by":"crossref","unstructured":"638. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: The prospective COMPASS-Cancer-Associated Thrombosis Study. <i>Oncologist<\/i> 2017; 22: 1222\u20131231.","DOI":"10.1634\/theoncologist.2016-0414"},{"key":"639","doi-asserted-by":"crossref","unstructured":"639. Imamura H, Yasui M, Nakai N, Haraguchi N, Nishimura J, Matsuda C, et al. Preoperative D-dimer value and lower limb venous ultrasound for deep venous thrombosis prevents postoperative symptomatic venous thromboembolism in patients undergoing colorectal surgery: A retrospective study. <i>J Anus Rectum Colon<\/i> 2023; 7: 159\u2013167.","DOI":"10.23922\/jarc.2022-071"},{"key":"640","doi-asserted-by":"crossref","unstructured":"640. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest<\/i> 2012; 141(Suppl): e227S\u2013e277S.","DOI":"10.1378\/chest.11-2297"},{"key":"641","doi-asserted-by":"crossref","unstructured":"641. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, et al. Factors at admission associated with bleeding risk in medical patients: Findings from the IMPROVE investigators. <i>Chest<\/i> 2011; 139: 69\u201379.","DOI":"10.1378\/chest.09-3081"},{"key":"642","doi-asserted-by":"crossref","unstructured":"642. Sahoo S, Hayssen H, Englum B, Mayorga-Carlin M, Siddiqui T, Nguyen P, et al. Prediction of bleeding in patients being considered for venous thromboembolism prophylaxis. <i>J Vasc Surg Venous Lymphat Disord<\/i> 2023; 11: 1182\u20131191.e13.","DOI":"10.1016\/j.jvsv.2023.07.007"},{"key":"643","doi-asserted-by":"crossref","unstructured":"643. Sochart DH, Hardinge K. The relationship of foot and ankle movements to venous return in the lower limb. <i>J Bone Joint Surg Br<\/i> 1999; 81: 700\u2013704.","DOI":"10.1302\/0301-620X.81B4.0810700"},{"key":"644","doi-asserted-by":"crossref","unstructured":"644. Hartman JT, Altner PC, Freeark RJ. The effect of limb elevation in preventing venous thrombosis: A venographic study. <i>J Bone Joint Surg Am<\/i> 1970; 52: 1618\u20131622.","DOI":"10.2106\/00004623-197052080-00010"},{"key":"645","unstructured":"645. \u77f3\u4e95\u653f\u6b21, \u5ddd\u8def\u535a\u4e4b, \u6d5c\u5d0e\u5141, \u4ed6. DVT\u4e88\u9632\u306e\u305f\u3081\u306e\u5927\u817f\u9759\u8108\u6d41\u901f\u304b\u3089\u307f\u305f\u8840\u6d41\u6539\u5584\u306e\u6bd4\u8f03. <i>Hip Joint<\/i> 2001; 27: 557\u2013559."},{"key":"646","doi-asserted-by":"crossref","unstructured":"646. McNally MA, Cooke EA, Mollan RA. The effect of active movement of the foot on venous blood \ufb02ow after total hip replacement. <i>J Bone Joint Surg Am<\/i> 1997; 79: 1198\u20131201.","DOI":"10.2106\/00004623-199708000-00012"},{"key":"647","doi-asserted-by":"crossref","unstructured":"647. Agu O, Hamilton G, Baker D. Graduated compression stockings in the prevention of venous thromboembolism. <i>Br J Surg<\/i> 1999; 86: 992\u20131004.","DOI":"10.1046\/j.1365-2168.1999.01195.x"},{"key":"648","doi-asserted-by":"crossref","unstructured":"648. Hirai M, Iwata H, Hayakawa N. Effect of elastic compression stockings in patients with varicose veins and healthy controls measured by strain gauge plethysmography. <i>Skin Res Technol<\/i> 2002; 8: 236\u2013239.","DOI":"10.1034\/j.1600-0846.2001.80401.x"},{"key":"649","doi-asserted-by":"crossref","unstructured":"649. Wells PS, Lensing AW, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism: A meta-analysis. <i>Arch Intern Med<\/i> 1994; 154: 67\u201372.","DOI":"10.1001\/archinte.1994.00420010095011"},{"key":"650","doi-asserted-by":"crossref","unstructured":"650. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest<\/i> 2012; 141(Suppl): e278S\u2013e325S.","DOI":"10.1378\/chest.11-2404"},{"key":"651","unstructured":"651. Nicolaides AN, Miles C, Hoare M, Jury P, Helmis E, Venniker R. Intermittent sequential pneumatic compression of the legs and thromboembolism-deterrent stockings in the prevention of postoperative deep venous thrombosis. <i>Surgery<\/i> 1983; 94: 21\u201325."},{"key":"652","doi-asserted-by":"crossref","unstructured":"652. Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement: A prospective, randomized trial. <i>J Bone Joint Surg Am<\/i> 1998; 80: 1158\u20131166.","DOI":"10.2106\/00004623-199808000-00009"},{"key":"653","doi-asserted-by":"crossref","unstructured":"653. Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby G, Reddy DJ, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. <i>Cochrane Database Syst Rev<\/i> 2016; 9: CD005258.","DOI":"10.1002\/14651858.CD005258.pub3"},{"key":"654","doi-asserted-by":"crossref","unstructured":"654. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration; Dennis M, Sandercock P, Reid J, Graham C, Forbes J, et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): A multicentre randomized controlled trial. <i>Lancet<\/i> 2013; 382: 516\u2013524.","DOI":"10.1016\/S0140-6736(13)61050-8"},{"key":"655","doi-asserted-by":"crossref","unstructured":"655. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: Overview of results of randomized trials in general, orthopedic, and urologic surgery. <i>N Engl J Med<\/i> 1988; 318: 1162\u20131173.","DOI":"10.1056\/NEJM198805053181805"},{"key":"656","doi-asserted-by":"crossref","unstructured":"656. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: Results of meta-analysis. <i>Ann Surg<\/i> 1988; 208: 227\u2013240.","DOI":"10.1097\/00000658-198808000-00016"},{"key":"657","unstructured":"657. \u7802\u5ddd\u6d69, \u4e8c\u795e\u4fe1\u592b, \u5d0e\u5c3e\u6d69\u7531, \u4ed6. \u5f53\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u8853\u5f8c\u80ba\u8840\u6813\u585e\u6813\u75c7\u306b\u5bfe\u3059\u308b\u4e88\u9632\u63aa\u7f6e\u3068\u65bd\u884c\u524d\u5f8c\u3067\u306e\u8853\u5f8c\u80ba\u8840\u6813\u585e\u6813\u75c7\u306e\u767a\u75c7\u4f8b\u6570\u306e\u5909\u5316\u3068\u767a\u75c7\u4f8b\u306e\u691c\u8a0e (1996\u20132002). <i>J Anesthesia<\/i> 2003; 17(Suppl): 359."},{"key":"658","doi-asserted-by":"crossref","unstructured":"658. Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. <i>N Engl J Med<\/i> 1983; 309: 954\u2013958.","DOI":"10.1056\/NEJM198310203091605"},{"key":"659","doi-asserted-by":"crossref","unstructured":"659. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. <i>N Engl J Med<\/i> 1993; 329: 1370\u20131376.","DOI":"10.1056\/NEJM199311043291902"},{"key":"660","doi-asserted-by":"crossref","unstructured":"660. Sakon M, Kobayashi T, Shimazui T. Ef\ufb01cacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: Results from a multicenter, randomized, open-label study. <i>Thromb Res<\/i> 2010; 125: e65\u201370.","DOI":"10.1016\/j.thromres.2009.09.009"},{"key":"661","doi-asserted-by":"crossref","unstructured":"661. Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: Two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. <i>J Orthop Sci<\/i> 2008; 13: 442\u2013451.","DOI":"10.1007\/s00776-008-1264-0"},{"key":"662","unstructured":"662. \u51a8\u58eb\u6b66\u53f2, \u85e4\u7530\u609f. \u80a1\u95a2\u7bc0\u9aa8\u6298\u624b\u8853\u65bd\u884c\u5f8c\u306e\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306e\u4e88\u9632\u306b\u5bfe\u3059\u308b fondaparinux sodium \u306e\u6709\u7528\u6027. \u9aa8\u6298 2008; <b>30:<\/b> 206\u2013209."},{"key":"663","unstructured":"663. \u5de6\u8fd1\u8ce2\u4eba, \u585a\u672c\u6cf0\u53f8, \u5c0f\u6797\u9686\u592b, \u4ed6. \u8179\u90e8\u624b\u8853\u5f8c\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306e\u4e88\u9632\u306b\u5bfe\u3059\u308b\u30d5\u30a9\u30f3\u30c0\u30d1\u30ea\u30cc\u30af\u30b9\u306e\u81e8\u5e8a\u7684\u8a55\u4fa1\u2015\u9593\u6b20\u7684\u7a7a\u6c17\u5727\u8feb\u6cd5\u3092\u30d9\u30f3\u30c1\u30de\u30fc\u30af\u3068\u3057\u305f\u7121\u4f5c\u70ba\u5316\u30aa\u30fc\u30d7\u30f3\u8a66\u9a13\u2015. \u81e8\u5e8a\u533b\u85ac 2008; <b>24:<\/b> 679\u2013689."},{"key":"664","doi-asserted-by":"crossref","unstructured":"664. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. <i>J Thromb Haemost<\/i> 2010; 8: 2458\u20132468.","DOI":"10.1111\/j.1538-7836.2010.04021.x"},{"key":"665","unstructured":"665. \u533b\u7642\u4e8b\u6545\u8abf\u67fb\u30fb\u652f\u63f4\u30bb\u30f3\u30bf\u30fc, \u65e5\u672c\u533b\u7642\u5b89\u5168\u8abf\u67fb\u6a5f\u69cb. \u533b\u7642\u4e8b\u6545\u306e\u518d\u767a\u9632\u6b62\u306b\u5411\u3051\u305f\u63d0\u8a00\u7b2c2\u53f7: \u6025\u6027\u80ba\u8840\u6813\u585e\u6813\u75c7\u306b\u4fc2\u308b\u6b7b\u4ea1\u4e8b\u4f8b\u306e\u5206\u6790 (\u5e73\u621029\u5e748\u6708). https:\/\/www.medsafe.or.jp\/uploads\/uploads\/files\/teigen-02.pdf (accessed January 22, 2026)."},{"key":"666","doi-asserted-by":"crossref","unstructured":"666. Imura M, Yamamoto T, Hiasa KI. Pulmonary thromboembolism developed during hospitalization: A nationwide retrospective observational study using claims data. <i>Cardiol Ther<\/i> 2023; 12: 127\u2013141.","DOI":"10.1007\/s40119-022-00290-6"},{"key":"667","doi-asserted-by":"crossref","unstructured":"667. Gibson CM, Spyropoulos AC, Cohen AT, Hull RD, Goldhaber SZ, Yusen RD, et al. The IMPROVEDD VTE risk score: Incorporation of D-dimer into the IMPROVE score to improve venous thromboembolism risk stratification. <i>TH Open<\/i> 2017; 1: e56\u2013e65.","DOI":"10.1055\/s-0037-1603929"},{"key":"668","doi-asserted-by":"crossref","unstructured":"668. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. <i>Circulation<\/i> 2003; 107(Suppl 1): I9\u2013I16.","DOI":"10.1161\/01.CIR.0000078469.07362.E6"},{"key":"669","doi-asserted-by":"crossref","unstructured":"669. CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: A randomized trial. <i>Ann Intern Med<\/i> 2010; 153: 553\u2013562.","DOI":"10.7326\/0003-4819-153-9-201011020-00280"},{"key":"670","unstructured":"670. \u65e5\u672c\u8133\u5352\u4e2d\u5b66\u4f1a \u8133\u5352\u4e2d\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u59d4\u54e1\u4f1a. \u8133\u5352\u4e2d\u6cbb\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 2021 [\u6539\u8a022023]. \u5354\u548c\u4f01\u753b 2023."},{"key":"671","doi-asserted-by":"crossref","unstructured":"671. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association. <i>Stroke<\/i> 2019; 50: e344\u2013e418.","DOI":"10.1161\/STR.0000000000000211"},{"key":"672","doi-asserted-by":"crossref","unstructured":"672. Kierkegaard A, Norgren L. Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction. <i>Eur Heart J<\/i> 1993; 14: 1365\u20131368.","DOI":"10.1093\/eurheartj\/14.10.1365"},{"key":"673","doi-asserted-by":"crossref","unstructured":"673. Kahale LA, Matar CF, Tsolakian I, Hakoum MB, Barba M, Yosuico VE, et al. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. <i>Cochrane Database Syst Rev<\/i> 2021; 10: CD006466.","DOI":"10.1002\/14651858.CD006649.pub8"},{"key":"674","doi-asserted-by":"crossref","unstructured":"674. Rutjes AW, Porreca E, Candeloro M, Valeriani E, Di Nisio M. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. <i>Cochrane Database Syst Rev<\/i> 2020; 12: CD008500.","DOI":"10.1002\/14651858.CD008500.pub5"},{"key":"675","doi-asserted-by":"crossref","unstructured":"675. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. <i>N Engl J Med<\/i> 2019; 380: 711\u2013719.","DOI":"10.1056\/NEJMoa1814468"},{"key":"676","doi-asserted-by":"crossref","unstructured":"676. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. <i>N Engl J Med<\/i> 2019; 380: 720\u2013728.","DOI":"10.1056\/NEJMoa1814630"},{"key":"677","doi-asserted-by":"crossref","unstructured":"677. Bosch FT, Mulder FI, Kamphuisen PW, Middeldorp S, Bossuyt PM, B\u00fcller HR, et al. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: A systematic review and meta-analysis. <i>Blood Adv<\/i> 2020; 4: 5215\u20135225.","DOI":"10.1182\/bloodadvances.2020003115"},{"key":"678","doi-asserted-by":"crossref","unstructured":"678. Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC Trial. <i>J Clin Oncol<\/i> 2016; 34: 488\u2013494.","DOI":"10.1200\/JCO.2015.64.0268"},{"key":"679","doi-asserted-by":"crossref","unstructured":"679. Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: Outcomes from the CONKO-004 Trial. <i>J Clin Oncol<\/i> 2015; 33: 2028\u20132034.","DOI":"10.1200\/JCO.2014.55.1481"},{"key":"680","doi-asserted-by":"crossref","unstructured":"680. Sch\u00fcnemann HJ, Ventresca M, Crowther M, Briel M, Zhou Q, Noble S, et al. Evaluating prophylactic heparin in ambulatory patients with solid tumours: A systematic review and individual participant data meta-analysis. <i>Lancet Haematol<\/i> 2020; 7: e746\u2013e755.","DOI":"10.1016\/S2352-3026(20)30293-3"},{"key":"681","doi-asserted-by":"crossref","unstructured":"681. Li A, Kuderer NM, Garcia DA, Khorana AA, Wells PS, Carrier M, et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>J Thromb Haemost<\/i> 2019; 17: 2141\u20132151.","DOI":"10.1111\/jth.14613"},{"key":"682","doi-asserted-by":"crossref","unstructured":"682. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group. <i>N Engl J Med<\/i> 1999; 341: 793\u2013800.","DOI":"10.1056\/NEJM199909093411103"},{"key":"683","doi-asserted-by":"crossref","unstructured":"683. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. <i>Circulation<\/i> 2004; 110: 874\u2013879.","DOI":"10.1161\/01.CIR.0000138928.83266.24"},{"key":"684","doi-asserted-by":"crossref","unstructured":"684. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. <i>BMJ<\/i> 2006; 332: 325\u2013329.","DOI":"10.1136\/bmj.38733.466748.7C"},{"key":"685","doi-asserted-by":"crossref","unstructured":"685. Mahan CE, Fisher MD, Mills RM, Fields LE, Stephenson JJ, Fu AC, et al. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. <i>Thromb Res<\/i> 2013; 132: 520\u2013526.","DOI":"10.1016\/j.thromres.2013.08.013"},{"key":"686","doi-asserted-by":"crossref","unstructured":"686. Hull RD, Merali T, Mills A, Stevenson AL, Liang J. Venous thromboembolism in elderly high-risk medical patients: Time course of events and in\ufb02uence of risk factors. <i>Clin Appl Thromb Hemost<\/i> 2013; 19: 357\u2013362.","DOI":"10.1177\/1076029613481105"},{"key":"687","doi-asserted-by":"crossref","unstructured":"687. Amin AN, Varker H, Princic N, Lin J, Thompson S, Johnston S. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. <i>J Hosp Med<\/i> 2012; 7: 231\u2013238.","DOI":"10.1002\/jhm.1002"},{"key":"688","doi-asserted-by":"crossref","unstructured":"688. Alshouimi RA, Al Rammah SM, Alzahrani MY, Badreldin HA, Al Yami MS, Almohammed OA. The use of direct oral anticoagulants for extended duration thromboprophylaxis in medically ill patients: A systematic review and meta-analysis. <i>J Thromb Thrombolysis<\/i> 2019; 48: 422\u2013429.","DOI":"10.1007\/s11239-019-01900-2"},{"key":"689","doi-asserted-by":"crossref","unstructured":"689. Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, et al. Extended-duration betrixaban reduces the risk of rehospitalization associated with venous thromboembolism among acutely ill hospitalized medical patients: Findings from the APEX Trial (Acute Medically Ill venous thromboembolism Prevention With Extended Duration Betrixaban Trial). <i>Circulation<\/i> 2018; 137: 91\u201394.","DOI":"10.1161\/CIRCULATIONAHA.117.031187"},{"key":"690","doi-asserted-by":"crossref","unstructured":"690. Cohen AT, Spiro TE, B\u00fcller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. <i>N Engl J Med<\/i> 2013; 368: 513\u2013523.","DOI":"10.1056\/NEJMoa1111096"},{"key":"691","doi-asserted-by":"crossref","unstructured":"691. Bhalla V, Lamping OF, Abdel-Latif A, Bhalla M, Ziada K, Smyth SS. Contemporary meta-analysis of extended direct-acting oral anticoagulant thromboprophylaxis to prevent venous thromboembolism. <i>Am J Med<\/i> 2020; 133: 1074\u20131081.e8.","DOI":"10.1016\/j.amjmed.2020.01.037"},{"key":"692","doi-asserted-by":"crossref","unstructured":"692. Sch\u00fcnemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: Prophylaxis for hospitalized and nonhospitalized medical patients. <i>Blood Adv<\/i> 2018; 2: 3198\u20133225.","DOI":"10.1182\/bloodadvances.2018022954"},{"key":"693","unstructured":"693. National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline NG89. 2019. https:\/\/www.nice.org.uk\/guidance\/ng89 (accessed January 22, 2026)."},{"key":"694","doi-asserted-by":"crossref","unstructured":"694. Arabi YM, Al-Hameed F, Burns KE, Mehta S, Alsolamy SJ, Alshahrani MS, et al. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. <i>N Engl J Med<\/i> 2019; 380: 1305\u20131315.","DOI":"10.1056\/NEJMoa1816150"},{"key":"695","doi-asserted-by":"crossref","unstructured":"695. Shalhoub J, Lawton R, Hudson J, Baker C, Bradbury A, Dhillon K, et al. Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study): Randomised controlled trial. <i>BMJ<\/i> 2020; 369: m1309.","DOI":"10.1136\/bmj.m1309"},{"key":"696","doi-asserted-by":"crossref","unstructured":"696. Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip: A multicentre, multinational, randomised, open-label, parallel-group comparative study. <i>J Bone Joint Surg Br<\/i> 2007; 89: 887\u2013892.","DOI":"10.1302\/0301-620X.89B7.18556"},{"key":"697","doi-asserted-by":"crossref","unstructured":"697. Vignon P, Dequin PF, Renault A, Mathonnet A, Paleiron N, Imbert A, et al. Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding hospitalized in intensive care units: The CIREA1 randomized trial. <i>Intensive Care Med<\/i> 2013; 39: 872\u2013880.","DOI":"10.1007\/s00134-013-2814-2"},{"key":"698","doi-asserted-by":"crossref","unstructured":"698. Haykal T, Zayed Y, Dhillon H, Miran MS, Kerbage J, Bala A, et al. Meta-analysis of the role of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in critically ill patients. <i>Int J Low Extrem Wounds<\/i> 2022; 21: 31\u201340.","DOI":"10.1177\/1534734620925391"},{"key":"699","doi-asserted-by":"crossref","unstructured":"699. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. <i>Circulation<\/i> 2020; 141: 1648\u20131655.","DOI":"10.1161\/CIRCULATIONAHA.120.046941"},{"key":"700","doi-asserted-by":"crossref","unstructured":"700. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. <i>J Am Coll Cardiol<\/i> 2020; 75: 2352\u20132371.","DOI":"10.1016\/j.jacc.2020.03.031"},{"key":"701","doi-asserted-by":"crossref","unstructured":"701. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. <i>J Thromb Haemost<\/i> 2020; 18: 844\u2013847.","DOI":"10.1111\/jth.14768"},{"key":"702","doi-asserted-by":"crossref","unstructured":"702. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. <i>JAMA<\/i> 2003; 290: 374\u2013380.","DOI":"10.1001\/jama.290.3.374"},{"key":"703","doi-asserted-by":"crossref","unstructured":"703. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. <i>Lancet<\/i> 2020; 395: 1033\u20131034.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"704","doi-asserted-by":"crossref","unstructured":"704. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. <i>N Engl J Med<\/i> 2020; 382: e38.","DOI":"10.1056\/NEJMc2007575"},{"key":"705","doi-asserted-by":"crossref","unstructured":"705. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. <i>J Thromb Haemost<\/i> 2020; 18: 1421\u20131424.","DOI":"10.1111\/jth.14830"},{"key":"706","doi-asserted-by":"crossref","unstructured":"706. Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. <i>Thromb Res<\/i> 2020; 191: 145\u2013147.","DOI":"10.1016\/j.thromres.2020.04.013"},{"key":"707","doi-asserted-by":"crossref","unstructured":"707. Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. <i>Res Pract Thromb Haemost<\/i> 2020; 4: 1178\u20131191.","DOI":"10.1002\/rth2.12439"},{"key":"708","doi-asserted-by":"crossref","unstructured":"708. Yamashita Y, Yamada N, Mo M. The primary prevention of venous thromboembolism in patients with COVID-19 in Japan: Current status and future perspective. <i>Ann Vasc Dis<\/i> 2021; 14: 1\u20134.","DOI":"10.3400\/avd.ra.20-00145"},{"key":"709","doi-asserted-by":"crossref","unstructured":"709. Yamashita Y, Hara N, Obana M, Ikeda S, Furuichi M, Ishiguro S, et al. Clinical features of venous thromboembolism in patients with coronavirus disease 2019 (COVID-19) in Japan: A case series study. <i>Circ J<\/i> 2021; 85: 309\u2013313.","DOI":"10.1253\/circj.CJ-20-1302"},{"key":"710","doi-asserted-by":"crossref","unstructured":"710. Horiuchi H, Morishita E, Urano T, Yokoyama K; Questionnaire-survey Joint Team on The COVID-19-related thrombosis. COVID-19-related thrombosis in Japan: Final report of a questionnaire-based survey in 2020. <i>J Atheroscler Thromb<\/i> 2021; 28: 406\u2013416.","DOI":"10.5551\/jat.RPT001"},{"key":"711","doi-asserted-by":"crossref","unstructured":"711. Yamashita Y, Maruyama Y, Satokawa H, Nishimoto Y, Tsujino I, Sakashita H, et al. Incidence and clinical features of venous thromboembolism in hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan. <i>Circ J<\/i> 2021; 85: 2208\u20132214.","DOI":"10.1253\/circj.CJ-21-0169"},{"key":"712","doi-asserted-by":"crossref","unstructured":"712. Nishimoto Y, Yachi S, Takeyama M, Tsujino I, Nakamura J, Yamamoto N, et al. The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. <i>J Cardiol<\/i> 2022; 80: 285\u2013291.","DOI":"10.1016\/j.jjcc.2022.03.015"},{"key":"713","doi-asserted-by":"crossref","unstructured":"713. Schulman S, Sholzberg M, Spyropoulos AC, Zarychanski R, Resnick HE, Bradbury CA, et al. ISTH Guidelines for antithrombotic treatment in COVID-19. <i>J Thromb Haemost<\/i> 2022; 20: 2214\u20132225.","DOI":"10.1111\/jth.15808"},{"key":"714","doi-asserted-by":"crossref","unstructured":"714. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Thromboprophylaxis in patients with COVID-19: A brief update to the CHEST guideline and expert panel report. <i>Chest<\/i> 2022; 162: 213\u2013225.","DOI":"10.1016\/j.chest.2022.02.006"},{"key":"715","doi-asserted-by":"crossref","unstructured":"715. Lopes RD, de Barros E Silva PG, Furtado RH, Macedo AV, Bronhara B, Damiani LP, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial. <i>Lancet<\/i> 2021; 397: 2253\u20132263.","DOI":"10.1016\/S0140-6736(21)01203-4"},{"key":"716","doi-asserted-by":"crossref","unstructured":"716. INSPIRATION Investigators; Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial. <i>JAMA<\/i> 2021; 325: 1620\u20131630.","DOI":"10.1001\/jama.2021.4152"},{"key":"717","doi-asserted-by":"crossref","unstructured":"717. REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. <i>N Engl J Med<\/i> 2021; 385: 777\u2013789.","DOI":"10.1056\/NEJMoa2103417"},{"key":"718","doi-asserted-by":"crossref","unstructured":"718. ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. <i>N Engl J Med<\/i> 2021; 385: 790\u2013802.","DOI":"10.1056\/NEJMoa2105911"},{"key":"719","doi-asserted-by":"crossref","unstructured":"719. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: An Asian perspective. <i>Thromb Haemost<\/i> 2014; 111: 789\u2013797.","DOI":"10.1160\/TH13-11-0948"},{"key":"720","unstructured":"720. \u65e5\u672c\u9759\u8108\u5b66\u4f1a, \u80ba\u585e\u6813\u75c7\u7814\u7a76\u4f1a, \u65e5\u672c\u8840\u7ba1\u5916\u79d1\u5b66\u4f1a, \u65e5\u672c\u8108\u7ba1\u5b66\u4f1a, \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7 (COVID-19) \u306b\u304a\u3051\u308b\u8840\u6813\u75c7\u4e88\u9632\u304a\u3088\u3073\u6297\u51dd\u56fa\u7642\u6cd5\u306e\u8a3a\u7642\u6307\u91dd (2023\u5e742\u670825\u65e5 \u7248 Version 4.1). https:\/\/js-phlebology.jp\/wp\/wp-content\/uploads\/2023\/03\/\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\uff08COVID-19\uff09\u306b\u304a\u3051\u308b\u8840\u6813\u75c7\u4e88\u9632\u304a\u3088\u3073\u6297\u51dd\u56fa\u7642\u6cd5\u306e\u8a3a\u7642\u6307\u91ddVer.4.1\uff08\u56f3\u3042\u308a\uff0920230225.pdf (accessed January 22, 2026)."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/10\/90_CJ-25-1144\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:33:13Z","timestamp":1790393593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/10\/90_CJ-25-1144\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":720,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-25-1144","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"CJ-25-1144"}}